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Abstract
Persistent human papillomavirus (HPV) infections cause about 4.5% of the human cancer burden. The
HPV E7 oncoprotein is one of the primary drivers of HPV-mediated carcinogenesis and facilitates HPV
replication. The most well-studied HPV E7 activity is inactivation of the retinoblastoma tumor suppressor
(RB1), which dysregulates the cell cycle. However, there is substantial evidence to suggest that HPV E7
must have other activities in addition to RB1 inactivation. HPV E7 proteins from diverse HPV genotypes
interact with the host cell tumor suppressor protein tyrosine phosphatase non-receptor 14 (PTPN14).
Many HPV E7 proteins also direct PTPN14 for proteosome-mediated degradation. Through my
dissertation work, I sought to identify the role of PTPN14 degradation by HPV E7 in the HPV replicative
cycle and carcinogenesis. To initially characterize PTPN14 function in keratinocytes, we used mutant HPV
E7 proteins that cannot degrade PTPN14, CRISPR knockout of PTPN14, and high throughput RNA
sequencing to assess differential gene expression. We found that PTPN14 degradation by HPV E7
broadly represses genes related to keratinocyte differentiation. In a subsequent study, we used threedimensional organotypic epithelial cultures to study the mechanism downstream of PTPN14 degradation.
We found that PTPN14 loss in keratinocytes promotes basal cell-specific activation of the HIPPO pathway
transcriptional regulator YAP1. PTPN14 degradation and YAP1 activation by HPV E7 did not prevent
terminal differentiation in these cultures. Instead, the repression of differentiation observed in monolayer
culture translated to delayed commitment to differentiation and promotion of basal cell identity in the
three-dimensional system. This indicated that PTPN14 degradation by HPV E7 may help HPV resist
epithelial turnover and facilitate persistent infection. YAP1 and its paralogue TAZ are oncogenes when
dysregulated. Accordingly, through these studies we also found that PTPN14 degradation and YAP1/TAZ
transcriptional activity contribute to the ability of HPV E7 proteins from oncogenic genotypes to extend
the lifespans of primary keratinocytes, a metric of E7 carcinogenic activity. Overall, the experiments
described in this dissertation outline the effects of PTPN14 degradation by HPV E7 in keratinocytes and
stratified squamous epithelia which have implications for HPV persistence and HPV-mediated
carcinogenesis.
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ABSTRACT

E7, PTPN14, AND YAP1: HOW PAPILLOMAVIRUSES RETAIN CELLS IN THE BASAL
EPITHELIAL LAYER WITH IMPLICATIONS FOR PERSISTENCE AND
CARCINOGENESIS
Joshua Hatterschide
Elizabeth A. White

Persistent human papillomavirus (HPV) infections cause about 4.5% of the human
cancer burden. The HPV E7 oncoprotein is one of the primary drivers of HPV-mediated
carcinogenesis and facilitates HPV replication. The most well-studied HPV E7 activity is
inactivation of the retinoblastoma tumor suppressor (RB1), which dysregulates the cell
cycle. However, there is substantial evidence to suggest that HPV E7 must have other
activities in addition to RB1 inactivation. HPV E7 proteins from diverse HPV genotypes
interact with the host cell tumor suppressor protein tyrosine phosphatase non-receptor 14
(PTPN14). Many HPV E7 proteins also direct PTPN14 for proteosome-mediated
degradation. Through my dissertation work, I sought to identify the role of PTPN14
degradation by HPV E7 in the HPV replicative cycle and carcinogenesis. To initially
characterize PTPN14 function in keratinocytes, we used mutant HPV E7 proteins that
cannot degrade PTPN14, CRISPR knockout of PTPN14, and high throughput RNA
sequencing to assess differential gene expression. We found that PTPN14 degradation
by HPV E7 broadly represses genes related to keratinocyte differentiation. In a
subsequent study, we used three-dimensional organotypic epithelial cultures to study the
mechanism downstream of PTPN14 degradation. We found that PTPN14 loss in
keratinocytes promotes basal cell-specific activation of the HIPPO pathway transcriptional
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regulator YAP1. PTPN14 degradation and YAP1 activation by HPV E7 did not prevent
terminal differentiation in these cultures. Instead, the repression of differentiation observed
in monolayer culture translated to delayed commitment to differentiation and promotion of
basal cell identity in the three-dimensional system. This indicated that PTPN14
degradation by HPV E7 may help HPV resist epithelial turnover and facilitate persistent
infection. YAP1 and its paralogue TAZ are oncogenes when dysregulated. Accordingly,
through these studies we also found that PTPN14 degradation and YAP1/TAZ
transcriptional activity contribute to the ability of HPV E7 proteins from oncogenic
genotypes to extend the lifespans of primary keratinocytes, a metric of E7 carcinogenic
activity. Overall, the experiments described in this dissertation outline the effects of
PTPN14 degradation by HPV E7 in keratinocytes and stratified squamous epithelia which
have implications for HPV persistence and HPV-mediated carcinogenesis.
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CHAPTER 1 | INTRODUCTION
Human papillomaviruses in health and disease
HPV-mediated diseases
Infections are predicted to cause nearly one in six human cancers. A substantial
portion of these cancers are caused by a single group of viruses: human papillomaviruses
(HPVs), which alone cause about 4.5% of the human cancer burden (1). HPVs are well
known as the etiological agents of nearly all cervical cancers, but these viruses also cause
many other malignancies of the anogenital tract including anal, vaginal, vulvar, and penile
cancers (2). Importantly, HPVs are also the driving force behind an increasing proportion
of head and neck cancers, predominantly arising from the oropharynx (3-5).
Papillomaviruses are a diverse family of viruses that cause a wide variety of benign
and malignant lesions in nearly all vertebrate animals (6, 7). However, papillomaviruses
are highly species-specific, and only five genera of papillomaviruses have members that
infect humans: alpha, beta, gamma, mu, and nu papillomavirus (8). These genera are
further broken down into species and genotypes. Distinct HPV genotypes are defined as
having less than 10% nucleotide identity in their L1 gene (9, 10). To date, there are 227
recognized HPV genotypes and 221 putative novel HPV genotypes with complete genome
sequences archived on the PApillomaVirus Episteme (PaVE). There are many genotypespecific differences between HPVs, including the body sites they infect and their
carcinogenic potential. At the broadest level, HPV genotypes can be classified based on
their tropism for cutaneous or mucosal stratified squamous epithelia. Infections with both
cutaneous and mucosal HPVs are commonplace (11, 12).
A portion of the alpha HPVs have evolved a tropism for mucosal epithelia in body
sites including the anogenital tract, oral cavity, and oropharynx (8). Mucosotropic alpha
HPVs can be further classified as “high-risk,” “low-risk,” or non-carcinogenic based on their
1

propensity to cause cancers, and 13-15 HPV genotypes are classified as high-risk (13).
The two most common high-risk HPV genotypes are HPV16, which is found in about 50%
of cervical cancers and 90% of HPV-positive head and neck cancers, and HPV18, which
is found in about 18% of cervical cancers and 3% of HPV-positive head and neck cancers
(4, 5, 14). The mechanism behind the dominance of HPV16 in head and neck cancers is
currently unknown. The most common low-risk HPV genotypes are HPV6 and HPV11,
which cause genital warts as well as recurrent respiratory papillomatosis (15).
Genus beta, gamma, mu, nu and the remaining genus alpha HPVs all primarily
infect cutaneous epithelia (11). Cutaneous HPVs cause a variety of benign skin lesions
including verruca vulgaris (common warts; frequently caused by α-HPV2, 7, 27, 57, and
γ-HPV4), verruca plantaris/palmaris (plantar/palmar warts; frequently caused by α-HPV2,
γ-HPV4, μ-HPV1, and 63), and verruca plana (flat warts, frequently caused by α-HPV3,
and 10) (16). Additionally, genus beta HPVs (frequently β-HPV5, and 8) are pathogenic in
the context of the rare, heritable immunodeficiency epidermodysplasia verruciformis (17).
The exact mechanism causing increased beta HPV susceptibility in epidermodysplasia
verruciformis is unknown but is associated with loss-of-function mutations in
TMC6/EVER1 or TMC8/EVER2 (18). There are many interesting open questions
regarding the biology of cutaneous HPV genotypes. However, as mucosotropic alpha
HPVs are the primary drivers of HPV-mediated cancers, these genotypes will be the focus
of most of this body of work.
HPV is the most common sexually transmitted infection in the United States (19).
Due to the prevalence of screening, the progression from cervical HPV infection to cancer
is well-characterized (20). In contrast, the epidemiology of precancerous HPV infection in
the oral cavity or at other anogenital sites is not as well documented. However, a similar
progression from infection to disease likely occurs. Most cervical HPV infections are
2

readily cleared by the immune system and epithelial turnover in under two years without
intervention (21-23). However, a small proportion of HPV infections are able to persist,
which increases the likelihood of progression to cervical intraepithelial neoplasia (CIN)
and malignant disease (24). CIN has three precancerous grades ranging from low grade
(CIN1) to high grade cancer precursor lesions (CIN3) (25). CIN1 and CIN2 frequently
regress spontaneously (2). However, about one in three CIN3 lesions will progress to
invasive cervical cancer within several decades, and intervention is required at this stage
of disease (26).

Prevention and treatment
There are two major strategies employed to prevent HPV-related disease:
vaccination and screening. The currently recommended vaccine for HPV is the 9-valent
Gardasil 9, that immunizes against the L1 capsid proteins of 7 high-risk HPV genotypes
(including HPV16 and HPV18), as well as the two common genital warts causing
genotypes, HPV6 and HPV11 (27). These vaccines are highly effective at preventing
infection with these HPV genotypes, and HPV vaccination has the capacity to prevent as
much as 90% of HPV-related cancers (14). Although HPV vaccination rates are
increasing, they remain much lower than those of other vaccinations. In a 2020 Centers
for Disease Control and Prevention (CDC) survey, 75% of adolescents ages 13-17 had at
least one dose of an HPV vaccine, and only 59% were up to date on the vaccination series
(28). This is very low in comparison to the 90% of adolescents in the same study that had
received ≥1 dose of Tdap (tetanus, diphtheria, and pertussis vaccine), 92% that had
received ≥2 doses of MMR (measles, mumps, and rubella vaccine), and 93% that had
received ≥3 doses of the HBV (hepatitis B virus) vaccine. Despite the promise of HPV
vaccination to one day eliminate HPV-related disease, low vaccination rates indicate that
3

HPV infection will remain a problem among the next generation of adults, emphasizing the
continued need for HPV-targeted therapeutics.
There are no HPV-targeted drugs currently approved for clinical use. Compounds
that are used for the treatment of either cutaneous or mucosal HPV infections instead aim
to disrupt host cell physiology (systemic retinoids), stimulate a local immune response
(imiquimod), or outright kill or strip local epithelial cells (salicylic acid, 5-FU, and
bleomycin) (29, 30). None of these treatments are curative, and resurgence of infection is
common (31). Due to the lack of effective HPV-targeted therapeutics, persistent HPV
infection or high-grade cervical dysplasia is often treated by removal of the HPV infected
tissue through cone biopsy, cryosurgery, or laser surgery (32). These methods resemble
those used to remove cutaneous warts (33). Following progression from infection to
cancer, HPV-positive tumors are likewise treated with non-HPV-specific therapies
including combinations of surgery, radiation, and chemotherapy (34). It is clear that the
development of HPV-targeted therapeutics could improve the clinical outcomes of patients
with both precancerous HPV lesions and HPV-positive cancers. Building our knowledge
of the activities of HPV proteins and the cellular pathways they dysregulate could facilitate
the development of such therapeutics.
Through my dissertation work, I sought to expand our mechanistic understanding
of HPV biology. Specifically, I explored the function of degradation of the host tumor
suppressor PTPN14 (protein tyrosine phosphatase non-receptor 14) by the HPV E7
oncoprotein. We found that this interaction leads to activation of the host cellular
transcriptional co-regulator YAP1, which represses differentiation and retains HPV E7
expressing cells in the basal epithelial layer. Furthermore, the results presented herein
shed light on how this pathway could contribute to HPV persistence and HPV-mediated
carcinogenesis. Aspects of the mechanism that I will propose are potentially targetable.
4

Indeed, compounds that target YAP1 activity have already been discovered (35). A better
understanding of the dependency of HPV on this activity could present opportunities for
HPV-targeted therapies. In this chapter, I will explain HPV E7, PTPN14, YAP1, and
epithelial differentiation in detail, elaborate on how they relate to one another, and give
sufficient context to understand how each is important for HPV biology and HPV-mediated
carcinogenesis.

HPV biology
Genomic organization and gene function
HPVs are nonenveloped, dsDNA viruses with circular genomes of around 8 kb
(Figure 1.1). The HPV genome is replicated in the nucleus of infected cells (25). As HPVs
do not encode their own polymerase genes, the viral genome is replicated using the host
DNA replication machinery (36). High-risk alpha HPV genomes encode eight open reading
frames: E1, E2, E4, E5, E6, E7, L1, and L2. E1 is the viral ATP-dependent DNA helicase,
the only enzyme encoded by papillomaviruses (37). E1 is responsible for directing the host
cellular DNA replication machinery to the viral origin of replication to promote viral DNA
amplification. E2, a viral DNA binding protein, both regulates viral transcription and
mediates tethering of the viral genome to the host cell chromatin to ensure infection is
maintained upon cell division (38). E4, E5, E6, and E7 are viral non-structural proteins that
contribute to modulating the host cellular environment in many ways that facilitate the
different phases of HPV infection (39-42). HPV E6 and E7 are also the viral oncoproteins
and will be discussed in greater detail later in the chapter. L1 is the major viral capsid
protein, that is capable of self-assembly into virions and is the major component of the
HPV vaccines (43). L2 is the minor viral capsid protein that coordinates viral entry into the
cell (44).
5

Figure 1.1. HPV is a circular dsDNA virus with a genome of around 8 kb.
Schematic of the HPV18 genome. HPV18 ORFs are drawn in tracks representing the frame of the
ORF (blue = frame 1, green = frame 2, and gray = frame 3). Tick marks indicate 1 kb increments
running clockwise.
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The HPV replicative cycle
All HPVs productively infect stratified squamous epithelia, regardless of whether
they have a mucosal or cutaneous tropism (2, 25). The stratified squamous epithelial
architecture is comprised of layers of cells called keratinocytes (Figure 1.2A). The basal
layer of keratinocytes is the only proliferative layer and includes stem cells that replenish
all layers of the epithelium (45). When a keratinocyte leaves the basal layer and enters
the suprabasal layers of the epithelium (either through asymmetric, vertical cell division or
through delamination), it begins the process of terminal differentiation (46-48). Through
differentiation, keratinocytes lose the proliferative capacity of basal cells and begin to
express transcriptional programs that allow them function as a unit of these barrier tissues
(45, 49, 50). When a terminally differentiated cell reaches the surface of the epithelium, it
is shed and replaced by cells from the layers below. Through this process, cells in stratified
squamous epithelia continually turnover (51, 52). The HPV infectious cycle can be broken
down into three major phases: establishment, maintenance, and productive replication (2,
25). Each of these phases has a unique and intimate relationship with the differentiation
program of the constantly regenerating stratified squamous epithelia (Figure 1.2B).
The entry and establishment phase of the HPV infectious cycle begins with
infection of a keratinocyte in the undifferentiated basal layer of stratified squamous
epithelia, which HPV virions gain access to through abrasions or other micro wounding in
the epithelium (53-55). In these sites of wounding, the HPV L1 capsid protein first binds
to heparan sulfate proteoglycans present in basement membrane (56). The HPV virion
can then bind to receptors on the membrane of nearby cells to mediate endocytosis. A
single specific cellular receptor for HPV has yet to be identified, although many cellular
proteins have been implicated as important contributors [reviewed in (57, 58)]. Within the
endocytic pathway, HPV L2 extrudes a portion of its N-terminus to penetrate the
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endosomal membrane and engage the host retromer complex (59). This interaction
mediates the retrograde transport of the HPV virion through the endosome and Golgi
apparatus. The L2-bound episomal viral DNA genome finally gains access to the nucleus
following nuclear envelope breakdown during the cell cycle (60). In the nucleus, the viral
genome localizes to promyelocytic leukemia (PML) nuclear bodies and undergoes an
initial round of amplification to reach a base line level of viral DNA (61).
The stable maintenance phase of the HPV infectious cycle takes place in the basal
layer of the epithelium and is believed to be central to persistent HPV infection (Figure
1.2B). In the basal layer, HPV genomic DNA is amplified once per cell cycle along with the
cellular DNA during S-phase and consequently is maintained at a low level (62). Upon
symmetric, horizontal cell division of an infected basal cell, the HPV genome is maintained
in both daughter cells. This effect is mediated by HPV E2, which tethers the HPV genome
to the host chromatin and prevents it from being lost to the cytoplasm upon nuclear
envelope breakdown (63, 64). During the maintenance phase, HPV gene expression is
also very low, and the primary genes that are expressed are HPV E1 and E2, and to a
lesser extent E6 and E7 (65).
The productive phase of the HPV infectious cycle takes place in the suprabasal
layers of stratified squamous epithelia and is coordinated with the keratinocyte
differentiation program (2, 25). Infected basal keratinocytes can enter the suprabasal layer
either through delamination or asymmetric, vertically oriented cell division in which the
HPV genome is maintained in both the resulting basal and suprabasal daughter cells (46,
48) (Figure 1.2B). The newly suprabasal keratinocyte then begins to differentiate. This
initiates vegetative viral DNA amplification, increasing viral genome copy number per cell
by hundreds to thousands of times (66). Suprabasal keratinocytes under normal
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Figure 1.2. The HPV replicative cycle depends on the differentiation program in stratified
squamous epithelia.
(A) Schematic of a normal stratified squamous epithelia highlighting the names of different layers
of the epithelium on the right and the cell fate decisions that basal keratinocytes can make along
the bottom. Basal keratinocytes can either divide horizontally to replenish basal layer cells or divide
vertically or delaminate to replenish cells in the suprabasal layers. Differentiation is initiated when
a keratinocyte leaves the basal layer. (B) Schematic of an HPV infected stratified squamous
epithelia. The three phases of the HPV replicative cycle (entry and establishment, maintenance /
persistence, and productive replication) are highlighted along the periphery. The impact of basal
cell fate decisions on the phase of the HPV replicative cycle is highlighted along the bottom. Cell
fate decisions that lead to infected cells entering the suprabasal layers will trigger differentiation
and productive HPV replication. The sequence of HPV productive replication is labeled along the
right.
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conditions do not express the cellular DNA replication machinery. This would pose a
barrier to HPV vegetative DNA replication, which is dependent upon host polymerases.
However, HPV induces the expression of the cellular DNA replication machinery in the
cells of these layers through the activity of the HPV E7 oncoprotein (described more
below) (67, 68). Keratinocyte differentiation also induces dramatic changes in the profile
of expressed HPV transcripts, owing to alterations in promoter usage and splicing (69).
This leads to increased E1, E2, E6, and E7 expression and the activation of the viral late
promoter, allowing for the expression of E4, E5, L1 and L2 (65). As infected cells approach
the surface of the epithelium, the viral genome is packaged into self-assembling viral
capsids, and viral particles are released with dying cells as they are shed at the surface
of the epithelium (43).

Mechanisms of HPV-mediated carcinogenesis
The viral oncoproteins, E6 and E7, are the primary drivers of HPV-mediated
carcinogenesis. Repression of E6 and E7 transcripts in HPV-positive tumor cells leads to
senescence and cell death, indicating the necessity of their sustained expression for
carcinogenesis (70-72). Additionally, E6 and E7 together are sufficient to convey many of
the cellular properties necessary for carcinogenesis including uncontrolled cellular
proliferation, resistance to senescence, and resistance to cell death (73-75). However,
when comparing HPV16 genome sequences in cervical cancers/precancers to infections,
HPV16 E7 was found to tolerate fewer mutations than HPV16 E6 or other HPV ORFs,
suggesting that unimpaired E7 function is particularly important for carcinogenesis (76).
Persistent HPV infection is a prerequisite for HPV-mediated carcinogenesis.
Although HPV-positive tumor cells are “addicted” to the expression of the viral
oncoproteins, E6 and E7 expression is not sufficient to fully transform cells on their own.
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In fact, HPV infections can persist for years before progressing to malignant disease (2124). However, a consequence of this length of persistent infection is that it allows time for
additional alterations and mutations to accumulate in the viral and cellular genomes (77,
78). The exact genetic and epigenetic changes required to fully transform HPV-positive
cells are not completely understood. However, viral genome integration into the host
chromatin is a common occurrence in HPV-positive cancers, and this often occurs in a
manner that increases the expression of the viral oncoproteins (78).
The activities of high-risk HPV E6 and E7 are proposed to act synergistically to
enable transformation (79). HPV E7 binds the retinoblastoma tumor suppressor protein
(RB1), inactivating it and directing it for proteosome mediated degradation (80-83). RB1
is the gatekeeper of the cell cycle, and its inactivation promotes cellular proliferation. This
unscheduled reentry into the cell cycle triggers the stabilization of the cellular tumor
suppressor p53, which left unchecked, would cause cell cycle arrest or apoptosis (84, 85).
However, HPV E6 binds to p53 and the cellular E3-ubiquitin ligase E6AP to direct p53 for
proteosome mediated degradation (86, 87). This simplistic model nicely portrays how the
HPV oncoproteins cooperate to promote carcinogenesis. That said, both oncoproteins are
believed to have additional activities that are necessary for HPV-mediated carcinogenesis.
One such activity of HPV E7, binding to the host tumor suppressor PTPN14, is the focus
of this work.

Mechanisms of HPV persistence
How HPV establishes and maintains persistent infections remains incompletely
understood. However, as basal keratinocytes are the only long-lived cells in stratified
squamous epithelia, it is widely believed that HPV persistence occurs in this layer of the
epithelium (30, 88, 89). The first requirement of HPV persistence is simply maintaining the
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viral genome in both daughter cells upon cell division. This phenomenon is well known to
be mediated by HPV E2 (38, 63, 64). However, HPV also faces two other significant
threats to its long-term colonization of the epithelium: the host immune response and cell
turnover in the epithelium. HPV E6 and E7 are also required for HPV persistent infection
and likely contribute to overcoming these barriers (21, 72, 90).
One way HPV evades the immune system is by directly impairing signaling
pathways that control cell intrinsic and cell extrinsic immune responses to infection
[reviewed in: (91-93)]. The known pathways that are targeted by HPV include, toll-like
receptor (TLR) signaling, cGAS-STING signaling, the type 1 interferon response, and
antigen presentation. HPV E6 and E7 together or separately have been shown to bind to
or promote the transcriptional repression of many important signaling molecules in these
pathways. HPV also evades the immune system by coordinating its replicative cycle with
the different layers of the epithelium. Viral gene expression increases as infected cells
differentiate, and the highly antigenic viral capsid proteins are only expressed in cells near
the surface of the epithelium (65). If infected cells in these layers are detected and cleared
by the immune system, this likely does not significantly impact viral persistence because
they are already terminally differentiated and committed to being shed from the epithelium.
In contrast, there are very low levels of viral gene expression in infected basal cells, which
are the reservoir for persistent infection (65, 94). This low level of gene expression can
help these infected cells evade detection from the immune system, thereby facilitating
HPV persistence.
Another phenomenon that could clear HPV infected cells out of the basal layer is
the normal process of epithelial turnover. The rate of turnover of different stratified
squamous epithelia varies based on body site, but ranges from weeks to several months
(51, 52). It is evident that HPV infected cells resist cellular turnover because HPV
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infections can last for many years (21-23, 89). However, there are many gaps in our
understanding of how HPV evades cellular turnover in the epithelium. Certain HPV
genotypes induce cellular proliferation, so a simple model for how HPVs evade cellular
turnover could be that HPV infected cells outpace the replication of neighboring uninfected
cells. Another logical strategy that HPV could employ to overcome epithelial turnover is
delaying commitment to differentiation, and there is evidence to suggest that HPV may
engage mechanisms that specifically bias cells toward remaining in the basal layer of the
epithelium.
Several recent studies have explored whether HPV E6 and E7 can enable HPVinfected cells to compete with neighboring uninfected cells for space in the basal layer (30,
95, 96). When keratinocytes are at confluence in the basal layer of the epithelium yet
continue to expand, this forces the dividing cell and neighboring cells in its path to decide
which cell will remain in the basal layer and which will differentiate. These recent studies
have proposed that high-risk HPV E6 proteins and Mus musculus papillomavirus 1
(MmuPV1) E6 proteins but not the corresponding E7 proteins increase success in
competition at confluence (30, 95, 96). The mechanism for MmuPV1 E6 proteins is
partially dependent on binding to the host transcription factor MAML1, a component of the
NOTCH signaling pathway with a clear role in regulating differentiation (96-99). The
mechanism for how high-risk HPV E6 accomplishes the same effect is less clear but may
function through binding to p53 (95, 100).
HPV could also delay commitment to differentiation by regulating related
transcriptional programs. Both high-risk HPV E6 and E7 have been shown to repress
many genes related to the differentiation program (100-104). At the outset of the research
herein, the mechanisms by which each of the HPV oncoproteins represses differentiation
were not well understood. Furthermore, it was not known whether repression of
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differentiation gene expression by either of the oncoproteins lead to a propensity for basal
cell identity or reduced differentiation gene expression in suprabasal keratinocytes. In this
dissertation, I describe a mechanism downstream of HPV E7 that leads to accumulation
of E7 expressing cells in the basal layer. This mechanism may contribute to how HPV
resists epithelial turnover.

HPV E7
HPV E7 structure and function
E7 is a small viral non-structural protein and is one of the two viral oncoproteins
expressed by all HPVs. The high-risk HPV E7 proteins are around 100 amino acids (41)
(Figure 1.3A). The N-terminus of E7 possesses significant amino acid sequence similarity
to the adenovirus E1A protein and is divided into two sections called conserved region 1
(CR1) and CR2 (105, 106). The C-terminal domain of HPV E7 contains a zinc-binding
domain characterized by two CxxC amino acid sequences (107). Biochemical, NMR, and
crystallography studies of HPV E7 have revealed that the C-terminal domain is highly
structured, while CR1/2 are largely unfolded (108-111). HPV E7 has no enzymatic
activities and mediates its effects on the cellular environment through protein-protein
interactions that modulate the activities of cellular protein targets. For example, HPV E7
binds to several E3-ubiquitin ligases and can impair the activity of other targets by directing
them for proteasome-mediated degradation (112, 113). In the context of high-risk HPV
genotypes, E7 is the primary driver of HPV-mediated carcinogenesis.
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Figure 1.3. HPV E7 binds and inactivates host proteins.
(A) Schematic of the domain structure of HPV16 E7. Amino acid residues in CR1 and CR2 that
mediate UBR4 and RB1 binding are highlighted below, along with amino acid residues that mediate
zinc binding and are crucial for the structure of the C-terminal domain. PTPN14 binds to this region
of E7. A more specific amino acid that contributes to this interaction is explored in Chapter 2. (B)
HPV E7 inactivates RB1. This culminates in cell cycle progression and increased expression of the
host cell DNA replication machinery. (C) HPV E7 forms a ternary complex with UBR4 (E3 ubiquitin
ligase) and PTPN14. This leads to the proteasomal degradation of PTPN14. However, the
downstream impacts of PTPN14 in keratinocytes were previously not known.
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HPV E7 and RB1
The most well-characterized cellular interactor of HPV E7 is RB1, which E7 binds
and directs for proteosome-mediated degradation (80-83, 113). HPV E7 proteins have a
conserved LxCxE motif in the CR2 region that mediates binding to RB1 as well as the
other RB1-like proteins RBL1 (p107) and RBL2 (p130) (81, 83, 114) (Figure 1.3A). RB1
binds to E2F transcription factors on the host cell chromatin, repressing transcription and
preventing cell cycle progression. Thus, degradation of RB1 by HPV E7 leads to
dysregulated cell cycle progression (67) (Figure 1.3B). Inactivation of RB1 by HPV E7
plays a critical role in the productive phase of the virus replicative cycle (67, 115). When
an infected keratinocyte begins to differentiate, inactivation of RB1 by HPV E7 is how HPV
promotes the expression of the cellular DNA replication machinery, which is required for
amplification of the viral genome (94) (Figure 1.2B). This effect is also central to the
carcinogenic activity of HPV E7 from high-risk genotypes, and mutant E7 proteins that do
not bind RB1 lose many of their carcinogenic properties (82, 83, 116).

Evidence of RB1-independent activities of HPV E7
Beyond RB1 inactivation, several lines of evidence suggest that there are
additional activities of high-risk HPV E7 that are necessary for carcinogenesis. Mutational
analyses of HPV E7 demonstrate that many amino acids outside of the E7 LxCxE motif
can disrupt the carcinogenic activity of HPV E7 without disrupting RB1 binding or
degradation (82, 107, 117, 118). Furthermore, E7 proteins from low-risk and noncarcinogenic alpha HPVs as well as beta HPVs bind to RB1, but do not have transforming
properties (119-121). Inversely, bovine papillomavirus 1 (BPV1) E7 lacks an LxCxE motif,
cannot bind or inactivate RB1, but has transforming activity (122-124). Finally, in mouse
models of cervical cancer, expression of HPV16 E7 under a keratinocyte-specific promoter
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promotes tumorigenesis more efficiently than keratinocyte-specific homozygous deletion
of RB1 (116). Taken together, these observations suggest that other host proteins that
interact with HPV E7 contribute to its carcinogenic activity though such interactions have
not been fully defined.

HPV E7 and PTPN14
Proteomics approaches have been employed in the attempt to identify other host
proteins that HPV E7 interacts with that contribute to its carcinogenic activity (125, 126).
These studies have identified many conserved, species-specific, and genotype specific
interactors of E7 proteins. Two host proteins that are bound by diverse HPV E7 are the
E3-ubiquitin ligase, UBR4, and the non-receptor protein tyrosine phosphatase, PTPN14.
UBR4 (also known as p600) binds the N-terminal amino acids of HPV E7 and contributes
to the RB1-independent carcinogenic activity of high-risk HPV E7 and BPV1 E7 (112, 127)
(Figure 1.3A). The mechanism through which UBR4 binding contributes to transformation
was previously not well understood. More recently, our lab discovered that high-risk HPV
E7 directs PTPN14 for proteosome mediated degradation and that this requires the activity
of UBR4 (128) (Figure 1.3C). PTPN14 binds to the C-terminal domain of HPV E7, and
PTPN14, UBR4, and E7 all are found in the same protein complex (128) (Figure 1.3A).
Therefore, we hypothesized that like UBR4 binding, PTPN14 degradation may contribute
to the RB1 independent carcinogenic activity of high-risk HPV E7.
PTPN14 is proposed to be a tumor suppressor. Somatic mutations in PTPN14
accumulate in a significant portion of certain types of cancers including basal cell
carcinoma (BCC) (alteration rate: 23%) and gastrointestinal cancers (alteration rate: 5%),
and human germline variants of PTPN14 increase the lifetime risk of basal cell carcinoma
by 4- to 8- fold (129-131). Additionally, PTPN14 is an evolutionarily conserved inhibitor of
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the oncogenes YAP1 and TAZ (described more in the next section) (132-135). However,
the effect of PTPN14 degradation by HPV E7 on keratinocytes and whether this plays a
role in the carcinogenic activity of HPV E7 had yet to be identified (Figure 1.3C).

PTPN14, YAP1/TAZ, and the HIPPO pathway
PTPN14
Lacking a transmembrane domain, PTPN14 is classified as a “non-receptor”
protein tyrosine phosphatase (PTP “N” 14) and belongs in a sub-group of non-receptor
PTPs with one other human gene, PTPN21 (136). PTPN14 and PTPN21 share a protein
architecture characterized by an N-terminal four-point-one, ezrin, radixin, and moesin-like
(FERM) domain and a C-terminal PTP domain connected by a ~550 amino acid linker
region that contains little predicted structure (Figure 1.4A). PTPN14 has been proposed
to participate in several cellular signaling pathways through enzymatic and non-enzymatic
activities (135, 137).

PTPN14 in the HIPPO pathway
The most well-studied activity of PTPN14 is to act as a negative regulator of yes
associated protein 1 (YAP1) and TAZ (also known as WWTR1), the effector proteins and
transcriptional co-regulators of the HIPPO signaling pathway (130, 132-135, 138). The
HIPPO signaling pathway is a kinase cascade that integrates many mechanical signals
such as cell crowding, contact with the basement membrane, and tension in the extra
cellular matrix to control organ size (139, 140). The core components of the kinase
cascade are MST1 and MST2, which phosphorylate and activate LATS1 and LATS2,
which subsequently phosphorylate YAP1/TAZ (Figure 1.4B). Following phosphorylation,
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Figure 1.4. PTPN14 may inhibit YAP1/TAZ in keratinocytes.
(A) Schematic of the domain structure of PTPN14. Relevant protein sequence motifs are identified
below along with their names and reported functions. (B) Schematic of regulation of YAP1 and TAZ
in keratinocytes. YAP1/TAZ are known to be activated by integrin/SRC signaling, which leads to
Y357 phosphorylation on YAP1. YAP1 and TAZ are also inhibited by α-Catenin in stratified
squamous epithelia, and LATS1/2 of the core HIPPO pathway, which phosphorylate S127 on
YAP1. Whether PTPN14 and its protein-protein interactions also inhibit YAP1/TAZ in keratinocytes
was previously not known.
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YAP1/TAZ are rendered inactive by sequestration in the cytoplasm. Therefore, when the
HIPPO kinase cascade is active, YAP1/TAZ are inactivated. Conversely, when HIPPO is
inactive, YAP1/TAZ are activated. YAP1/TAZ lack DNA-binding domains. Thus, nuclear
YAP1/TAZ regulate cellular transcription primarily by binding to TEA domain family
members one through four (TEAD1-4) transcription factors, but YAP1/TAZ transcriptional
activity can also be mediated through other transcription factors including Runx, Smad,
p63, p73, and several others (141-145). Many different signaling molecules feed into the
HIPPO pathway, and inputs into the pathway can be mediated through MST1/2, LATS1/2,
or even YAP1/TAZ directly (139). A role for PTPN14 in the HIPPO signaling pathway was
originally discovered by studying the Drosophila homolog of PTPN14 called Pez (134).
The conserved relationship between PTPN14 and the HIPPO pathway effector YAP1 was
later identified in mammals through immunoprecipitation (IP) of YAP1 from 293T and
MCF10A (breast epithelial cells) followed by mass spectrometry (146) and then confirmed
through IP of PTPN14 followed by mass spectrometry (135). However, prior to the studies
herein, the role of PTPN14 in regulating YAP1/TAZ activity in stratified squamous
epithelial keratinocytes was not appreciated.
PTPN14 overexpression has been shown to promote markers of YAP1/TAZ
inactivation, such as phosphorylation and cytoplasmic localization, and PTPN14
knockdown or knockout has the opposite effect (130, 132-135, 138). There are two main
mechanisms through which PTPN14 is proposed to regulate YAP1/TAZ. Neither of the
proposed mechanisms involve the catalytic activity of PTPN14, but instead involve the
four proline-proline-x-tyrosine (PY) motifs that are present in the PTPN14 linker region.
The first and simplest mechanism occurs through direct interaction between PTPN14 and
YAP1 or TAZ (130, 132, 135). The two PY motifs in the linker 2 (L2) region of PTPN14
have been shown to directly bind to the WW domains of YAP1 (Figure 1.4A). In some
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reports, the L2 PY motifs have been shown to be required for PTPN14 overexpression to
inactivate YAP1 and mediate YAP1 cytoplasmic sequestration (130, 132, 135). The
second mechanism for how PTPN14 inactivates YAP1 is less direct, involving the
interaction between PTPN14 and KIdney and BRAin expressed protein (KIBRA), a
scaffolding protein upstream of the core HIPPO pathway kinase cascade (138, 147, 148).
KIBRA, also known as WWC1, is a WW domain containing protein that is associated with
the apical domain of differentiated epithelial cells (149, 150). KIBRA has been identified
as an interacting partner of PTPN14 through several unbiased proteomic approaches
(135, 138). Subsequently, this interaction was found to be mediated by a pair of “cryptic”
PY motifs only two amino acids apart and located in the linker 1 (L1) region of PTPN14
(147) (Figure 1.4A). Unlike direct binding to YAP1, PTPN14 binding to KIBRA likely
transduces signals through the HIPPO signaling pathway. Indeed, it has been proposed
that PTPN14 and KIBRA may form a ternary complex with LATS1 or modulate RHO kinase
activity, which can lead to HIPPO-dependent inactivation of YAP1/TAZ (138, 147, 148).
The exact contexts in which PTPN14 engages one or the other of these mechanisms to
inactivate YAP1/TAZ remains unclear.

HIPPO-independent activities of PTPN14
Although the activity of PTPN14 in the HIPPO pathway is mediated through
protein-protein interactions and therefore independent of its phosphatase activity, the
active site of PTPN14 has evolutionarily retained the necessary residues for catalysis
(Figure 1.4A). This is unlike many other PTPs (pseudophosphatases) that act exclusively
through protein-protein interactions and have lost their catalytic activity (136). Several
studies have identified targets of the catalytic activity of PTPN14, including p130Cas in
colorectal cancer cells (151), β-catenin in Madin-Darby canine kidney (MDCK) cells (137),
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RIN1 and PRKCD in breast cancer cells (152), and Roquin2 in HEK293T cells (153). The
diverse cellular roles of these targets suggest that in the right contexts, PTPN14 can
regulate many cellular signaling pathways through its phosphatase activity. HPV E7 binds
allosterically to the PTP domain of PTPN14 (128, 154). Whether this leads to alterations
in the phosphatase activity of PTPN14 is unknown.

YAP1/TAZ in stratified squamous epithelia and cancer
YAP1/TAZ regulate the balance between proliferation and differentiation in
stratified squamous epithelia (155-157). Under normal conditions, YAP1/TAZ are most
active in basal keratinocytes (149). Early studies of YAP1/TAZ in these tissues identified
that overexpression of YAP1 in epidermal keratinocytes both in vitro and in vivo leads to
the expansion of basal keratinocytes and repression of keratinocyte differentiation gene
expression (155-157). Accordingly, these studies also identified that knockdown of
YAP1/TAZ in keratinocytes leads to spontaneous differentiation. YAP1/TAZ are well
documented to regulate wound healing in many tissue types including the epidermis (158).
As YAP1 expands the basal layer of keratinocytes and represses differentiation, it has
also been proposed to regulate stemness in the normal stratified squamous epithelia
(159).
When dysregulated, YAP1 and TAZ are oncogenes in many different cell types
(139). Indeed, many studies have shown that expression of hyperactive YAP1 mutants or
dysregulation of YAP1/TAZ through mutation of critical upstream regulators promotes
tumorigenesis in mouse models of mucosal stratified squamous epithelia (160, 161).
Additionally, there is evidence for the importance of YAP1/TAZ and the HIPPO pathway
in HPV-positive cancers. YAP1 nuclear localization and expression correlates with the
clinical stage of HPV infection (161), and HPV-positive tumor xenografts are sensitive to
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the YAP1/TAZ inhibitor verteporfin (162). The HIPPO pathway is frequently mutated in
HPV-negative HNSCC tumors, suggesting that dysregulation of this pathway may be
selected for in these cancers. However, the HIPPO pathway is much less frequently
mutated in HPV-positive cancers of the same anatomical sites, indicating that an HPV
protein may contribute to dysregulating this pathway (77).
Both how YAP1/TAZ activity is regulated and how YAP1/TAZ regulate
transcriptional programs in keratinocytes are complex and incompletely understood.
YAP1/TAZ activity in keratinocytes is sensitive to mechanical signals (163). YAP1/TAZ
are activated by contact with the basement membrane, low cell density, and large cell
size, and inhibited by soft extracellular matrix, high cell density, and small cell size. Two
of the identified molecular mechanisms of YAP1/TAZ regulation in keratinocytes link their
activity to mechanical signals: integrin signaling and Cadherin/α-Catenin signaling (149,
156, 164, 165) (Figure 1.4B). Integrins are membrane proteins and components of focal
adhesions that anchor cells to the basement membrane. Contact between focal adhesions
and the basement membrane leads to actin cytoskeletal polymerization, which inhibits the
HIPPO pathway and prevents inhibition of YAP1/TAZ (149). Activation of focal adhesion
signaling also activates SRC kinases, which phosphorylate YAP1 at Y357 and promote
its activation (149). α-Catenin was identified as a prominent binding partner of YAP1 in
tissue culture keratinocytes and has been shown to be an important upstream inhibitor of
YAP1 activity in these cells both in vitro and in vivo (156). α-Catenin links cadherin to the
cytoskeleton, suggesting this pathway may serve to inhibit YAP1/TAZ activity following
sensing of neighboring cells (166).
Several distinct molecular mechanisms for how YAP1/TAZ regulate transcriptional
programs in keratinocytes have also been identified. ΔNp63α, an isoform of p63, is a
defining transcription factor for undifferentiated, basal keratinocyte identity (167). Several
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studies have shown that YAP1 binds directly to ΔNp63α on chromatin and regulates its
stability, which can account for some of the repression of differentiation by YAP1/TAZ
(145, 164, 168). Activation of NOTCH signaling is a critical component of initiation of
differentiation in keratinocytes (48, 167). YAP1/TAZ promote the transcription of NOTCH
inhibitors by binding nearby enhancers, suggesting that crosstalk between YAP1/TAZ and
NOTCH signaling also contributes to repression of differentiation downstream of
YAP1/TAZ activation (163). Finally, the interaction between YAP1/TAZ and TEAD
transcription factors has recently been shown to repress transcriptional programs
controlled by the transcription factor KLF4 (169). KLF4 is one of the transcription factors
central to promoting keratinocyte differentiation (49). Though distinct, these mechanisms
of
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regulating

the

progenitor/differentiated state of keratinocytes. There is strong evidence that YAP1/TAZ
promote the progenitor cell state in several other epithelia as well (145, 170).

Goal of this work
The work described in this dissertation builds upon the research of the White lab
investigating the cellular factors that interact with the papillomavirus oncoproteins (126,
171). This led to the discovery that HPV E7 binds and degrades the tumor suppressor
PTPN14 (126, 128). It has been appreciated for some time that high-risk HPV E7 likely
has carcinogenic activities that are independent of inactivating RB1 (82, 112, 116-120,
172-175). As PTPN14 is a putative tumor suppressor, we hypothesized that PTPN14
degradation by HPV E7 constitutes part of its carcinogenic activity. The literature
described above highlights the potential importance of PTPN14 degradation to the
carcinogenic activities of HPV E7. The above context also suggests how PTPN14
degradation could play a significant role in the virus replicative cycle. Diverse
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papillomavirus E7 proteins bind to PTPN14 and direct it for proteosome mediated
degradation, indicating a potential selective pressure to conserve this interaction (126,
128). Furthermore, the HPV replicative cycle is intimately linked to the differentiation
program in stratified squamous epithelia (25). In certain reports, PTPN14 inhibits YAP1
and TAZ, which play an important role in regulating keratinocyte differentiation (157, 163,
169). Consequently, the main goals of these studies have been to 1) identify the function
of PTPN14 in keratinocytes, 2) identify a mechanism through which PTPN14 mediates
this function, 3) determine if PTPN14 degradation contributes to E7 carcinogenic activity,
and 4) investigate the implications of PTPN14 degradation for the HPV replicative cycle.
In Chapter 2, I will discuss the initial characterization of the function of PTPN14 in
keratinocytes. We employed poly(A) selection RNA sequencing, an HPV16 E7 mutant that
does not bind UBR4 (or degrade PTPN14), and CRISPR knockout of PTPN14 to
determine that PTPN14 degradation by HPV E7 represses keratinocyte differentiation
(176).
In Chapter 3, I will build upon these findings and discuss how a conserved arginine
residue in the C-terminal domain of HPV E7 mediates PTPN14 binding. Experiments using
an HPV18 E7 with a mutation in this residue confirmed that PTPN14 regulates
differentiation and contributes to the carcinogenic activity of high-risk HPV E7 (177).
In Chapter 4, I will discuss how we employed three-dimensional organotypic
epithelial cultures to show that PTPN14 degradation by HPV E7 leads to activation of
YAP1. We also found that the carcinogenic activity of HPV E7 requires YAP1/TAZ-TEAD
activity. Finally, we showed that YAP1 activation by HPV E7 promotes basal cell identity,
which has significant implications for HPV persistence (178).
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Overall, the goal of this work was to augment our understanding of how PTPN14
degradation by E7 impacts both HPV-mediated carcinogenesis and the HPV replicative
cycle.
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CHAPTER 2 | PTPN14 DEGRADATION BY HIGH-RISK HUMAN PAPILLOMAVIRUS
E7 LIMITS KERATINOCYTE DIFFERENTIATION AND CONTRIBUTES TO HPVMEDIATED ONCOGENESIS

The contents of this chapter have been previously published as:
Hatterschide J, Bohidar AE, Grace M, Nulton TJ, Kim HW, Windle B, Morgan IM, Munger
K, White EA. 2019. PTPN14 degradation by high-risk human papillomavirus E7 limits
keratinocyte differentiation and contributes to HPV-mediated oncogenesis. Proc Natl Acad
Sci U S A 116:7033–7042.
Supplemental tables can be found on the journal’s website.
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transformation of HPV-infected cells by inactivating host cellular proteins. High-risk but not
low-risk HPV E7 target PTPN14 for proteolytic degradation, suggesting that PTPN14
degradation may be related to their oncogenic activity. HPV infects human keratinocytes
but the role of PTPN14 in keratinocytes and the consequences of PTPN14 degradation
are unknown. Using an HPV16 E7 variant that can inactivate retinoblastoma tumor
suppressor (RB1) but cannot degrade PTPN14, we found that high-risk HPV E7-mediated
PTPN14 degradation impairs keratinocyte differentiation. Deletion of PTPN14 from
primary human keratinocytes decreased keratinocyte differentiation gene expression.
Related to oncogenic transformation, both HPV16 E7-mediated PTPN14 degradation and
PTPN14 deletion promoted keratinocyte survival following detachment from a substrate.
PTPN14 degradation contributed to high-risk HPV E6/E7-mediated immortalization of
primary keratinocytes and HPV+ but not HPV− cancers exhibit a gene-expression
signature consistent with PTPN14 inactivation. We find that PTPN14 degradation impairs
keratinocyte differentiation and propose that this contributes to high-risk HPV E7-mediated
oncogenic activity independent of RB1 inactivation.

Significance Statement
Human papillomaviruses (HPV) uncouple proliferation from differentiation to
enable virus replication in epithelial cells. HPV E7 proteins are well established to promote
proliferation by binding to and inactivating retinoblastoma family proteins and other cell
cycle inhibitors. However, mechanisms by which high-risk HPV oncoproteins inhibit
differentiation have not been defined. This paper identifies a mechanism by which highrisk HPV E7 inhibit keratinocyte differentiation. The inhibition of differentiation requires
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degradation of the cellular protein PTPN14 by high-risk HPV E7, and this degradation is
related to the ability of high-risk HPV oncoproteins to immortalize keratinocytes and to
cause cancer.

Introduction
Human papillomaviruses (HPVs) are nonenveloped, double-stranded DNA viruses
that infect and replicate in the stratified squamous epithelium. HPV initially infects
keratinocytes in the basal, proliferative layer of the epithelium, and subsequent steps in
the HPV replicative cycle—including viral genome amplification, encapsidation, and
egress—are dependent on keratinocyte differentiation (65, 179, 180). However, HPV
genome amplification also requires components of the cellular machinery for DNA
replication that are not expressed in differentiating cells. Thus, productive HPV infection
must uncouple proliferation and differentiation in the epithelium. Infection with one of the
13-15 “high-risk” HPVs causes nearly all cervical cancer, some other anogenital cancers,
and an increasing proportion of HPV+ head and neck squamous cell carcinomas (HNSCC)
(181-183). In total, HPV infection causes ~5% of cancers worldwide.
The high-risk HPV E7 oncoprotein is able to immortalize human keratinocytes and
the efficiency of immortalization is increased by high-risk HPV E6 (74, 75, 184). A wellcharacterized activity of many HPV E7 is to bind and inactivate the retinoblastoma tumor
suppressor (RB1) via the LxCxE motif present in HPV E7 conserved region 2 (81, 83,
114). In addition, HPV16 E7 can direct the proteasome-mediated degradation of RB1 (80,
185, 186). RB1 inactivation releases the inhibition of E2F transcription factors (TF), thus
allowing cell cycle progression and acting as a major driver of proliferation. HPV E7 also
promote proliferation by inhibiting the CDK inhibitors p21WAF1/CIP1 and p27KIP1 (186-188). In
addition to promoting proliferation, transcriptional studies indicate that human cells
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harboring high-risk HPV genomes express lower levels of differentiation marker genes
and that both high-risk HPV E6 and E7 likely contribute to this repression (67, 101-103,
189-191). However, a mechanism by which high-risk HPV E6 and E7 inhibit differentiation
has not been defined.
RB1 binding by HPV E7 is necessary but insufficient for immortalization and
transformation, and several observations highlight the need for other contributors to
transformation. First, in multiple assays, the oncogenic activity of high-risk HPV E7 is
disrupted by mutations in regions that do not include the LxCxE motif (41, 82, 107, 117,
118). Second, low-risk HPV E7 bind RB1 but do not have activity in transformation assays
and other HPV E7, such as HPV1 E7, bind RB1 with high affinity but do not transform
(119-121). Finally, bovine papillomavirus (BPV) E7 does not bind to RB1, but in some
assays it is required for BPV-mediated transformation (122-124). The idea that RB1
inactivation is insufficient for transformation is additionally supported by studies in mouse
models of cervical cancer (116, 192). Overall, updates to the model of transformation by
HPV E6 and E7 have been suggested (79) and additional binding partners of HPV E7
have been proposed to mediate transformation independent of RB1 binding (193-195).
However, not all of these interactions are conserved among the high-risk HPV E7.
The E3 ubiquitin ligase UBR4 is a conserved interactor of diverse papillomavirus
E7 (126). UBR4 is required by both HPV16 E7 and BPV E7 for RB1-independent
transformation, but for some years the reason for this requirement was unknown (112,
127). Recently, we discovered that the cellular protein PTPN14 binds to HPV E7 proteins
from diverse HPV genotypes and that high-risk HPV E7 use UBR4 to direct PTPN14 for
proteasome-mediated degradation. Although low-risk HPV E7 also binds UBR4, only highrisk HPV E7 mediates PTPN14 degradation, and HPV E7 binding to PTPN14 and to UBR4
does not require interaction with RB1 (126, 128).
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PTPN14 is a non-receptor protein tyrosine phosphatase that is evolutionarily
conserved as a regulator of developmental signaling from Drosophila to humans; however,
phenotypes associated with PTPN14 loss vary (134, 196-199). Hereditary variations in
human PTPN14 are associated with developmental disorders, including dysregulated
angiogenesis, improper lymphatic development, and improper choanal development (196,
197). Mutations in human cancer have implicated PTPN14 as a putative tumor suppressor
(129, 148, 151, 152). PTPN14 is mutated in cancers, such as colorectal cancer and basal
cell carcinoma, and in both cancer types mutations occur along the length of the gene
(129, 200). Several potential substrates for dephosphorylation by PTPN14 are related to
cell growth control (137, 151, 152). PTPN14 also has phosphatase-independent activities
such as the ability to regulate Hippo signaling through direct interaction with YAP1 or with
its upstream regulators LATS1/2 (132, 133, 135, 148). These interactions are mediated
through central PPxY motifs in PTPN14.
Based upon the observations that the ability of HPV E7 to degrade PTPN14
correlates with HPV E7 oncogenic activity, that the regions of high-risk HPV E7 required
for PTPN14 degradation are the same as those that confer RB1-independent transforming
activity, and that PTPN14 is a putative tumor suppressor, we hypothesized that PTPN14
degradation could be required for high-risk HPV E7-mediated oncogenic transformation.
The biological activities of PTPN14 in keratinocytes have not been studied, and the
molecular consequences of PTPN14 degradation by high-risk HPV E7 have not been
defined. Here we report that PTPN14 loss impaired the differentiation program in human
keratinocytes and that HPV16 E7 could inhibit the expression of differentiation marker
genes in response to a stimulus. This inhibition was dependent upon HPV16 E7’s ability
to degrade PTPN14 and was retained in the absence of RB1 binding. Moreover, the ability
of HPV16 E7 to degrade PTPN14 contributed to the immortalization of primary human
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keratinocytes by HPV16 E6 and E7. Repression of differentiation is a potentially oncogenic
event, and we found that repression of keratinocyte differentiation describes the major
gene-expression differences between HPV+ and HPV- HNSCC. Taken together, our
results suggest that high-risk HPV E7-mediated PTPN14 degradation impairs keratinocyte
differentiation. This is an RB1-independent, and potentially carcinogenic, activity of highrisk HPV E7.

Results
The HPV16 E7 E10K variant is impaired in PTPN14 degradation but binds RB1 and
promotes E2F target gene expression.
PTPN14 degradation by high-risk HPV E7 requires the E3 ubiquitin ligase UBR4,
which interacts with the N-terminus of HPV E7. PTPN14 binding maps broadly to the HPV
E7 C-terminus (Figure 2.1A). The recent identification of HPV16 E7 variants from over
5,000 patient samples (76) prompted us to test whether an N-terminal variant might be
impaired in the ability to degrade PTPN14. One variant, HPV16 E7 E10K (glutamic acid
to lysine change at amino acid 10), is altered in the region that is required for binding to
UBR4 (112, 128). To assess the biological activities of this HPV16 E7 variant, we used
hTert-immortalized human foreskin keratinocytes (N/Tert-1) (201) to establish cell lines
that stably express Flag and HA epitope-tagged versions of the prototypical HPV16 E7
(WT), the HPV16 E7 E10K variant, HPV16 E7 Δ21-24, or an empty vector control. The
∆21-24 deletion eliminates the LxCxE motif that is required for E7 to bind to RB1 (83).
HPV16 E7 cells exhibited reduced PTPN14 protein levels and binding to RB1 was not
required for this effect (Figure 2.1B). However, HPV16 E7 E10K did not promote the
reduction in steady-state PTPN14 protein levels. UBR4 did not coimmunoprecipitate with
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Figure 2.1. The HPV16 E10K variant is impaired in PTPN14 degradation but binds RB1 and
promotes the expression of E2F-regulated genes.
(A) Schematic of protein complexes including HPV E7/RB1 and HPV E7/PTPN14/UBR4. (B)
N/Tert-1 keratinocytes were transduced with control and HPV16 E7 retroviruses. Total cell lysates
were analyzed by SDS/PAGE/Western blotting and probed with antibodies to PTPN14, RB1, HA,
and actin (Upper). HPV16 E7-FlagHA was immunoprecipitated with anti-HA from N/Tert lysates
and coimmunoprecipitation of UBR4 and RB1 was assessed by SDS/PAGE/Western blotting
(Lower). (C) qRT-PCR for E2F-regulated genes in primary HFK transduced with control and HPV16
E7 retroviruses. Bar graphs display the mean ± SD of two (16E7 Δ21-24) or three (empty vector,
16E7 WT, and 16E7 E10K) independent experiments. Statistical significance was determined by
ANOVA followed by multiple t tests with the Holm-Šídák family-wise error rate correction (** = p <
0.01; *** = p < 0.001; **** = p < 0.0001). (D) NTert-1 keratinocytes expressing HPV16 E7 WT were
treated with control siRNAs or siRNAs targeting UBR4. Protein levels were assessed by Western
blot.
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the HPV16 E7 E10K variant (Figure 2.1B), suggesting that this variant cannot target
PTPN14 for degradation because it is deficient in binding to the required E3 ubiquitin
ligase.
HPV16 E7 E10K was comparable to HPV16 E7 WT in its ability to bind RB1 (Figure
2.1B). In primary human foreskin keratinocytes (HFK) stably transduced with the same
retroviral vectors, both HPV16 E7 WT and HPV16 E7 E10K could induce the expression
of E2F target genes CCNE1 and MCM2 (Figure 2.1C). This supported the notion that
UBR4 binding and PTPN14 degradation by HPV16 E7 is independent of RB1 binding.
In all stable keratinocyte cell lines we have tested, the steady-state levels of
HPV16 E7 E10K protein are lower than those of prototypical HPV16 E7 (Figure 2.1B).
Depletion of UBR4 was previously observed to reduce the steady-state level of HPV18 E7
(128), leading us to speculate that the ability to bind UBR4 is a determinant of HPV E7
protein levels. To test whether HPV16 E7 is expressed at a lower level when it cannot bind
to UBR4, we depleted UBR4 transcripts from N/Tert-HPV16 E7 cells using small
interfering RNA (siRNA). Indeed, siRNA knockdown of UBR4 resulted in reduced
expression of HPV16 E7 WT (Figure 2.1D). This suggested that the inability of HPV16 E7
E10K to bind to UBR4 could itself contribute to the reduced expression of HPV16 E7 E10K.
In subsequent experiments, we used HPV16 E7 E10K and HPV16 E7 ∆21-24
together to separate RB1-dependent and RB1-independent activities of HPV16 E7. We
emphasize that the HPV16 E7 E10K variant retained the ability to bind RB1 and activate
E2F-dependent promoters and that HPV16 E7 ∆21-24 has lost RB1-dependent activities
(Figure 2.1B, C). It is possible that even though the reduced levels of HPV16 E7 E10K did
not impact the RB1-dependent activity that we assessed, they could impact other activities
of HPV16 E7 related to or independent of PTPN14 degradation.
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HPV16 E7 degrades PTPN14 to inhibit keratinocyte differentiation.
To determine whether HPV16 E7 has effects on cellular gene expression that are
dependent on its ability to degrade PTPN14, we performed an unbiased analysis of gene
expression in keratinocytes expressing HPV16 E7 variants. Duplicate or triplicate primary
HFK cell populations were established by transduction with retroviral vectors encoding
HPV16 E7 WT, HPV16 E7 E10K, and HPV16 E7 Δ21-24 and selected with puromycin.
Total RNA was isolated from independent cell populations, then polyA-selected RNA was
subjected to RNA sequencing (RNA-seq). As predicted by our initial validation of the E10K
variant, HPV16 E7 E10K behaved like HPV16 E7 WT with respect to the up-regulation of
DNA replication genes and had a comparable effect on genes related to RB1 binding
(Supplemental Table 1 and Supplemental Figure 2.1).
Next, we assessed the differences between HPV16 E7 WT and HPV16 E7 E10K.
Seventy-five genes were differentially regulated in HPV16 E7 E10K cells compared with
HPV16 E7 WT cells with fold-change ≥1.5 and adjusted p-value ≤0.05. Approximately half
of these differentially regulated genes were repressed more by HPV16 E7 WT than by
HPV16 E7 E10K. Gene ontology (GO) enrichment analysis showed that the genes
repressed by HPV16 E7, dependent on its ability to degrade PTPN14, were described by
developmental GO terms that are related to the keratinocyte differentiation program
(Figure 2.2A). These included epithelial cell differentiation, cornification, keratinocyte
differentiation, epidermis development, epidermal cell differentiation, and keratinization.
Many of the individual genes that were repressed by HPV16 E7 but not by HPV16 E7
E10K are differentiation markers (Figure 2.2B, y axis). In contrast, genes that were
activated by HPV16 E7, dependent on its ability to degrade PTPN14, were not significantly
enriched for any GO terms (Supplemental Figure 2.2A).
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To test whether repression of keratinocyte differentiation was related to RB1
inactivation, we used HPV16 E7 Δ21-24 to assess the transcriptional impact of E7 in the
absence of RB1 binding. As expected, cell cycle and DNA replication-related GO
categories were the most significantly enriched categories among genes differentially
regulated by HPV16 E7 WT versus HPV16 E7 Δ21-24 (Figure 2.2C, Upper). In contrast,
comparing HPV16 E7 Δ21-24 to empty vector control identified the genes that are
repressed by HPV16 E7 independent of RB1 binding (Figure 2.2C, Lower). GO analysis
of these genes identified the same keratinocyte differentiation-related gene sets that were
seen in our analysis of PTPN14 degradation-dependent effects of HPV16 E7.
Furthermore, individual genes repressed by HPV16 E7 Δ21-24 relative to control
(Supplemental Figure 2.2C, y axis) are similar to those repressed by HPV16 E7 WT
dependent on its ability to degrade PTPN14. We concluded that repression of keratinocyte
differentiation through the degradation of PTPN14 was independent of RB1 binding. In the
absence of RB1 binding, HPV16 E7 acted mainly as a repressor but retained a modest
ability to promote gene expression (Supplemental Figure 2.2B).
To better understand the impacts of PTPN14 degradation on gene expression, we
examined individual genes that were significantly lower in HPV16 E7 WT cells than in
HPV16 E7 E10K cells. Many of the genes that are repressed by HPV16 E7 WT and HPV16
E7 Δ21-24, but not by HPV16 E7 E10K, are described by epidermis development and
more specific GO terms (Supplemental Figure 2.2D, Supplemental Table 2). Although
certain genes were not repressed by either HPV16 E7 E10K or HPV16 E7 Δ21-24, these
genes were largely related to other biological processes.
To validate the results obtained from RNA-seq, we used qRT-PCR to confirm the
altered expression of several genes related to keratinocyte differentiation in our cell lines.
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Figure 2.2. HPV16 E7-mediated degradation of PTPN14 inhibits keratinocyte differentiation.
Primary HFK were transduced with retroviruses encoding HPV16 E7, HPV16 E7 E10K, HPV16 E7
Δ21-24, or an empty vector control. PolyA selected RNA was analyzed by RNA-seq. (A) GO
enrichment analysis of genes with ≥1.5-fold lower expression in HPV16 E7 WT cells relative to
HPV16 E7 E10K cells and p ≤ 0.05. (B) Scatter plot of log2(fold-change) in gene expression
compares the gene expression changes of HPV16 E7 E10K relative to HPV16 E7 WT to those of
PTPN14 KO relative to control. Colors denote whether genes are altered by PTPN14 KO only
(blue), by HPV16 E7 WT more than HPV16 E7 E10K only (light red), or both (dark red). (C) Same
analysis as (A) of (C, Upper) genes with ≥1.5-fold higher expression in HPV16 E7 WT than HPV16
E7 Δ21-24 cells, and (C, Lower) genes ≥1.5-fold lower expression in HPV16 E7 Δ21-24 cells
relative to empty vector control cells and p ≤ 0.05. (D) Impacts of HPV16 E7 WT, HPV16 E7 E10K,
and HPV16 E7 Δ21-24 on gene expression in primary HFK cells were validated by qRT-PCR
targeting markers of differentiation. Bar graphs display the mean ± SD of two (16E7 Δ21-24) or
three (empty vector, 16E7 WT, and 16E7 E10K) independent experiments. Statistical significance
was determined by ANOVA followed by multiple t tests with the Holm-Šídák family-wise error rate
correction (* = p < 0.05; ** = p < 0.01; *** = p < 0.001; ns, not significant).
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Markers of keratinocyte differentiation, such as keratin 1 (KRT1), keratin 4 (KRT4), keratin
10 (KRT10), keratin 16 (KRT16), involucrin (IVL), and desmocollin 1 (DSC1) were
repressed by HPV16 E7 by 1.5- to 12-fold (Figure 2.2D). KRT1, KRT4, KRT10, and KRT16
are cytokeratins associated with the suprabasal layers of differentiating keratinocytes. IVL
constitutes a major component of the cornified envelope and is expressed at high levels
in the upper layers of the epidermis. DSC1 is a component of desmosome complexes
associated with keratinization and is expressed at higher levels in the upper spinous layer
and granular layer of the epidermis. Comparison of both HPV16 E7 WT and Δ21-24 to the
HPV16 E7 E10K variant indicated that the ability of HPV16 E7 to repress expression of
these genes was at least partially dependent on its ability to target PTPN14 for
degradation, but was not dependent on RB1 binding.

The ability of HPV E7 to degrade PTPN14 correlates with its ability to inhibit the cellular
response to a stimulus of differentiation.
Next, we wanted to determine whether the ability of HPV E7 to alter differentiationrelated gene expression in unstimulated cells correlated with changes following a
differentiation stimulus. In vivo, detachment from the basement membrane stimulates
keratinocyte differentiation, an effect that can be mimicked by growth of cultured cells in
suspension (202-204). HPV E7 has been previously shown to protect against cell death
following detachment in a UBR4-dependent manner (112, 205). Consequently, we first
chose to induce differentiation using detachment as a stimulus. In these experiments we
used N/Tert-1 cells engineered to stably express HPV16 E7 WT, HPV16 E7 E10K, HPV6
E7, or an empty vector control. HPV6 is a low-risk HPV encoding an E7 that, like HPV16
E7 E10K, has an intact C-terminal PTPN14 binding domain but does not direct PTPN14
for proteasome-mediated degradation.
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N/Tert-1 cells were harvested directly from adherent culture or subjected to growth
in suspension for 12 h to induce differentiation. KRT16 and IVL RNAs were analyzed by
qRT-PCR and were induced by detachment in all of the cell lines tested. Detached empty
vector cells expressed 7- to 30-fold more of these transcripts compared with adherent
cells, and each version of E7 limited the induction of KRT16 and IVL. KRT16 and IVL
expression was 2.3- or 3.4-fold lower in N/Tert-HPV16 E7 WT cells compared with the
empty vector control and repression of IVL was statistically significant (Figure 2.3A). The
statistical significance of some other comparisons was limited by the fact that there was a
wide range of induction of the differentiation markers following detachment. However, the
trend was highly reproducible: in three replicate experiments HPV16 E7 WT always
repressed differentiation marker gene expression more than HPV16 E7 E10K and HPV6
E7. This result indicated that PTPN14 degradation is required for maximal repression of
detachment-induced differentiation by HPV16 E7.
Several explanations could account for the observation that HPV E7 that does not
degrade PTPN14 still partially represses differentiation. Each of the HPV E7 tested here
bind and inactivate RB1 and it is possible that some inhibition of differentiation is due to
the increased proliferation resulting from RB1 inactivation. Another, not mutually exclusive
explanation could be that PTPN14 binding alone is enough to result in some inhibition of
differentiation. Our data support this idea, because HPV16 E7 E10K and HPV6 E7 both
contain the C-terminal domain that binds PTPN14 and they repressed differentiation to
similar levels.
In addition to stimulating differentiation, growth in suspension activates the Hippo
signaling pathway (163, 206) which represses the transcription of the well-characterized
YAP/TEAD targets CTGF and CYR61. PTPN14 knockdown in MCF10A cells has been
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Figure 2.3. The ability of HPV E7 to degrade PTPN14 correlates with its ability to inhibit
differentiation and promote survival upon detachment.
N/Tert-1 stably transduced with retroviruses encoding HPV16 E7, HPV16 E7 E10K, HPV6 E7, or
an empty vector control were subjected to growth in suspension for 12 h and assayed for markers
of differentiation, YAP/TEAD targets, and survival after detachment. (A and B) Gene-expression
changes induced by suspension were assayed by qRT-PCR targeting markers of differentiation:
KRT16 and IVL (A), and YAP/TEAD targets: CTGF and CYR61 (B). mRNA expression was
calculated relative to GAPDH. Bar graphs display the mean ± SD of three independent
experiments. (C) Survival after detachment was assayed by re-plating 1,000 cells from suspension
and measuring the surface area covered after 5 d of growth by Crystal violet staining. Three
independent experiments are displayed along with mean ± SD. Statistical significance was
determined by ANOVA followed by multiple t tests with the Holm-Šídák family-wise error rate
correction (*** = p < 0.001; **** = p < 0.0001)
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shown to induce the transcription of CTGF and CYR61 (132). Since PTPN14 has been
characterized as a negative regulator of YAP1 and shown to regulate CTGF and CYR61
in other cell types (132, 133, 135, 148), we measured these transcripts to determine
whether HPV E7 differentially impacts their expression. Compared with vector controls,
none of the HPV E7 cell lines exhibited altered expression of these YAP1/TEAD targets
before or after detachment (Figure 2.3B).
To further assess cell viability in the detachment experiment, 1,000 cells were
taken from suspension culture, replated in coated tissue culture plates, and allowed to
grow for 5 d. HPV16 E7 protected against cell death following detachment in a manner
that was dependent on the ability of E7 to target PTPN14 for degradation (Figure 2.3C).
This is consistent with previous reports demonstrating that HPV16 E7 and BPV E7 require
UBR4 to protect cells against cell death triggered following detachment from a substrate
(127, 205).
Finally, we used a second stimulus of differentiation to confirm that HPV16 E7
inhibits differentiation dependent on PTPN14 degradation. Treatment of keratinocytes with
high calcium induces markers of epithelial differentiation. We treated N/Tert-HPV E7 cells
with 1.5 mM calcium for 48 h and measured KRT10 expression by qRT-PCR. In
undifferentiated cells, HPV16 E7 WT repressed KRT10 expression to a greater degree
than either HPV16 E7 E10K or HPV6 E7 (Figure 2.4). Upon calcium treatment, the
variability in KRT10 induction was high, but in several independent experiments, HPV16
E7 was maximally able to repress KRT10 in differentiated cells. HPV6 E7 was least able
to repress KRT10 and HPV16 E7 E10K exhibited an intermediate effect. Taken together,
these data further support the idea that high-risk HPV E7 inhibits keratinocyte
differentiation dependent on PTPN14 degradation.
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Figure 2.4. The ability of HPV E7 to degrade PTPN14 correlates with its ability to inhibit
differentiation induced by Ca2+.
N/Tert-1 stably transduced with retroviruses encoding HPV16 E7, HPV16 E7 E10K, HPV6 E7, or
an empty vector control were treated with 1.5 mM Ca2+ and assayed for KRT10 as a marker of
differentiation. Bar graph displays the mean ± SD of four independent experiments. Statistical
significance was determined by ANOVA followed by multiple t tests with the Holm-Šídák familywise error rate correction (*** = p < 0.001; **** = p < 0.0001).
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PTPN14 knockout limits differentiation gene expression in primary human keratinocytes.
To test what cellular processes are affected when PTPN14 levels are reduced in
human keratinocytes, we performed an unbiased analysis of gene expression in the
presence and absence of PTPN14. Primary HFK were transduced with lentiviral vectors
encoding SpCas9 plus a single-guide RNA (sgRNA) targeting PTPN14 (sgPTPN14-3) or
a nontargeting control sgRNA (sgNT-2), then selected with puromycin to generate control
(HFK-control) and PTPN14-deleted [HFK-PTPN14 knockout (KO)] cell lines (Figure 2.5A).
It should be noted that PTPN14 KO cells exhibit a nearly complete loss of PTPN14 protein.
In contrast, the ability of high-risk HPV E7 to degrade PTPN14 is conserved, but can result
in residual PTPN14 protein levels that vary by HPV genotype (128). Total RNA was
isolated from two or three independent isolates of HFK-control and HFK-PTPN14 KO, then
polyA-selected RNA was subjected to RNA-seq. In cells that did not express PTPN14,
141 genes were differentially regulated with fold-change ≥1.5 and adjusted p-value ≤0.05.
Of these, 29 genes were up-regulated and 112 were down-regulated in the absence of
PTPN14 (Figure 2.5B and Supplemental Table 3). Thus, PTPN14 appeared to act largely
to promote, rather than to repress, gene expression. As in the analysis of the HPV16 E7
variants, keratinocyte differentiation-related GO terms were downregulated in PTPN14 KO
cells (Figure 2.5C, Figure 2.2A and C). More than half of the down-regulated genes were
in epidermis development-related or other developmental process-related GO categories
(Figure 2.5D). There was not a corresponding enrichment in differentiation-related GO
terms among the up-regulated genes; however, one GO category, inflammatory response,
was significantly enriched in this analysis (Supplemental Figure 2.3).
We hypothesized that individual genes might be similarly regulated by PTPN14
KO and HPV E7-mediated PTPN14 degradation. Indeed, the genes that were both down-
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Figure 2.5. PTPN14 depletion impairs differentiation-related gene expression in primary
human keratinocytes.
Primary HFK were transduced with LentiCRISPRv2 lentiviral vectors encoding SpCas9 and
nontargeting or PTPN14-directed sgRNAs and analyzed for changes in gene expression. (A) Cell
lysates were subjected to SDS/PAGE/Western analysis and probed with anti-PTPN14 and antiactin antibodies. (B) PolyA selected RNA was analyzed by RNA-seq. Genes differentially
expressed by ≥1.5-fold with p ≤ 0.05 are displayed in the heat map. Color coding on the right side
denotes whether genes are related to epidermis development (blue), other developmental
processes (green), or neither (gray). (C) GO enrichment analysis of genes down-regulated in HFK-
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PTPN14 KO compared with HFK-control. (D) Volcano plot of gene-expression changes in HFKcontrol vs. HFK-PTPN14 KO. Dots colored by GO terms. Pie chart displays the fraction of genes
downregulated in the absence of PTPN14 that fall into enriched GO Terms. (E-G) Transcript
abundance for selected genes in HFK-control and HFK-PTPN14 KO was measured by qRT-PCR
detecting differentiation markers (E), differentiation promoting TFs (F), and YAP/TEAD targets (G).
Bar graphs display the mean ± SD of two or three independent experiments. Statistical significance
was determined by Welch’s t tests (* = p < 0.05; ** = p < 0.01).

regulated by PTPN14 loss and down-regulated by HPV16 E7 WT in a PTPN14
degradation-dependent manner are involved in keratinocyte differentiation (Figure 2.2B).
Furthermore, gene-expression changes induced by HPV16 E7 Δ21-24 are positively
correlated with those resulting from PTPN14 KO (Supplemental Figure 2.2C). Taken
together, gene-expression analysis of HFK-PTPN14 KO and cells expressing HPV16 E7
variants is consistent with degradation of PTPN14 by HPV16 E7 acting to inhibit
keratinocyte differentiation. Our data suggest that PTPN14 degradation mediates the
predominant RB-independent effect of HPV16 E7 on gene expression.
We selected a subset of genes for validation by qRT-PCR. In agreement with the
RNA-seq results, markers of keratinocyte differentiation, such as KRT1, KRT4, KRT10,
KRT16, IVL, and DSC1, were expressed at 3- to 12-fold lower levels in the absence of
PTPN14 (Figure 2.5E). TFs such as MAF, MAFB, and GRLH3 that are transcriptionally
regulated during progression of the keratinocyte differentiation program (49, 207-209)
exhibited lower expression in the absence of PTPN14 (Figure 2.5F). Unlike the published
effects in other cell types, we found that PTPN14 loss did not impact the expression of the
well-characterized YAP/TEAD targets CTGF and CYR61 (Figure 2.5G). These data
support the idea that PTPN14 loss impairs the regulation of keratinocyte differentiation but
does not affect expression of canonical Hippo-regulated genes in primary HFK. They also
suggest that PTPN14 KO itself phenocopied much of the gene repression that was
enabled by HPV16 E7 ∆21-24 (does not bind RB1). Even though the expression of the
HPV16 E7 E10K variant protein was low, taken together these data support the hypothesis
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that PTPN14 loss represses keratinocyte differentiation and that PTPN14 inactivation is a
major RB1-independent activity of HPV16 E7.

PTPN14 contributes to the upregulation of differentiation markers upon detachment.
Having determined that PTPN14 loss reduces the basal expression of keratinocyte
differentiation-related genes, we next tested whether PTPN14 loss alters the cellular
response to a differentiation stimulus. We used CRISPR-Cas9 gene editing in N/Tert-1
cells to engineer control (N/Tert-mock) or PTPN14-deleted (N/Tert-PTPN14 KO) pooled
stable cell lines. Again, we stimulated these cells to differentiate through growth in low
adherence plates for 12 h. Consistent with the effect in primary cells, PTPN14 KO reduced
the expression of KRT16 and IVL in adherent cells. We further found that PTPN14 loss
also impaired the expression of KRT16 and IVL upon the induction of differentiation
(Figure 2.6A), mirroring the results observed in our N/Tert-E7 cells. As we observed in the
N/Tert-E7 cells as well as the primary HFK-PTPN14 KO cells, N/Tert-PTPN14 KO cells
did not express significantly more CTGF or CYR61 than mock controls in either the
adherent condition or following growth in suspension (Figure 2.6B).
Finally, we used cell growth after replating as a measure of viability after
detachment. The N/Tert-PTPN14 KO cells exhibited improved survival and colony
formation after detachment compared with control cells (Figure 2.6C). This is consistent
with the result that HPV E7 expression improved survival after suspension in a PTPN14
degradation-dependent manner (Figure 2.3C) and indicates that loss of PTPN14 is
sufficient to improve survival of keratinocytes after detachment.
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Figure 2.6. PTPN14 loss reduces the expression of differentiation markers after detachment.
Adherent N/Tert-mock and -PTPN14 KO cells were detached by trypsinization and replated in
ultralow adherence plates before harvesting 12 h postdetachment, then assayed for markers of
differentiation, YAP/TEAD targets, and survival after detachment. (A and B) Gene-expression
changes induced by suspension were assayed by qRT-PCR targeting markers of differentiation:
KRT16 and IVL (A), and YAP/TEAD targets: CTGF and CYR61 (B). mRNA expression was
calculated relative to GAPDH. Bar graphs display the mean ± SD of three independent
experiments. (C) Survival after detachment was assessed by replating 1,000 cells from suspension,
allowing cells to grow for 5 d, and measuring total viable cell area by Crystal violet staining. Three
independent experiments are displayed along with mean ± SD. Statistical significance was
determined by ANOVA followed by multiple t tests with the Holm-Šídák family-wise error rate
correction (* = p < 0.05; ** = p < 0.01; *** = p < 0.001).
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PTPN14 degradation contributes to high-risk HPV E6/E7 immortalization of primary
human keratinocytes.
Coexpression of HPV16 E6 and E7 can efficiently immortalize primary
keratinocytes in cell culture. To determine whether PTPN14 degradation is required for
immortalization by HPV16 oncoproteins, primary HFK were transduced with pairs of HPV
E6/E7-encoding retroviruses, selected with puromycin and blasticidin, and monitored for
cell growth over the next 17 passages, equivalent to 75 d for WT HPV16 E6/E7 cells
(Figure 2.7).
Primary HFK transduced with HPV6 E6/E7 or with empty vector controls rapidly
senesced, while cells transduced with HPV16 E6/E7 were immortalized in three of three
replicate experiments. The cells transduced with HPV16 E6/E7 ∆21-24 retroviruses were
severely growth-impaired and were not immortalized but exhibited a small degree of
lifespan extension, perhaps due to sporadic epigenetic inactivation of RB1. Cells
transduced with HPV16 E6/E7 E10K-expressing vectors retained some proliferative
capacity, but their growth was reproducibly impaired compared with that of HPV16 E6/E7
WT cells. We hypothesize that these cells are not fully immortalized and that both RB1
inactivation and PTPN14 degradation are required for immortalization of primary HFK by
HPV E6 and E7.

Keratinocyte differentiation gene expression describes the major differences between
HPV+ and HPV- HNSCC.
The changes in differentiation-related gene expression in HPV E7-expressing cell
lines appeared to be dependent on the ability of HPV E7 to degrade PTPN14 and to reflect
the same changes that result from PTPN14 loss in primary HFK. The ability of HPV E7 to
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Figure 2.7. PTPN14 degradation contributes to high-risk HPV E6/E7 immortalization of
primary human keratinocytes.
Primary HFK cells were transduced with pairs of retroviruses encoding various HPV E6 and E7 and
passaged for up to 75 d. (A) Growth curves from representative immortalization experiment.
Population doublings were calculated based upon the number of cells harvested at each passage.
Statistical significance was determined from three independent experiments by repeated measures
two-way ANOVA. Displayed p values represent the column (cell line) factor (* = p < 0.05; ** = p <
0.01). (B) Bar chart shows mean ± SD of selected passages from growth curves in A.
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degrade PTPN14 also correlates with its ability to immortalize primary HFK. We wished to
determine whether E7- or PTPN14-dependent changes in differentiation-related gene
expression are reflected in HPV-associated cancers. Using RNA-seq data from the
Cancer Genome Atlas (TCGA), we examined gene expression-signatures in 508 HNSCC
samples, 60 of which are HPV+ and 448 HPV- (210-212). Genes that were differentially
expressed by threefold or more in HPV+ vs. HPV- samples were selected for further
analysis.
Strikingly, the most enriched GO terms among genes down-regulated in HPV+
cancers relative to HPV- cancers were epidermis development, keratinocyte
differentiation, and epidermal cell differentiation (Figure 2.8). As in the PTPN14 KO cells
and in the presence of HPV16 E7, downregulated genes reflected a keratinocyte
differentiation signature. Furthermore, many of the other highly enriched GO terms were
related to more general developmental processes. In total, epidermis development and
other developmental processes accounted for about one-third of the differentially
regulated genes in HPV+ vs. HPV- HNSCC. In contrast, GO enrichment identified no clear
gene sets enriched among genes up-regulated in HPV+ compared with HPV- HNSCC
(Supplemental Figure 2.4). The downregulation of differentiation-related genes in HPV+
relative to HPV- cancers is consistent with the changes in gene expression induced by the
high-risk HPV E7-mediated degradation of PTPN14.

Discussion
Our previous finding that PTPN14 is targeted for degradation by high-risk HPV E7
but not by low-risk HPV E7 suggested that PTPN14 loss might be related to the biology of
the high-risk HPV (128). PTPN14 is a candidate tumor suppressor based on the
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Figure 2.8. Keratinocyte differentiation gene signature describes the major differences
between HPV+ and HPV- HNSCC.
Data from HNSCC samples on the TCGA database were determined to be HPV+ or HPV- and
analyzed for differences in gene expression. Bar chart portrays the ranked –log10(p values) of
enriched GO terms among genes down-regulated in HPV+ HNSCC. Pie chart displays fraction of
total down-regulated genes that fall into selected GO categories.
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observation that it is mutated in some cancers (129, 130, 200, 213-215). The targeted
degradation of PTPN14 by high-risk HPV E7 requires the E3 ubiquitin ligase UBR4 and
the interaction of UBR4 with papillomavirus E7 is required for E7 to transform cells (112,
127). Thus, PTPN14 degradation could be analogous to the well-established ability of
high-risk HPV E6 but not low-risk HPV E6 to target p53 for proteasome-mediated
degradation using the E3 ubiquitin ligase UBE3A (86, 87). However, neither our previous
studies nor those from another group provided insight regarding the downstream effects
of HPV E7-mediated PTPN14 degradation in human keratinocytes (128, 216).
PTPN14 has been implicated as a negative regulator of YAP1, a transcriptional
coactivator that is regulated by the Hippo signaling pathway (132, 135, 217). An appealing
hypothesis was that HPV E7-mediated PTPN14 degradation would activate YAP1 and
promote the expression of proproliferative YAP target genes, such as CTGF and CYR61.
However, we have not identified any cell type in which high-risk HPV E7 expression
causes an increase in CTGF or CYR61 RNA. In addition, we found that depletion or KO
of PTPN14 in human keratinocytes did not cause CTGF or CYR61 up-regulation (Figures
2.5 and 2.6). However, our cell-detachment experiments suggested that these genes are
indeed regulated by Hippo signaling in keratinocytes (Figures 2.3 and 2.6). Thus, our
results suggest that PTPN14 may not regulate canonical Hippo-YAP signaling in
keratinocytes.
In the absence of support for this initial hypothesis, we took an unbiased approach
to determine the effect of high-risk HPV E7-mediated PTPN14 degradation in
keratinocytes. By using an HPV16 E7 variant that cannot degrade PTPN14 (Figures 2.1
and 2.2) and by directly testing the effect of PTPN14 KO in primary HFK (Figure 2.5), we
determined that PTPN14 loss results in a down-regulation of several markers of epidermal
cell differentiation. Consistent with this idea, PTPN14 appears to be a target of regulation
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by p53 in mouse cells but is likely a p63 target in human cells (130, 218-220). p63 is a
master regulator of epidermal development (221). The link between PTPN14 and
differentiation directly connected PTPN14 degradation to HPV biology.
To further test how high-risk HPV E7-mediated PTPN14 degradation affects
processes related to epidermal cell differentiation, we used a keratinocyte detachment
and replating assay (Figure 2.3). Our studies indicated that high-risk HPV E7 inhibit the
expression of differentiation markers following cell detachment in a PTPN14 degradationdependent manner. The same inhibition of differentiation markers occurred in detached
PTPN14 KO keratinocytes (Figure 2.6). Anoikis is cell death triggered by detachment from
a substrate, and the ability to survive anoikis and proliferate in the absence of contact with
the basement membrane is a hallmark of cancer cells. The HPV E7 proteins that inhibited
differentiation marker gene expression promoted cell survival following detachment and
this correlated with the ability to degrade PTPN14 (Figure 2.3).
In support of the notion that HPV E7-mediated PTPN14 degradation contributes to
oncogenic transformation, our subsequent experiments indicated that PTPN14
degradation by high-risk HPV contributes to keratinocyte immortalization. Primary
keratinocytes were fully immortalized by HPV16 E6/E7 but not by HPV16 E6/E7 E10K
(Figure 2.7). In transcriptional profiles of human head and neck cancer samples, changes
in gene expression consistent with PTPN14 loss were reflected in HPV+ but not HPVcancers (Figure 2.8). Strikingly, we found that the GO terms related to keratinocyte
differentiation and epidermis development described both the PTPN14-dependent
differential gene expression in primary cells and the most significant differences between
HPV+ and HPV- head and neck carcinomas. We also observed that in previously
published data these same GO terms were downregulated by the co-expression of HPV16
E6 and E7 in primary HFKs (222). These findings are consistent with the effect of PTPN14
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loss being maintained throughout HPV-mediated carcinogenesis. Notably, the HPV16 E7
E10K variant that cannot bind UBR4 or degrade PTPN14 (Figure 2.1) was identified in a
CIN3 lesion (76). We hypothesize that other patient-specific genetic or epigenetic changes
may have compensated for the inability of HPV16 E7 to degrade PTPN14 in this lesion;
however, only viral sequence information was collected from the patient samples in this
study. Alternatively, this mutation may have impaired the progression of this lesion from
CIN3 to a malignant cancer.
Some previous studies suggested that differentiation inhibition by HPV E7 could
be RB/E2F-dependent. E2F TFs have been shown to limit keratinocyte differentiation
(223) and both the RB1-binding domain and the N-terminus of HPV16 E7 contributed to
HPV-mediated differentiation inhibition in one study (67). However, our unbiased
transcriptional analysis clearly showed that much of the HPV16 E7-mediated repression
of differentiation is independent of RB1 binding. Here we have focused on the genes
repressed by HPV16 E7, which includes many markers of keratinocyte differentiation that
were also downregulated upon PTPN14 KO (Figures 2.2 and 2.5). Using the HPV16 E7
∆21-24 mutant we have found that RB1 binding is not required for the repression of most
of these genes (Figure 2.2). RB1 binding did allow for the repression of some
differentiation genes by HPV16 E7 (Supplemental Figure 2.2D) and certain genes upregulated by HPV16 E7 but not by HPV16 E7 ∆21-24 were related to keratinocyte
differentiation. Nonetheless, differentiation-related GO terms comprised a minor part of
the HPV16 E7 gene induction signature, whereas they were the most significant terms
repressed by HPV16 E7 in the presence or absence of RB1 binding.
All HPVs, not only the high-risk types, likely manipulate differentiation to replicate.
PTPN14 is a conserved interactor of HPV E7, suggesting an evolutionary pressure to
maintain this interaction regardless of the ability to direct it for proteasomal degradation.
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Future studies could address whether low-risk HPV E7 impact keratinocyte differentiation
via their ability to bind to (but not degrade) PTPN14. Our study supports this hypothesis
as the HPV16 E7 E10K variant and the low-risk HPV6 E7 proteins both inhibited
keratinocyte differentiation to similar levels after stimulation and both contain a C-terminal
domain that binds PTPN14 (Figure 2.3 and 2.4). More broadly, genus β HPV E6 proteins
bind MAML1 to inhibit Notch signaling, resulting in impaired keratinocyte differentiation
and a cellular environment more conducive to virus replication (98, 99, 224). The genus α
HPVs, which include all of the high-risk and low-risk HPV discussed here, do not engage
MAML1 in the same way. It is interesting to speculate that all HPV promote proliferation
but that pathogenesis is related to their ability to further impair differentiation: via the HPV
E7-PTPN14 interaction in the case of mucosal, genus α HPV and via the E6-MAML
interaction in the case of cutaneous, genus β HPV.
Our results suggest that PTPN14 does not regulate canonical Hippo-YAP
signaling. Instead, it is possible that PTPN14 regulates differentiation by modulating other
cellular signaling pathways that have identified roles in epithelial development, such as
transforming growth factor β (TGFβ) or protein kinase C (PKC) signaling. Both TGFβ and
PKC have been proposed to be regulated by PTPN14 in other systems (152, 199). It also
remains possible that PTPN14 regulates YAP1 independently of Hippo signaling.
The binding and degradation of RB1 is a major component of high-risk HPV E7mediated transformation. However, many observations have suggested that there must
be RB1-independent contributions to E7-mediated transformation. We propose that
PTPN14 degradation is a critical contributor to the oncogenic activity of high-risk HPV E7
and that PTPN14 inactivation impairs keratinocyte differentiation. PTPN14 degradation is
conserved across the high-risk HPV E7 that we have tested so far, and it is not dependent
on the ability of E7 to bind or inactivate RB1. We have not yet established whether
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PTPN14 binding is sufficient to impair differentiation or whether PTPN14 degradation has
additional oncogenic effects. In either case, the identification of a mechanism by which
HPV E7 controls differentiation is significant. The potential of differentiation therapy has
been validated by the highly successful use of all-trans retinoic acid to treat acute
promyelocytic leukemia (225). It is tantalizing to speculate that inhibiting PTPN14
inactivation could similarly restore the cellular differentiation program in HPV+ cancer cells
and have therapeutic potential. Future work could aim to elucidate the mechanism of
PTPN14 signal transduction in keratinocytes and to further characterize the role of
PTPN14 degradation in HPV replication and in HPV-associated cancers.

Materials and Methods
Cells
Primary HFK (G5-Ep isolate, gift of James Rheinwald, Harvard Medical School,
Boston) and hTert-immortalized HFK (201) were cultured as previously described (171).
PTPN14 KO or nontargeting control primary HFK were established by transduction with
LentiCRISPR v2 vectors (Supplemental Table 4) followed by puromycin selection. N/TertCas9 cells were generated by transduction with pXPR_111 (Addgene #59702) and
blasticidin selection. PTPN14 KO or mock control N/Tert cell lines were established by
transfection of N/Tert-Cas9 with sgRNA targeting PTPN14 (Synthego, Supplemental
Table 4). Retroviruses and lentiviruses were generated as previously described (171).

siRNA transfection
NTert-1 cells expressing HPV16 E7 WT were transfected with a control siRNA
(siControl) or siRNAs targeting UBR4 (Dharmacon) (Supplemental Table 4) using
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Dharmafect 1 transfection reagent (Dharmacon). siRNA treated cells were harvested for
Western blot 48 h posttransfection.

Keratinocyte differentiation assays
To assess keratinocyte survival and changes in gene expression following
detachment from a substrate, N/Tert-mock or N/Tert-sgPTPN14, or N/Tert-1 cells
engineered to stably express HPV16 E7 WT, HPV16 E7 E10K, HPV6 E7, or an empty
vector control were harvested by trypsinization and replated in ultralow attachment plates
(Sigma-Aldrich CLS3471). After 0 or 12 h of culture in suspension, cells were harvested
for RNA analysis or 1,000 cells were re-plated in standard six-well tissue culture plates.
Replated cells were stained with Crystal violet 5 d postreplating.
To assess keratinocyte differentiation induced by calcium, NTert-1 cells
engineered to stably express HPV16 E7 WT, HPV16 E7 E10K, HPV6 E7, or an empty
vector control were treated with 1.5 mM CaCl2 in KBM media (Lonza) without supplements.
At 48 h posttreatment, cells were harvested for RNA analysis.

Keratinocyte immortalization assay
To assess the ability of HPV16 E7 variants to support keratinocyte immortalization,
primary HFK were transduced with one MSCV-based retroviral vector encoding conferring
puromycin resistance (HPV16 or HPV6 E6 or an empty vector control) and one retroviral
vector conferring blasticidin resistance (HPV16 or HPV6 E7 or an empty vector control)
(Supplemental Table 4). Cells were selected in puromycin and blasticidin and passaged
for ~110 d. Population doublings were calculated based upon the number of cells collected
and replated at each passage.
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Plasmids and cloning
LentiCRISPR v2 vectors were cloned according to standard protocols using
sgRNA sequences as contained in the Broad Institute Brunello library (226). The E10K
mutation was introduced by site-directed mutagenesis into pDONR-Kozak-16E7 and
recombined into MSCV-IP N-FlagHA GAW as previously described (126). Additional HPV
E6 and E7 retroviral vectors used in the study are listed in Supplemental Table 4.

Western blotting
Western blots were performed as previously described (128) using MiniPROTEAN or Criterion (Bio-Rad) SDS/PAGE gels and transferred to PVDF. Membranes
were blocked in 5% nonfat dried milk in TBS-T [Tris buffered saline (pH 7.4) with 0.05%
Tween-20], then incubated with primary antibodies as follows: RB1 (Calbiochem/EMD),
actin (Millipore), PTPN14 (R&D Systems), and UBR4 [gift of Dr. Yoshihiro Nakatani, DanaFarber Cancer Institute, Boston (227)]. Membranes were washed in TBS-T and incubated
with horseradish peroxidase (HRP)-coupled anti-mouse or anti-rabbit antibodies or an
Alexa-680

coupled

anti-mouse

antibody

and

detected

using

Amersham

600

chemiluminescent substrate or a Li-COR Infrared imaging system. HA-tagged proteins
were detected using an HA antibody conjugated to HRP (Roche) and visualized in the
same

way.

For

anti-HA

immunoprecipitations,

HA-tagged

proteins

were

immunoprecipitated and processed for Western blot, as previously described (128).

RNA-seq
Total RNA was isolated from two to three independent isolates of HFK-control,
HFK-PTPN14 KO, HFK-empty vector control, or HFK E7 cells using the RNeasy mini kit
(Qiagen). PolyA selection, reverse transcription, library construction, sequencing, and
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initial analysis were performed by Novogene. Differentially expressed genes were
selected based on a 1.5-fold change and adjusted p≤0.05 cut-off and were analyzed for
enriched biological processes using the GO enrichment analysis tool of the PANTHER
classification system (228). All GO terms in enrichment analyses are displayed in rank
order by adjusted p-value. RNA-seq data have been deposited in the National Center for
Biotechnology Information

Gene Expression

Omnibus

with accession

number

GSE121906.

qRT-PCR
Total RNA was isolated from N/Tert cells using the NucleoSpin RNA extraction kit
(Macherey-Nagel). RNA was then reverse transcribed using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems). cDNAs were assayed by qPCR using
Fast SYBR Green Master Mix (Applied Biosystems) using a QuantStudio 3 96-Well, 0.2
mL Block instrument (ThermoFisher). All gene qRT-PCR data were normalized to GAPDH
or to G6PD. qRT-PCR primer sequences are listed in Supplemental Table 4.

Acknowledgements
We thank the members of our laboratories for helpful discussions and suggestions and
Yoshihiro Nakatani for the antiUBR4 antibody. This work was supported by American
Cancer Society Grant 131661-RSG-18-048-01-MPC (to E.A.W.) and by National Institutes
of Health R01 CA066980 (to K.M.).

59

Author Contributions
J.H. and E.A.W. designed research; J.H., A.E.B., M.G., H.W.K., and E.A.W. performed
research; J.H., I.M.M., K.M., and E.A.W. contributed new reagents/analytic tools; J.H.,
T.J.N., B.W., I.M.M., K.M., and E.A.W. analyzed data; and J.H. and E.A.W. wrote the
paper.

60

Supplemental Figures

Supplemental Figure 2.1. The HPV16 E10K variant is impaired in PTPN14 degradation but
binds RB1 and promotes cell cycle progression.
Primary HFK were transduced with retroviruses encoding HPV16 E7 WT, HPV16 E7 E10K, HPV16
E7 Δ21-24, or an empty vector control. RNA from transduced cells was polyA selected and
analyzed by RNAseq for changes in gene expression. (A) Heat map displays top 75 genes
differentially expressed in HPV16 E7 Δ21-24 relative to HPV16 E7 WT cells. (B) Genes in the DNA
Replication GO Term (GO0006260) altered by HPV16 E7 WT relative to control ≥1.5 fold with pvalue ≤0.05 are displayed in heat map.
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Supplemental Figure 2.2. HPV16 E7 degrades PTPN14 to inhibit keratinocyte differentiation.
Primary HFK were transduced with retroviruses encoding HPV16 E7 WT, HPV16 E7 E10K, HPV16
E7 Δ21-24, or an empty vector control. RNA from transduced cells was polyA selected and
analyzed by RNA-seq for changes in gene expression. (A) GO enrichment analysis of genes >1.5
fold higher with p<0.05 in HPV16 E7 WT relative to HPV 16 E7 E10K shows no strong enrichment
for GO terms. (B) Same analysis as (A) of (C, Top) genes with ≥1.5 fold lower expression in HPV16
E7 WT than HPV16 E7 Δ21-24 cells, and (C, Bottom) genes ≥1.5 fold higher expression in HPV16
E7 Δ21-24 cells relative to empty vector control cells and p-value ≤0.05. (C) Scatter plot of log2(foldchange) in gene expression compares the gene expression changes of HPV16 E7 Δ21-24 relative
to empty vector control to those of PTPN14 KO relative to control. Colors denote whether genes
are altered by PTPN14 KO only (blue), by HPV16 E7 ∆21-24 only (light green), or both (dark green).
(D) Unbiased clustering of genes that are lower in HPV16 E7 WT cells relative to HPV16 E7 E10K
by ≥1.5 fold with p-value ≤0.05 in HPV16 E7. Gene names and clustering are displayed to the left
of the heat map, and selected GO categories are displayed on the right. Color coding on the right
side denotes whether genes in a cluster are related to epidermis development (blue), other
developmental processes (green), or neither (gray).
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Supplemental Figure 2.3. PTPN14 depletion upregulates inflammatory response genes in
primary human keratinocytes and down regulates similar keratinocyte differentiation genes
to HPV16 E7.
Primary HFK were transduced with LentiCRISPRv2 lentiviral vectors encoding SpCas9 and nontargeting or PTPN14-directed sgRNAs and analyzed for changes in gene expression. PolyA
selected RNA was analyzed by RNA-seq. Plot displays GO enrichment analysis of genes
upregulated in HFK-PTPN14 KO compared to HFK-control.
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Supplemental Figure 2.4. Keratinocyte differentiation gene signature describes the major
differences between HPV+ and HPV- HNSCC.
Data from HNSCC samples on the TCGA database were determined to be HPV+ or HPV- and
analyzed for differences in gene expression. (A) Bar chart portrays the ranked –Log10(p-values) of
enriched gene ontology terms among genes up-regulated in HPV+ HNSCC.
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CHAPTER 3 | A CONSERVED AMINO ACID IN THE C-TERMINUS OF HPV E7
MEDIATES BINDING TO PTPN14 AND REPRESSION OF EPITHELIAL
DIFFERENTIATION

The contents of this chapter have been previously published as:
Hatterschide J, Brantly AC, Grace M, Munger K, White EA. 2020. A Conserved Amino
Acid in the C Terminus of Human Papillomavirus E7 Mediates Binding to PTPN14 and
Repression of Epithelial Differentiation. Journal of Virology 94 (17) e01024-20.
Supplemental tables can be found on the journal’s website.
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Abstract
The human papillomavirus (HPV) E7 oncoprotein is a primary driver of HPVmediated carcinogenesis. The E7 proteins from diverse HPVs bind to the host cellular
nonreceptor protein tyrosine phosphatase type 14 (PTPN14) and direct it for degradation
through the activity of the E7-associated host E3 ubiquitin ligase UBR4. Here, we show
that a highly conserved arginine residue in the C-terminal domain of diverse HPV E7
mediates the interaction with PTPN14. We found that disruption of PTPN14 binding
through mutation of the C-terminal arginine did not impact the ability of several high-risk
HPV E7 proteins to bind and degrade the retinoblastoma tumor suppressor or activate
E2F target gene expression. HPVs infect human keratinocytes and we previously reported
that both PTPN14 degradation by HPV16 E7 and PTPN14 CRISPR knockout repress
keratinocyte differentiation-related genes. Now, we have found that blocking PTPN14
binding through mutation of the conserved C-terminal arginine rendered both HPV16 and
HPV18 E7 unable to repress differentiation-related gene expression. We then confirmed
that the HPV18 E7 variant that could not bind PTPN14 was also impaired in repressing
differentiation when expressed from the complete HPV18 genome. Finally, we found that
the ability of HPV18 E7 to extend the life span of primary human keratinocytes required
PTPN14 binding. CRISPR/Cas9 knockout of PTPN14 rescued keratinocyte life span
extension in the presence of the PTPN14 binding-deficient HPV18 E7 variant. These
results support the model that PTPN14 degradation by high-risk HPV E7 leads to
repression of differentiation and contributes to its carcinogenic activity.

Importance
The E7 oncoprotein is a primary driver of HPV-mediated carcinogenesis. HPV E7
binds the putative tumor suppressor PTPN14 and targets it for degradation using the
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ubiquitin ligase UBR4. PTPN14 binds to a C-terminal arginine highly conserved in diverse
HPV E7. Our previous efforts to understand how PTPN14 degradation contributes to the
carcinogenic activity of high-risk HPV E7 used variants of E7 unable to bind to UBR4.
Now, by directly manipulating E7 binding to PTPN14 and using a PTPN14 knockout
rescue experiment, we demonstrate that the degradation of PTPN14 is required for highrisk HPV18 E7 to extend keratinocyte life span. Our data show that PTPN14 binding by
HPV16 E7 and HPV18 E7 represses keratinocyte differentiation. HPV-positive cancers
are frequently poorly differentiated, and the HPV life cycle depends upon keratinocyte
differentiation. The finding that PTPN14 binding by HPV E7 impairs differentiation has
significant implications for HPV-mediated carcinogenesis and the HPV life cycle.

Introduction
Infection with oncogenic human papillomaviruses (HPVs) can cause several
epithelial carcinomas including essentially all cervical cancers, a subset of oropharyngeal
cancers, and several other anogenital cancers. These HPV-positive cancers account for
approximately 5% of the human cancer burden (229). HPVs are nonenveloped doublestranded DNA (dsDNA) viruses that infect the basal keratinocytes of cutaneous or
mucosal stratified squamous epithelia and couple their replication to keratinocyte
differentiation (65). Hundreds of genetically diverse HPV genotypes have been identified
to date (10). Only 13 to 15 of the mucosal-tropic HPVs, termed the “high-risk” HPVs, are
significantly associated with carcinogenesis. Infection with a high-risk HPV is the first step
in the carcinogenic process. Cells persistently infected with high-risk HPV can accumulate
secondary hits, such as viral genome integration into a host chromosome. This can lead
to dysregulated, constitutive expression of the viral E6 and E7 oncoproteins, which are
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required for keratinocyte immortalization and for the transformed phenotype in cervical
carcinoma cell lines (70, 71, 73-75).
HPV E6 and E7 are multifunctional viral proteins that lack enzymatic activity. They
can alter host cellular processes through interactions with cellular proteins. One activity of
many HPV E7s is to bind and inactivate the retinoblastoma tumor suppressor (RB1) (83,
114). This results in the release of E2F transcription factors and promotes entry into the
cell cycle. High-risk HPV E7 additionally promotes the proteasomal degradation of RB1,
in the case of HPV16 E7 through the recruitment of a Cullin 2-Zer1 E3 ubiquitin ligase
complex (113, 126). High-risk HPV E6 directs the tumor suppressor p53 for proteasomemediated degradation (86, 87), blocking the induction of apoptosis that would arise from
E7-mediated stabilization of p53 (84, 85).
Binding to RB1 is necessary but not sufficient to explain the carcinogenic activities
of HPV E7 (82, 112, 116-120, 172-175). We have begun to characterize a second putative
tumor suppressor, the nonreceptor protein tyrosine phosphatase PTPN14, that is bound
and degraded by HPV E7 (126, 128, 176). High-risk HPV E7 direct PTPN14 for
proteasome-mediated degradation dependent on the interaction between E7 and the host
E3 ubiquitin ligase UBR4 (128, 216). Our early experiments determined that amino
terminal sequences in HPV E7 were required for the interaction with UBR4, whereas
binding to PTPN14 mapped broadly to the C-terminus of E7. HPV E7 binds to the
conserved C-terminal protein tyrosine phosphatase domain of PTPN14. The
E7/UBR4/PTPN14 complex is genetically and biochemically separable from the E7/RB1
complex (128, 176).
PTPN14 is proposed to inhibit the HIPPO pathway transcriptional coactivators
YAP1 and TAZ. The inhibitory activity of PTPN14 may involve interaction(s) with the
HIPPO pathway regulators KIBRA and LATS1 (138, 147, 148) and/or direct binding of
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PTPN14 to YAP1, promoting YAP1 cytoplasmic sequestration (135). PTPN14
phosphatase activity is not required for its inhibition of YAP1. The consequences of
PTPN14 degradation in HPV E7-expressing or HPV-positive cells are incompletely
understood.
To determine the effect of PTPN14 degradation by HPV E7, we have begun to
characterize E7 variants that cannot degrade PTPN14. We recently described a variant of
HPV16 E7, HPV16 E7 E10K, that was found among HPV16 sequences from clinical
samples (76). HPV16 E7 E10K could not bind to UBR4 and could not direct PTPN14 for
degradation (176). Our experiments indicated that PTPN14 degradation by HPV16 E7
impaired the expression of differentiation-related genes in keratinocytes. Our data also
supported that PTPN14 degradation could contribute to the carcinogenic activity of highrisk HPV E7. Compared with the prototypical HPV16 E7, HPV16 E7 E10K was impaired
in its ability to immortalize human foreskin keratinocytes (HFKs) when co-expressed with
HPV16 E6.
Yun and colleagues recently reported the crystal structure of the phosphatase
domain of PTPN14 in complex with the C-terminal domain of HPV18 E7 (154). The two
proteins bind directly and with high affinity (dissociation constant [KD] = 18.2 nM). Several
interactions between amino acids on PTPN14 and on HPV18 E7 contribute to the proteinprotein interaction, including an electrostatic interaction of HPV18 E7 Arg84 with PTPN14
Glu1095. Using a structure-guided mutational approach, the authors designed a PTPN14binding-deficient HPV18 E7 and found that it was impaired in promoting keratinocyte
growth and migration. The C-terminal arginine that was identified by Yun and colleagues
to directly contribute to PTPN14 binding is highly conserved among HPV E7s. Eighty-three
percent of genus alpha E7 have an arginine at this position and 92% have a positively
charged residue.
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Here, we characterize a naturally occurring HPV E7 variant and use it to
demonstrate that the conserved C-terminal arginine is required for diverse HPV E7
proteins to bind and degrade PTPN14 in cells. Our previous study focused on HPV16 E7.
We showed that blocking PTPN14 degradation by disrupting the HPV16 E7-UBR4
interaction led to increased expression of keratinocyte differentiation genes. However,
UBR4 might have been responsible for the degradation of PTPN14 and of additional
substrates. Our new data demonstrate that a mutation specifically blocking PTPN14
binding renders both HPV16 and HPV18 E7 unable to repress keratinocyte differentiation.
We extend this result to include cells that contain the complete HPV18 genome. Finally,
we find that PTPN14 binding by HPV18 E7 is required for the keratinocyte life span
extension activity of HPV18 E7. CRISPR/Cas9-mediated deletion of PTPN14 rescues the
ability of the PTPN14 binding mutant HPV18 E7 to extend the keratinocyte life span. The
rescue experiment strongly supports that PTPN14 binding and degradation are required
for keratinocyte life span extension by HPV18 E7.

Results
Mutation of a conserved C-terminal arginine residue in diverse HPV E7 restores PTPN14
protein levels
HPV E7 proteins form a complex with PTPN14 and the host E3 ubiquitin ligase
UBR4 to direct PTPN14 for proteasome-mediated degradation (128). We have shown that
mutations in HPV16 E7 that abrogate UBR4 binding also impair degradation of PTPN14
and prevent HPV16 E7 from repressing differentiation gene expression (176). However,
we had not characterized any variant of E7 that did not bind to PTPN14 nor had we
extended our analysis to include genotypes other than HPV16.
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HPV E7 proteins from diverse genotypes have some conserved and some
divergent amino acid sequences (Figure 3.1A). Diverse HPV E7 proteins bind to PTPN14
(126, 128). Given the connection we recently established between PTPN14 and
differentiation (176), we re-examined the relationship between diverse genus alpha HPV
E7 and PTPN14 protein levels. We transduced hTert-immortalized human foreskin
keratinocyte (N/Tert-1) cells with retroviral vectors encoding HPV E7 from several genus
alpha HPV genotypes. Using newly derived, passage-matched keratinocyte pools stably
expressing HPV E7, we found that E7 proteins from high-risk, low-risk, and non-cancerous
genus alpha HPV reduced steady-state PTPN14 protein levels (Figure 3.1B). Consistent
with our previous results, high-risk HPV18 E7 expression resulted in the most substantial
reduction in PTPN14 protein levels.
We and others previously determined that PTPN14 binding maps broadly to the
carboxyl terminus of HPV E7 (128, 216). A recent crystal structure of the C-terminus of
HPV18 E7 in complex with the PTP domain of PTPN14 determined that the two proteins
bind directly and elucidated the PTPN14-HPV18 E7 binding interface (154). Several
residues of HPV18 E7 were found to be critical for this interaction, including Arg84 (R84;
R77 in HPV16 E7) which makes an electrostatic interaction with Glu1095 of PTPN14. The
corresponding arginine residue is highly conserved among HPV E7 proteins. It is
completely conserved among the prototypical E7 open reading frames (ORFs) from highrisk HPV (Figure 3.1A), 83% conserved among E7 ORFs from genus alpha, and 80%
conserved among E7 ORFs from 193 diverse HPV genotypes. The high degree of
conservation of the C-terminal arginine may indicate strong selective pressure for HPV E7
to maintain the ability to bind PTPN14.
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Figure 3.1. Conserved PTPN14 binding and degradation by HPV E7.
(A) Protein sequence alignment of 22 HPV E7 ORFs from diverse HPV genotypes. Alignments
were generated using the Clustal Omega algorithm and colored using the ClustalX color scheme.
(B) Cell lysates from N/Tert-1 cells expressing E7 proteins from various HPV genotypes were
subjected to SDS/PAGE/Western analysis and probed with antibodies to PTPN14, RB1, HA (E7),
and actin. (C and D) Cell lysates from N/Tert-1 cells expressing WT or variant HPV16, HPV31,
HPV18, and HPV6 E7 were subjected to SDS/PAGE/Western analysis and probed with antibodies
to PTPN14, RB1, HA (E7), and actin. Band intensity was quantified using ImageJ. Values represent
PTPN14 band intensity relative to actin band intensity. BG indicates that band intensity was ≤
background intensity.
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The requirement for the C-terminus of E7 to bind PTPN14 led us to characterize a
naturally occurring variant of HPV16 E7 identified by Mirabello and colleagues (76). The
variant HPV16 E7 R77S has a mutation in the conserved arginine residue (Arg77 to Ser;
R77S). We hypothesized that HPV16 E7 R77S might be unable to bind and degrade
PTPN14. To test if the mutation of the C-terminal arginine impairs PTPN14 degradation
by HPV E7 proteins, we engineered the arginine-to-serine mutation into the E7 ORFs from
HPV16, HPV31, HPV18, and HPV6. We then transduced N/Tert-1 cells with retroviruses
encoding the E7 variants, the corresponding wild-type/prototypical (WT) E7s, and several
additional mutants as controls. The additional variants are: HPV16 E7 E10K (does not
bind UBR4) (176), HPV16 E7 Δ21-24 (does not bind RB1) (83), and HPV18 E7 D10K
(contains the mutation analogous to HPV16 E7 E10K). We found that cells expressing
HPV16 E7 R77S, HPV31 E7 R77S, HPV18 E7 R84S, and HPV6 E7 R77S exhibited higher
PTPN14 protein levels than the corresponding WT E7-expressing cell lines (Figure 3.1C
and 3.1D). This finding is consistent with the idea that the C-terminal arginine is required
for diverse genus alpha HPV E7 proteins to interact with PTPN14. In agreement with our
previous results, PTPN14 expression was restored in cells expressing the HPV16 E7
E10K variant (176). HPV18 E7 D10K only partially restored PTPN14 expression (Figure
3.1D). These results support the notion that the C-terminal HPV E7 binding interface may
be highly conserved to mediate PTPN14 binding.

Mutation of the C-terminal arginine in high-risk HPV E7 does not affect RB1 degradation
or E2F target gene activation.
In addition to binding PTPN14, HPV E7 proteins bind and inactivate RB1 (83, 114).
High-risk HPV E7 proteins additionally direct RB1 for proteasomal degradation (113, 126).
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Figure 3.2. PTPN14 binding and degradation by HPV E7 are not required to promote the
expression of E2F-regulated genes.
Primary HFKs were transduced with retroviral vectors encoding various HPV16 and HPV18 E7
proteins. qRT-PCR was used to measure the expression of the E2F-regulated genes (A) CCNE2
and (B) MCM2 relative to GAPDH. Graphs display the mean ± SD of three independent replicates.
Statistical significance was determined by analysis of variance (ANOVA) (**p < 0.01, ****p <
0.0001).
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We found that HPV16 E7 R77S, HPV31 E7 R77S, and HPV18 E7 R84S were comparable
to WT E7 proteins with respect to their capacity to reduce RB1 steady-state protein levels
(Figure 3.1C). To test whether HPV16 E7 R77S and HPV18 E7 R84S could induce the
expression of E2F target genes downstream of RB1 inactivation, we transduced primary
human foreskin keratinocytes (HFKs) with retroviral vectors encoding a panel of HPV16
and HPV18 E7 variants. Total RNA was collected from these cell lines, and the expression
of the E2F target genes CCNE2 and MCM2 was assessed by reverse transcriptionquantitative PCR (qRT-PCR). With the exception of HPV16 E7 Δ21-24, which cannot bind
RB1, all HPV16 and HPV18 E7 variants, including HPV16 E7 R77S and HPV18 E7 R84S,
were able to induce E2F target gene expression (Figure 3.2A and B). We conclude that
mutation of the C-terminal arginine does not affect RB1 inactivation by high-risk HPV E7
proteins.

Mutation of the conserved C-terminal arginine disrupts PTPN14 binding by high-risk HPV
E7
To confirm that mutation of the conserved C-terminal arginine disrupted PTPN14
binding, we immunoprecipitated E7 from the N/Tert cell lines that stably express Flag and
hemagglutinin (HA)-tagged HPV16 and HPV18 E7 and variant E7. We found that PTPN14
coimmunoprecipitated minimally with HPV16 E7 R77S or HPV18 E7 R84S (Figures 3.3A
and 3.3B). In contrast, PTPN14 coimmunoprecipitated with HPV16 E7 WT, HPV18 E7
WT, and HPV16 E7 Δ21-24, which cannot bind RB1. In agreement with the analysis of
total cell protein and RNA (Figures 3.1 and 3.2), HPV16 E7 R77S and HPV18 E7 R84S
input cell lysates contained more PTPN14 protein than the respective WT E7 cell lysates.
A small amount of residual PTPN14 binding by HPV16 E7 R77S could explain the
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Figure 3.3. HPV16 E7 R77S and HPV18 E7 R84S cannot bind to PTPN14.
N/Tert-1 keratinocytes were transduced with retroviruses encoding various HPV16 E7 (A), HPV18
E7 (B), or the empty vector control. HPV E7-FlagHA was immunoprecipitated with anti-HA beads
from total cell lysates, and coimmunoprecipitation of PTPN14 and RB1 was assessed by
SDS/PAGE/Western analysis (top). Total cell lysates were subjected to SDS/PAGE/Western
analysis and probed with antibodies to PTPN14, RB1, HA (E7), and actin (bottom).

76

incomplete restoration of PTPN14 protein levels in HPV16 E7 R77S cells. HPV16 E7
R77S and HPV18 E7 R84S retained the capacity to coimmunoprecipitate with RB1 and
reduce steady-state RB1 levels. These data support the model that diverse HPV E7
require the conserved C-terminal arginine to bind to PTPN14 in keratinocytes.

PTPN14 binding is required for high-risk HPV E7 to repress differentiation
We previously determined that PTPN14 degradation by HPV16 E7 is required for
an E7-mediated repression of keratinocyte differentiation (176). Therefore, we
hypothesized that impairing PTPN14 binding by mutating the C-terminal arginine residue
would likewise render high-risk HPV E7 proteins unable to repress differentiation. We used
a panel of N/Tert cell lines expressing WT and arginine-to-serine mutated HPV E7 proteins
from the high-risk HPV16 and HPV18. Cells were induced to differentiate by culture in
growth factor-free media supplemented with 1.5 mM CaCl2. We collected whole-cell
lysates at 0 and 72 h post-differentiation and analyzed cytokeratin 1 (KRT1), cytokeratin
10 (KRT10), and involucrin (IVL) by Western blotting. KRT1 and KRT10 are early
differentiation markers, and IVL is a component of the cornified envelope. We found that
HPV16 E7 WT and HPV18 E7 WT were able to repress the expression of all three
differentiation markers, whereas HPV16 E7 R77S and HPV18 E7 R84S were not (Figure
3.4).
Because HPV18 E7 leads to the greatest depletion in PTPN14 protein levels, we
chose to focus on HPV18 E7 for the remainder of this study. Loss of contact with the
basement membrane induces keratinocyte differentiation in vivo. This can be simulated in
cultured cells by growing keratinocytes in suspension (202-204), which promotes
expression of markers of late differentiation. To test whether PTPN14 binding by HPV E7

77

Figure 3.4. HPV16 E7 R77S and HPV18 E7 R84S are impaired in their ability to repress
differentiation gene expression induced by calcium treatment.
N/Tert-1 keratinocytes expressing HPV16 E7 WT and R77S, HPV18 E7 WT and R84S, or the
empty vector control were maintained in growth medium (-) or were induced to differentiate with
1.5 mM CaCl2 for 72h (+). Cell lysates were subjected to SDS/PAGE/Western analysis and probed
with antibodies to PTPN14, IVL, KRT1, KRT10, HA (E7), and actin.
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also impairs differentiation in response to detachment, we cultured N/Tert cell lines
expressing HPV18 E7 WT, HPV18 E7 R84S, and the empty vector control in ultralow
adherence plates for 12 h. We collected RNA from adherent cells or cells in suspension
and measured the expression of the late differentiation marker IVL by qRT-PCR. IVL
mRNA expression was induced in all cell lines after suspension. However, HPV18 E7
R84S displayed modestly increased IVL expression postdifferentiation compared with
HPV18 E7 WT (Figure 3.5A), mirroring our results obtained from CaCl2 differentiation.
These data indicate that PTPN14 binding by HPV18 E7 is necessary for the repression of
differentiation gene expression following differentiation stimuli.
Keratinocytes exit the cell cycle after differentiating, which leads to decreased
growth capacity. To test if PTPN14 binding by HPV18 E7 affects cellular viability after
suspension, we replated 1,000 cells that were grown in ultralow adherence plates for 12
h onto standard tissue culture plates and cultured them for an additional 5 days. We then
fixed and stained them with crystal violet and measured the area covered by viable cells.
We found that HPV18 E7 WT increased viability after stimulus to differentiate in
suspension, while the growth of HPV18 E7 R84S-expressing cells resembled the empty
vector control (Figure 3.5B). These data support that PTPN14 binding by high-risk HPV
E7 is required for the impairment of keratinocyte differentiation, promoting cellular viability
following a differentiation stimulus.

Repression of differentiation is the predominant effect of PTPN14 binding by HPV18 E7
on the transcriptome of primary keratinocytes
We hypothesized that comparing HPV18 E7 and HPV18 E7 R84S in an unbiased
analysis of gene expression might reveal additional cellular processes that are up- or
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Figure 3.5. HPV18 E7 binding to PTPN14 contributes to the repression of differentiation
induced by suspension and improves survival of cells grown in suspension.
N/Tert-1 keratinocytes expressing HPV18 E7 WT, HPV18 E7 R84S, or the empty vector control
were induced to differentiate by culturing in ultralow adherence plates for 12 h. (A) qRT-PCR was
used to measure the expression of the differentiation marker IVL relative to GAPDH in adherent or
suspended cells. Graph displays the mean ± SD of three independent replicates. (B) Survival after
suspension was assessed by replating 1,000 cells from suspension, allowing cells to grow for 5
days, and measuring total viable cell area by crystal violet staining. Graph displays the mean ± SD
of three independent replicates. Representative images of crystal violet staining are displayed.
Statistical significance was determined by ANOVA (*p < 0.05, ***p < 0.001).
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downregulated by E7-mediated PTPN14 binding and degradation. To test this, we
transduced primary HFKs with retroviral vectors encoding HPV18 E7 WT, HPV18 E7
R84S, or the empty vector control. Triplicate primary cell populations were established
and selected with puromycin. RNA isolated from these cell populations was poly(A)selected and analyzed by RNA sequencing (RNA-seq). We found that 271 genes were
differentially regulated between HFK expressing HPV18 E7 WT and HPV18 E7 R84S,
with cut offs of >1.5-fold change and a false discovery rate (FDR)-adjusted p-value of
<0.05. The majority of these genes (247) were found to be more repressed in cells
expressing HPV18 E7 WT than those expressing the HPV18 E7 R84S mutant (Figure
3.6A). We performed a gene ontology (GO) enrichment analysis on the list
of genes with lower expression in wild-type HPV18 E7-expressing cells and found that this
list was highly enriched for GO terms related to keratinocyte differentiation (Figure 3.6B).
Further analysis revealed that a high percentage of these 247 genes were related to the
following GO terms: cornification, 13%; keratinocyte differentiation, 16%; skin
development, 18%; and epidermis development, 19%. A complete list of the GO terms
enriched among the 247 genes that were downregulated in cells expressing HPV18 E7
WT compared with HPV18 E7 R84S is in Table S2 in the supplemental material. Among
the 24 genes that were upregulated in cells expressing HPV18 E7 WT versus cells
expressing HPV18 E7 R84S, there were no statistically significantly enriched GO terms.
Based on the strong differentiation signature we specifically focused on a broad
array of differentiation-related genes involved in early differentiation, the differentiationassociated desmosome complexes, cornified envelope formation, differentiationpromoting signaling, and differentiation-promoting transcription factors. Analysis of these
selected genes revealed that HPV18 E7 WT indeed broadly represses differentiation-
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Figure 3.6. Repression of differentiation is the predominant effect of PTPN14 binding by
HPV18 E7 on the transcriptome of primary keratinocytes.
Primary HFKs were transduced with retroviruses encoding HPV18 E7 WT, HPV18 E7 R84S, or the
empty vector control. The poly(A)-selected RNA collected from early passages was analyzed by
RNA-seq. (A) Volcano plot of gene expression changes in HFKs expressing HPV18 WT and HPV18
R84S. Vertical and horizontal dotted lines represent 1.5-fold change, and p adjusted value of 0.05.
Representative genes are highlighted in red. (B) Gene ontology (GO) enrichment analysis of genes
down-regulated in HFKs expressing HPV18 WT compared with HPV18 R84S. GO terms are
displayed in rank order of their FDR-adjusted p-value. Circle chart displays the fraction of
downregulated genes that fall into enriched GO terms. (C) Heat map displaying the expression
patterns of selected genes related to differentiation and the cell cycle. Early, early differentiation
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markers; Des., genes encoding components of the differentiation-associated desmosome
complexes; Cornif., genes involved in cornified envelope formation; Sig., genes involved in
differentiation-promoting signals; TF., genes encoding differentiation-promoting transcription
factors. (D) qRT-PCR was used to measure the expression of the differentiation-related genes IVL,
KRT1, and MAF relative to GAPDH. Graphs display the mean ± SD of three independent replicates.
Statistical significance was determined by ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001).

related genes compared with the empty vector control and that the expression of these
genes is restored in cells that express HPV18 E7 R84S (Figure 3.6C). Furthermore, this
RNA-seq analysis confirmed that both HPV18 E7 WT and HPV18 E7 R84S promote the
expression of cell cycle-related genes, such as CCNE2, MCM2, and PCNA, that are
activated downstream of RB1 degradation. To validate our RNA-seq results, we measured
the mRNA expression of several key genes using qRT-PCR. These included genes IVL,
KRT1, and MAF, which is a transcription factor that promotes early differentiation (49).
The expression of these three differentiation-related genes was significantly lower in HFKs
expressing HPV18 E7 WT than those expressing HPV18 E7 R84S or the empty vector
control (Figure 3.6D). In summary, we found that repressing genes related to
differentiation was the predominant effect of PTPN14 binding by HPV18 E7 on
keratinocyte gene expression in unstimulated keratinocytes.

The HPV18 E7 C-terminal arginine contributes to differentiation repression in
keratinocytes harboring the complete HPV genome
Our data support that PTPN14 binding is required for HPV E7 to repress
differentiation when HPV E7 is expressed in the absence of other viral proteins. However,
other HPV proteins, particularly E6, have been shown to repress differentiation (104, 189,
191). To test whether PTPN14 binding by HPV E7 contributes to repression of
differentiation when E7 is expressed from its native context in the complete viral genome,
we introduced the HPV18 E7 R84S mutation into pNeo-loxP-HPV18 (230). We transfected
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the WT and mutant pNeo-loxP-HPV18 vectors along with NLS-Cre into primary HFKs and
selected stable populations with G418 (Figure 3.7A). The resulting cell pools are HFKHPV18E7

WT

and HFK-HPV18E7 R84S. Uptake and excision of the HPV18 genome were

confirmed by PCR from DNA collected at an early passage posttransfection (Figure 3.7B).
To characterize the effect of HPV18 E7 WT and R84S on PTPN14 in the presence of the
complete HPV genome, protein lysates were collected from each cell line and compared
with lysates from the untransfected parental HFKs. We found that PTPN14 expression
was strongly diminished in HFK-HPV18E7 WT but not in HFK-HPV18E7 R84S (Figure 3.7C).
Reduction in RB1 protein levels can serve as a surrogate for high-risk HPV E7 expression.
As expected, HFKs harboring either genome displayed reduced RB1 protein levels,
suggesting that E7 is expressed from both pNeo-loxP-HPV18 vectors. To test how
PTPN14 binding by HPV18 E7 impacts differentiation in the context of the complete
genome, these cell populations were stimulated to differentiate with media containing 1.5
mM CaCl2. Total RNA was collected 0, 2, and 6 days postdifferentiation, and expression
of the early differentiation markers KRT1 and KRT10 was measured by qRT-PCR. We
found that throughout the time course, HFK-HPV18E7

WT

exhibited a 2.3- to 5.9-fold

reduction in KRT1 and KRT10 expression compared with HFK-HPV18E7 R84S (Figure 3.7D).
These data indicate that PTPN14 binding by HPV18 E7 contributes to the ability of HPV
E7 to repress differentiation gene expression even in the context of the complete HPV
genome.
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Figure 3.7. PTPN14 degradation is required for repression of differentiation in primary
keratinocytes harboring the HPV18 genome.
Primary HFKs were transfected with pNeo-loxP-HPV18 vectors and NLS-Cre. (A) Schematic of the
pNeo-loxP-HPV18 transfection experimental strategy. (B) PCR/agarose gel analysis of DNA
isolated from HFKs was used to confirm the transfection and excision of the HPV18 genome
following selection. (C) Cell lysates were subjected to SDS/PAGE/Western analysis and probed
with antibodies to PTPN14, RB1, and actin. (D) Cells were treated with 1.5 mM CaCl2 for 0, 2, and
6 days. qRT-PCR was used to measure the expression of the differentiation markers KRT1 and
KRT10 relative to GAPDH. Graphs display the mean ± SD of two or three independent replicates.
Statistical significance was determined by repeated measures two-way ANOVA (***p < 0.001, ****p
< 0.0001).
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PTPN14 binding is required for HPV18 E7 to extend the lifespan of primary human
keratinocytes
High-risk HPV E7 extends the lifespan of primary keratinocytes in vitro (74, 184).
We have previously reported that the E10K mutation in HPV16 E7, which blocks PTPN14
degradation, also impairs its ability to extend the lifespan of primary keratinocytes (176).
To assess whether PTPN14 binding by HPV18 E7 is also necessary for lifespan extension
by E7, we transduced primary HFK with retroviral vectors encoding HPV18 E7 WT, HPV18
E7 R84S, or the empty vector control and selected for stable populations. By counting
cells at each passage, we tracked the number of times each cell population doubled over
time. We found that HPV18 E7 R84S was unable to extend the lifespan of primary HFK
and that these cells behaved comparably to the HFK-empty vector control (Figure 3.8A).
In contrast, HPV18 E7 WT extended the lifespan of primary HFK until the experiment was
terminated 49 days postransduction. This result supports that PTPN14 binding by HPV18
E7 is essential for its ability to extend the lifespan of primary cells. To establish that
lifespan extension by HPV18 E7 is dependent on PTPN14 degradation and not on another
activity of HPV18 E7 related to the C-terminal arginine residue, we tested whether deletion
of PTPN14 could rescue the defect of the HPV18 E7 R84S mutant and extend
keratinocyte life span. These experiments were conducted by cotransducing HFKs from
two different keratinocyte donors with the HPV18 E7 retroviral vectors and LentiCRISPR
v2 vectors encoding control or PTPN14 targeting guide RNAs (two of each). We found
that PTPN14 deletion rescued the defect in the lifespan extension capability of HPV18 E7
R84S to a level that resembled that of HPV18 E7 WT (Figure 3.8B). PTPN14 KO did not
extend the lifespan of cells transduced with the empty vector control and did not further
extend the lifespan of cells expressing HPV18 E7 WT. These results further support the
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Figure 3.8. PTPN14 degradation is required for HPV18 E7 to extend the life span of primary
human keratinocytes.
(A) Primary HFKs were transduced with retroviruses encoding HPV18 E7 WT, HPV18 E7 R84S,
or the empty vector control and passaged for up to 49 days. The graph displays the growth of these
cell lines over the course of the experiment. Statistical significance was determined from three
independent experiments by repeated measures two-way ANOVA (*p < 0.05; **p < 0.01). (B)
Primary HFKs from two different donors were transduced with the same retroviruses as (A), along
with LentiCRISPRv2 lentiviral vectors encoding SpCas9 and nontargeting or PTPN14-directed
sgRNAs, and were cultured for up to 58 days. The graph displays the final population doubling
values under each condition along with the mean.
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model that PTPN14 binding and degradation are required for the carcinogenic activity of
high-risk HPV E7.

Discussion
HPV E7 from diverse virus genotypes binds PTPN14 and uses the host E3
ubiquitin ligase UBR4 to target PTPN14 for degradation (126, 128, 154, 216). A potential
tumor suppressive role of PTPN14 is consistent with its mutation rates in certain cancers
(basal cell carcinoma, 23%; gastrointestinal cancers, 5%) (129, 130) and its role as an
inhibitor of the HIPPO pathway proto-oncogenes YAP and TAZ (130, 135, 138). The high
degree of conservation of E7-PTPN14 binding suggests that PTPN14 binding and/or
degradation play an important role in HPV biology. We hypothesize that one consequence
of PTPN14 degradation is a contribution to high-risk HPV-mediated carcinogenesis.
High-risk E7 is central to carcinogenesis. In a recent analysis of the HPV16
sequences from >5,000 patient samples, E7 was found to be the most highly conserved
HPV ORF in high-grade lesions. This finding was interpreted to reflect strong selective
pressure to maintain prototypical E7 sequences during carcinogenic progression. The
requirement for UBR4 in PTPN14 degradation connects PTPN14 degradation to HPVmediated carcinogenesis. Binding to UBR4 was reported by several groups to contribute
to the carcinogenic activities of oncogenic papillomavirus E7 (112, 127). We recently
characterized the HPV16 E7 E10K variant that cannot bind UBR4 and is unable to
degrade PTPN14 (176). We found that HPV16 E7 E10K was impaired in assays of E7
carcinogenic activity. Using HPV16 E7 E10K, we also discovered that HPV16 E7
represses keratinocyte differentiation downstream of PTPN14 degradation.
In the current study, we characterized a newly described E7 variant with a mutation
in a highly conserved C-terminal arginine residue. A recently published crystal structure
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of HPV18 E7 and PTPN14 determined that the conserved arginine is a central component
of the E7-PTPN14 binding interface (154). We found that mutation of this arginine
rendered the E7 proteins from four HPV genotypes across three species unable to
degrade PTPN14 (Figure 3.1). These results extend the findings from previous studies to
show that PTPN14 binding to the C-terminal arginine is highly conserved, particularly
among high-risk HPV E7 proteins. In contrast, mutation of an acidic amino acid in the E7
N-terminus (the UBR4 binding region) had a somewhat variable effect on PTPN14 levels.
The HPV16 E7 E10K mutation almost completely restored PTPN14 protein levels,
whereas the analogous HPV18 E7 D10K mutation had an intermediate effect. One
possibility is that HPV18 E7 D10K retains some capacity to bind to UBR4.
Our prior work showed that the E7/PTPN14/UBR4 protein complex is distinct from
the E7/RB1 complex (128) and that the impacts of the two on the keratinocyte
transcriptome are genetically separable (176). We confirmed that HPV16 E7 R77S and
HPV18 E7 R84S retain the capacity to bind and degrade RB1 (Figures 3.1 and 3.3) and
to promote the expression of E2F target genes (Figures 3.2 and 3.6). These data strongly
support the model that PTPN14 binding and degradation are conserved activities of HPV
E7 separate from RB1 inactivation. The rare HPV16 E7 R77S and E10K variants were
found by Mirabello and colleagues in HPV16-positive precancerous lesions (76). We do
not know whether genetic polymorphisms or a characteristic of the tumor
microenvironment in the patients harboring the variants enabled their progression past the
initial infection nor whether the lesions would have progressed to frank carcinoma.
However, identifying the cell biological activities of naturally occurring variants is crucial to
our understanding of the viral and/or host cellular factors that enable variability in HPV
oncogene sequences in HPV-positive lesions.
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Either PTPN14 degradation by HPV16 E7 or PTPN14 CRISPR knockout (KO)
represses the expression of differentiation-related genes (176). In this study, we confirmed
that blocking PTPN14 binding through mutation of the conserved C-terminal arginine
likewise renders high-risk HPV16 E7 and HPV18 E7 unable to repress differentiation
(Figures 3.4 and 3.5). Furthermore, we confirmed by RNA-seq analysis that repression of
differentiation is the primary effect of PTPN14 binding by HPV18 E7 on the transcriptome
of unstimulated primary keratinocytes (Figure 3.6). Other alpha papillomavirus proteins,
including E6, repress differentiation, although the downstream mechanisms remain to be
elucidated (104, 189, 191). Mouse PTPN14 is proposed to be a downstream effector of
p53 in the “p53-PTPN14-YAP axis” (130). If PTPN14 is also downstream of p53 in human
cells, inactivation of PTPN14 by E7 could be more complex in the context of p53
degradation by E6. Nonetheless, we observed substantially higher expression of
differentiation marker expression in HFKs harboring the HPV18E7 R84S genome than those
harboring the HPV18E7

WT

genome (Figure 3.7). This finding indicates that PTPN14

degradation contributes to repression of differentiation even in the presence of E6. To our
knowledge, this is the first report that PTPN14 degradation by E7 represses differentiation
in the context of the complete virus genome. Beta papillomavirus E6 represses
differentiation by binding to MAML and directly inhibiting NOTCH signaling (98, 99, 224,
231). However, alpha papillomavirus E6 proteins do not bind MAML1 (125, 171). We posit
that all papillomaviruses require repression of differentiation gene expression and that
alpha HPV depend on PTPN14 degradation by E7 to repress differentiation.
Although HPV E7 repress differentiation-related genes through PTPN14
degradation, our experiments indicate that E7-expressing cells retain the capacity to
ultimately differentiate, which is consistent with the differentiation-dependent nature of the
HPV life cycle (62, 65, 179, 232-234). Additionally, we observed that PTPN14 binding by
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HPV18 E7 had a much stronger effect on cell viability after growth in suspension (Figure
3.5B) than it did on differentiation-related gene expression in pools of differentiated
keratinocytes (Figures 3.4 and 3.5A). This is particularly apparent in the modest increase
in IVL mRNA expression observed in HPV18 E7 R84S compared with HPV18 E7 WT
following growth in suspension. These observations may be related to the stage of the
keratinocyte differentiation program at which PTPN14 degradation has the most impact.
For example, it is possible that PTPN14 affects cell fate decisions early in differentiation.
Our findings are consistent with PTPN14 binding by E7 delaying or impairing the
commitment to terminal differentiation—thereby allowing for continued proliferation of
some cells—as opposed to completely blocking the differentiation program.
High-risk HPV E7 expression extends the life span of primary keratinocytes (74,
184) and life span extension is directly correlated with E7 carcinogenic activity. Using life
span extension experiments in primary HFKs, we found that HPV18 E7 R84S was
substantially impaired in its ability to extend the life span of primary cells compared with
WT HPV18 E7 (Figure 3.8A). Moreover, CRISPR/Cas9 knockout of PTPN14 in primary
HFK rescued the lifespan-extending activity of HPV18 E7 R84S (Figure 3.8B). HPV E7
can bind to PTPN21 (126, 154), a homolog of PTPN14. The new rescue experiment
strongly supports that PTPN14, not PTPN21, is the primary target involved in life span
extension. These data and our analysis of survival after growth in suspension (Figure
3.5B) implicate PTPN14 binding and degradation as a carcinogenic activity of high-risk
HPV E7.
Our finding that PTPN14 binding and degradation leads to repression of
differentiation-related genes also has implications for its role in carcinogenesis. This
activity is significant because it suggests that PTPN14 degradation could contribute to the
tendency of HPV-positive oropharyngeal carcinomas to be poorly differentiated (235, 236).
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It is interesting to consider that targeting PTPN14 binding to promote differentiation could
present an opportunity for the treatment of HPV-positive cancers. All-trans-retinoic acid
(ATRA) is a highly successful differentiation therapy used to treat acute promyelocytic
leukemia (225). ATRA has shown promise in mouse models of nonmelanoma skin cancer
and in reducing proliferation of human squamous cell carcinoma cells (237-239).
Previous reports have demonstrated that diverse HPV E7 bind PTPN14 and that
HPV E7 from high-risk genotypes direct PTPN14 for degradation. Here, we made the new
observation that diverse HPV E7 proteins reduce PTPN14 protein levels, indicating that
both PTPN14 binding and degradation are highly conserved activities of HPV E7 proteins.
By characterizing an HPV E7 variant that cannot bind PTPN14, we have also shown that
inactivation of PTPN14 rather than another target of E7 or of UBR4 leads to the repression
of differentiation. Furthermore, we found that the PTPN14 degradation-dependent
repression of differentiation occurs even when E7 is expressed from the complete HPV18
genome. Finally, we demonstrated that PTPN14 degradation contributes to the
carcinogenic properties of HPV18 E7 and confirmed that PTPN14 KO can rescue this
activity. Future studies aimed at elucidating the mechanism by which PTPN14 degradation
represses differentiation, promotes carcinogenesis, and influences the differentiationdependent HPV life cycle will further our understanding of this highly conserved HPV E7
activity.

Materials and Methods
Plasmids and cloning
Mutations in HPV E7 ORFs were introduced by site-directed mutagenesis into
pDONR-Kozak-E7 plasmids and recombined into MSCV-P C-FlagHA GAW or MSCV-Neo
C-HA GAW as previously described (126). LentiCRISPR v2 (Addgene number 52961)
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vectors were cloned according to standard protocols using single guide RNA (sgRNA)
sequences as contained in the Broad Institute Brunello library (226). pNeo-loxP-HPV18
was the kind gift of Thomas Broker and Louise Chow (230) and was used as the template
to generate pNeo-loxP-HPV18 E7 R84S by PCR site-directed mutagenesis of the E7containing portion of the genome, followed by reassembly of this fragment into the pNeoloxP-HPV18 vector using HiFi DNA assembly (New England Biolabs [NEB]). Plasmids
used in the study are listed in Table S1 in the supplemental material.

Cells
Primary human foreskin keratinocytes (HFK) from two donors were isolated and
provided as deidentified material by the Penn Skin Biology and Diseases Resource-based
Center Core B. N/Tert-1 are hTert-immortalized HFKs (201). Keratinocytes were cultured
as previously described (176). HPV E7-expressing cell populations were established by
transduction with MSCV retroviral vectors, followed by puromycin selection. PTPN14
knockout or nontargeting control primary HFKs were established by transduction with
LentiCRISPR v2 vectors, followed by puromycin selection. HPV E7 expression in the
CRISPR/Cas9-edited cells was achieved by simultaneous transduction of MSCV retroviral
vectors and selection with G418 and puromycin. Retroviruses and lentiviruses were
generated as previously described (126). To generate HFKs containing complete HPV
genomes, cells were co-transfected with pNeo-loxP-HPV18 or pNeo-loxP-HPV18 E7
R84S and a Cre expression plasmid using FuGENE HD (Promega) as previously
described (230). HFK populations containing the HPV genomes were selected for with
G418 for 4 days.
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Western blotting
Western blots were performed using Mini-Protean or Criterion (BioRad) SDSPAGE gels and transferred to polyvinylidene difluoride (PVDF). After blocking in 5% nonfat
dried milk in Tris-buffered saline [pH 7.4] with 0.05% Tween-20 (TBS-T), membranes were
incubated with the following primary antibodies: RB1 (Calbiochem/EMD), actin (Millipore),
PTPN14 (R&D Systems or Cell Signaling Technology), KRT1 (Santa Cruz), KRT10 (Santa
Cruz), or involucrin (Santa Cruz)). Membranes were washed in TBS-T and incubated with
horseradish peroxidase (HRP)-coupled anti-mouse or anti-rabbit antibodies and detected
using a chemiluminescent substrate. HA-tagged proteins were detected and visualized
using an HA antibody conjugated to HRP (Roche). For anti-HA immunoprecipitations, HAtagged proteins were immunoprecipitated and processed for Western blot as previously
described (128).

qRT-PCR
Total RNA was isolated from N/Tert or HFK cells using the NucleoSpin RNA
extraction kit (Macherey-Nagel). RNA was reverse transcribed using the high capacity
cDNA reverse transcription kit (Applied Biosystems). cDNAs were assayed by qPCR using
Fast SYBR green master mix (Applied Biosystems) using a QuantStudio 3 system
(ThermoFisher). KiCqStart SYBR green primers for qRT-PCR (Sigma-Aldrich) were
specific for MCM2, CCNE2, KRT1, KRT10, IVL, MAF, GAPDH, and G6PD. All qRT-PCR
data were normalized to GAPDH or to G6PD.

Keratinocyte Differentiation Assays
N/Tert-E7 or empty vector cells were stimulated to differentiate by growth in highcalcium medium or by culture in suspension. For calcium differentiation, cells were grown
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to ~30% confluence in 6-well plates using standard growth conditions in keratinocyte
serum-free medium (K-SFM) with growth factors. To induce differentiation, growth factors
were withdrawn and cells were refed with keratinocyte basal medium (Lonza)
supplemented to achieve 1.5 mM (final) CaCl2. Cells were harvested for RNA analysis 72
h posttreatment. For culture in suspension, cells were harvested by trypsinization and
replated in ultralow attachment plates (Sigma-Aldrich). After 0 or 12 h of culture in
suspension cells were harvested for RNA analysis or 1000 cells were replated on standard
6-well tissue culture plates. Replated cells were stained with crystal violet 5 days
postreplating. pNeo-loxP-HPV18 transfected HFK cells were also grown to high
confluence and were stimulated to differentiate by culturing for 0, 2, or 6 days in growth
factor-free keratinocyte basal medium (Lonza) supplemented to achieve 1.5 mM (final)
CaCl2.

RNA-seq
Total RNA was isolated from 3 independent isolates of HFK-empty vector control,
HFK-18E7, or HFK 18E7 R84S cells using the RNeasy minikit (Qiagen). The poly(A)
selection, reverse transcription, library construction, sequencing, and initial analysis were
performed by Novogene. Differentially expressed genes were selected based on a 1.5fold change and FDR-adjusted p value of < 0.05 cutoff and were analyzed for enriched
biological processes (BPs) using the GO enrichment analysis tool of the PANTHER
classification system (228). All GO terms in enrichment analyses are displayed in rank
order by the FDR-adjusted p value.
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Keratinocyte Lifespan Extension
To assess the ability of HPV18 E7 variants to extend the keratinocyte life span,
primary HFKs were transduced with MSCV-E7 retroviruses and selected with puromycin.
Cells were selected in puromycin and passaged for approximately 50 days. Population
doublings were calculated based upon the number of cells collected and replated at each
passage. Each experiment consisted of three independent replicates conducted
simultaneously.

Data Availability
RNA-seq data from HFK-empty, HFK-18E7, and HFK-18E7 R84S are freely
accessible in the NCBI GEO database under accession number GSE150201.
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CHAPTER 4 | YAP1 ACTIVATION BY HUMAN PAPILLOMAVIRUS E7 PROMOTES
BASAL CELL IDENTITY IN SQUAMOUS EPITHELIA

The contents of this chapter have been previously published as:
Hatterschide J, Castagnino P, Kim HW, Sperry SM, Montone KT, Basu D, White EA.
2022. YAP1 activation by human papillomavirus E7 promotes basal cell identity in
squamous epithelia. eLife 11:e75466.
Supplemental tables can be found on the journal’s website.
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Abstract
Persistent human papillomavirus (HPV) infection of stratified squamous epithelial
cells causes nearly 5% of cancer cases worldwide. HPV-positive oropharyngeal cancers
harbor few mutations in the Hippo signaling pathway compared to HPV-negative cancers
at the same anatomical site, prompting the hypothesis that an HPV-encoded protein
inactivates the Hippo pathway and activates the Hippo effector yes-associated protein
(YAP1). The HPV E7 oncoprotein is required for HPV infection and for HPV-mediated
oncogenic transformation. We investigated the effects of HPV oncoproteins on YAP1 and
found that E7 activates YAP1, promoting YAP1 nuclear localization in basal epithelial
cells. YAP1 activation by HPV E7 required that E7 binds and degrades the tumor
suppressor protein tyrosine phosphatase non-receptor type 14 (PTPN14). E7 required
YAP1 transcriptional activity to extend the lifespan of primary keratinocytes, indicating that
YAP1 activation contributes to E7 carcinogenic activity. Maintaining infection in basal cells
is critical for HPV persistence, and here we demonstrate that YAP1 activation causes HPV
E7 expressing cells to be retained in the basal compartment of stratified epithelia. We
propose that YAP1 activation resulting from PTPN14 inactivation is an essential,
targetable activity of the HPV E7 oncoprotein relevant to HPV infection and
carcinogenesis.

Introduction
Human papillomaviruses (HPV) are nonenveloped viruses with circular doublestranded DNA genomes that infect keratinocytes in stratified squamous epithelia (2, 62,
179). Although most HPV infections are cleared by the immune system, some infections
persist and form higher grade lesions that can lead to cancer (22-25). HPV infection at
mucosal epithelial sites causes cancers including oropharyngeal, cervical, vaginal, penile,
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and anal malignancies (181, 229). Nearly 5% of human cancer cases are caused by
persistent infection with one of the high-risk (oncogenic) HPV genotypes (1).
Inactivation of host cell tumor suppressors by the high-risk HPV E6 and E7
oncoproteins modulates cellular processes that enable HPV persistence. Two wellcharacterized instances of tumor suppressor inactivation by HPV are high-risk HPV E6
proteins targeting p53 for proteasome-mediated degradation and high-risk HPV E7
proteins binding and degrading the retinoblastoma protein (RB1) (75, 86, 87, 240). Both
p53 degradation and RB1 inactivation are required for productive HPV infection (67, 68,
115, 230, 241). In addition to supporting productive infection, E7 is essential for HPVmediated carcinogenesis (76). The impact of the HPV oncoproteins on cell growth control
pathways is reflected in human cancer genomic data: genes in the p53 pathway and in
the RB1-related cell cycle pathway are frequently mutated in HPV-negative head and neck
squamous cell carcinoma (HNSCC) but infrequently mutated in HPV-positive HNSCC
(77).
Although some of the growth-promoting activities of high-risk HPV E6 and E7 are
well established, open questions remain. RB1 binding/degradation by high-risk HPV E7 is
necessary but insufficient for E7 transforming activity (82, 112, 116-120, 172-175).
Papillomavirus researchers have sought to identify one or more activities of HPV E7 that
cooperate with RB1 inactivation to promote carcinogenesis and to identify the cellular
pathway affected by such an activity. Human cancer genomic data indicates that like the
p53 and cell cycle pathways, the Hippo signaling pathway is more frequently mutated in
HPV-negative than in HPV-positive HNSCC. The core Hippo pathway consists of a kinase
cascade upstream of the effector proteins yes-associated protein (YAP1) and its paralog
transcriptional coactivator with PDZ binding motif (TAZ). When the Hippo kinases are
inactive, YAP1 and TAZ are activated and translocate to the nucleus. In stratified
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squamous epithelia, YAP1 is primarily expressed in the basal layer, where YAP1
activation is regulated by contextual cues including cell density, tension in the extracellular
matrix, and contact with the basement membrane (149, 157, 242). In normal stratified
squamous epithelia, activation of YAP1 and TAZ promotes expansion of the basal cell
compartment and inhibition of YAP1 and TAZ allows keratinocytes to differentiate (149,
156, 157, 159, 163, 169). Mutations in many of the tumor suppressors upstream of
YAP1/TAZ are common in a variety of cancer types (243).
Protein tyrosine phosphatase non-receptor type 14 (PTPN14) has been implicated
as a tumor suppressor and negative regulator of YAP1 (130, 134, 135, 138). Diverse HPV
E7 bind directly to PTPN14 and recruit the E3 ligase UBR4 to direct PTPN14 for
proteasome-mediated degradation (126, 128, 154, 216). We have shown that PTPN14
degradation and RB1 binding/degradation are separable activities of HPV E7 that each
contributes to E7 carcinogenic activity (128, 176, 177). However, the downstream
consequences of PTPN14 degradation are poorly understood, and so far we have not
observed that PTPN14 inactivation in human keratinocytes causes an increase in
canonical YAP1 target genes CTGF and CYR61.
These observations regarding an additional transforming activity of HPV E7, the
ability of E7 to inactivate PTPN14, and the relative paucity of mutations in the Hippo
pathway in HPV-positive HNSCC led us to hypothesize that HPV E7-mediated activation
of YAP1 is required for the transforming activity of high-risk HPV E7. Here we show that
expression of high-risk HPV E7 is sufficient to activate YAP1 and that HPV E7 requires
YAP1/TAZ-TEAD transcriptional activity to promote cell growth. We demonstrate that HPV
E7 must bind PTPN14 to activate YAP1 and that PTPN14 inactivation alone is sufficient
to activate YAP1. YAP1 activation by HPV E7 is restricted to the basal layer of the
epithelium where we found PTPN14 expression to be enriched.
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Our finding that either HPV E7 or PTPN14 loss activated YAP1 specifically in basal
epithelial cells led us to investigate the role of YAP1 activation during normal HPV
infection. HPV infection begins in basal epithelial keratinocytes (54, 244, 245) and infected
basal cells are the site of persistent HPV infection (88). The basal cell compartment
contains the only long-lived cells in the epithelium and the HPV genome can be maintained
in dividing cells in a largely dormant state (63, 64, 246). Activation of YAP1 and TAZ has
been proposed to maintain the progenitor cell state in several different epithelia (145, 159,
170, 247, 248). If YAP1 activation by E7 promotes the maintenance of a basal cell state
in stratified squamous epithelia, YAP1 activation could facilitate the persistence of HPVpositive cells. Testing this hypothesis, we found that YAP1 activation and PTPN14
degradation by E7 both promote the maintenance of cells in the basal compartment of
stratified epithelia. We propose that YAP1 activation facilitates HPV persistence and
contributes to the carcinogenic activity of high-risk HPV E7.

Results
HPV E7 activates YAP1 in basal keratinocytes
A comprehensive analysis of somatic mutations and copy number variations in
human tumor samples revealed that the cell cycle, p53, and Hippo pathways are the three
pathways that exhibit the greatest difference in alteration frequency in HPV-negative vs
HPV-positive HNSCC (77). We used data made available by The Cancer Genome Atlas
(TCGA) through cBioPortal (249) to recapitulate the finding that genes in these pathways
are altered at a lower frequency in HPV-positive than in HPV-negative HNSCC (Figure
4.1A and Supplemental Figure 4.1). However, most HPV-positive HNSCC arise in the
oropharynx. We repeated the analysis of pathway alteration rates using data only from
HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas (OPSCC)
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(Figure 4.1A and Supplemental Figure 4.1). Consistent with previous findings, HPVnegative OPSCC were more frequently altered in the p53, cell cycle, and Hippo pathways
than HPV-positive OPSCC. Hippo pathway alterations in HPV-negative HNSCC or
OPSCC include amplification of the YAP1/TAZ oncogenes or inactivating mutations in one
or more of the upstream inhibitors of YAP1/TAZ, including PTPN14. Either alteration type
is consistent with a carcinogenic role for YAP1 activation in HNSCC.
To test whether an HPV-encoded protein activates YAP1, we grew three
dimensional (3D) organotypic epithelial cultures to model the differentiation of
keratinocytes into basal and suprabasal compartments. Organotypic cultures of primary
human foreskin keratinocytes (HFK) harboring an HPV18 genome exhibited increased
YAP1 staining and increased YAP1 nuclear localization, indicative of YAP1 activation, in
the basal layer of the epithelium compared to HFK cultures (Figure 4.1B and Supplemental
Figure 4.2A-E). Proliferating cell nuclear antigen (PCNA) transcription increases upon
RB1 inactivation and is a marker of HPV E7 expression (94, 115, 250). Although YAP1
activation in the HPV18 genome containing cells was restricted to the basal cells, PCNA
levels were elevated in both the basal and suprabasal layers of the epithelium in the same
cultures.
We next tested whether either high-risk HPV E6 or E7 alone was sufficient to
activate YAP1. HFK transduced with retroviral expression vectors encoding HPV16 E6,
HPV16 E7, or HPV18 E7 were used to grow organotypic cultures. YAP1 expression and
nuclear localization were increased in the HPV16 E7 and HPV18 E7 expressing cells
relative to parental HFK (Figure 4.1C, Supplemental Figure 4.3A-C, and Supplemental
Figure 4.5A-C). Similar to our observation in the HPV18 genome-containing cells, YAP1
activation was restricted to the basal epithelial layer. YAP1 nuclear localization increased

102

Figure 4.1. HPV E7 activates YAP1 in basal epithelial keratinocytes.
(A) cBioPortal analysis for total genomic mutations and copy number alterations in HPV-positive
and HPV-negative oropharyngeal squamous cell carcinoma (OPSCC) and head and neck
squamous cell carcinoma (HNSCC). Graph displays the percent of tumors with alterations in each
pathway. Statistical significance was determined by Fisher’s exact test (**p<0.01, ****p<0.0001).
(B–D) Organotypic cultures were grown from primary human foreskin keratinocytes (HFK), HFK
harboring the HPV18 genome, or HFK transduced with retroviral expression vectors encoding HPV
E6 or E7 proteins. Formalin-fixed paraffin-embedded sections of cultures grown from (B) HFK or
HFK harboring the HPV18 genome, (C) HFK or HFK expressing HPV16 E7 or HPV18 E7, or (D)
HFK or HFK expressing HPV16 E6 or HPV16 E7 were stained for YAP1 (magenta), proliferating
cell nuclear antigen (PCNA) (green), and Hoechst (gray). White dashed lines indicate the basement
membrane. White boxes indicate the location of insets in main images. Main image scale bars =
100 μm. Inset scale bars = 25 μm.
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modestly in organotypic cultures of HPV16 E6 expressing cells (Figure 4.1D,
Supplemental Figure 4.4, and Supplemental Figure 4.5A-C). Constitutive expression of
either HPV16 E7 or HPV18 E7 induced PCNA expression in basal and suprabasal cells.
We conclude that HPV promotes increased YAP1 expression and nuclear localization in
basal keratinocytes and that E7 is sufficient for YAP1 activation.

HPV E7 activates YAP1 in keratinocytes through PTPN14 degradation
We previously discovered that HPV E7 binds and targets the YAP1 inhibitor
PTPN14 for proteasome-mediated degradation (126, 128). We tested whether loss of
PTPN14 expression in keratinocytes was sufficient to activate YAP1 in stratified epithelia
by growing 3D organotypic cultures from existing control and PTPN14 knockout (KO)
N/Tert-Cas9 keratinocytes (176). We found that YAP1 levels and YAP1 nuclear
localization were increased in PTPN14 KO cultures compared to controls (Figure 4.2A
and Supplemental Figure 4.6A-F). YAP1 activation in basal epithelial cells lacking
PTPN14 was comparable to YAP1 activation in HPV E7 cells. We conclude that loss of
PTPN14 expression activates YAP1 in basal keratinocytes.
A highly conserved C-terminal arginine in E7 makes a direct interaction with the Cterminus of PTPN14 and the HPV18 E7 R84S variant is unable to bind or degrade
PTPN14 (154, 177). To test whether PTPN14 degradation by HPV E7 is required for
activation of YAP1, we grew 3D organotypic cultures using primary HFK transduced with
retroviral expression vectors encoding HPV18 E7 wild type (WT) or HPV18 E7 R84S.
Indeed, YAP1 expression and nuclear localization in the basal layer of HPV18 E7 R84S
cultures were reduced compared to HPV18 E7 WT controls (Figure 4.2B, Supplemental
Figure 4.5A-C, and Supplemental Figure 4.7).
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Figure 4.2. HPV E7 activates YAP1 in basal keratinocytes through PTPN14 degradation.
Organotypic cultures were grown from N/Tert-Cas9 keratinocytes transfected with sgRNA or from
primary human foreskin keratinocytes (HFK) transduced with retroviral expression vectors
encoding HPV18 E7 WT or R84S. (A) Formalin-fixed paraffin-embedded (FFPE) sections of
cultures grown from mock or sgPTPN14 transfected N/Tert-Cas9 keratinocytes were stained for
YAP1 (magenta), involucrin (IVL) (green), and Hoechst (gray). (B) FFPE sections of cultures grown
from parental HFK, HPV18 E7 WT, or HPV18 E7 R84S expressing HFK were stained for YAP1
(magenta), proliferating cell nuclear antigen (PCNA) (green), and Hoechst (gray). White dashed
lines indicate the basement membrane. White boxes indicate the location of insets in main images.
Main image scale bars = 100 μm. Inset scale bars = 25 μm. (C–F) Quantification of the number of
(C and D) basal cells and (E and F) suprabasal cells per 100 μm of epidermis. Graphs display the
mean ± SD and each individual data point (independent organotypic cultures). (C and E) Statistical
significance was determined by t-test. (D and F) Statistical significance was determined by ANOVA
using the Holm-Sídák correction for multiple comparisons (*p<0.05, ***p<0.001).
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In addition to activating YAP1, PTPN14 loss increased basal cell density from an
average of 5.5 cells per 100 μm in control cultures to 9.0 cells per 100 μm in PTPN14 KO
cultures (Figure 4.2C). Basal cell density was higher in HPV18 E7 WT cultures (9.4 cells
per 100 μm) than in HPV18 E7 R84S cultures (7.1 cells per 100 μm) (Figure 4.2E). No
statistically significant difference in suprabasal cell density was observed in either
comparison (Figure 4.2D,F). We conclude that E7 expression or PTPN14 loss in stratified
squamous epithelia is sufficient to activate YAP1 in the basal layer of the epithelium and
increase basal cell density.

PTPN14 expression is enriched in basal keratinocytes
YAP1 activation was restricted to basal epithelial cells in our organotypic cultures,
leading us to hypothesize that PTPN14 may act as a basal layer specific inhibitor of YAP1.
We therefore sought to determine whether PTPN14 expression is restricted to a specific
subset of cells in the stratified epithelium. In a recent single-cell RNA sequencing analysis
of human neonatal foreskin epidermis, PTPN14 mRNA expression was enriched in the
basal-III cluster (Figure 4.3A,B) (45). The basal-III cell cluster was described to be
nonproliferating, marked by COL17A1 expression, and predicted to differentiate directly
into spinous cells based on pseudotime analysis. PTPN14 expression was higher in basalIII cells than in the spinous or granular cell clusters. To measure PTPN14 expression in
basal and suprabasal cells in our cultures, we used laser capture microdissection to isolate
basal and suprabasal layers from 3D organotypic cultures grown from unmodified primary
HFK (Figure 4.3C). We found that there was an approximately fivefold enrichment of
PTPN14 mRNA in the basal epithelial layer compared to the suprabasal layers (Figure
4.3D). As expected, the basal integrins ITGA6 and ITGB4 were expressed in the basal
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Figure 4.3. PTPN14 expression is enriched in basal keratinocytes.
(A-B) Single-cell RNA sequencing data and clustering analysis from Wang et al. was reanalyzed to
assess PTPN14 expression in different subsets of epidermal cells. (A) Diagram of epidermis;
shading depicts tissue localization of cell clusters. (B) For each donor, the mean of PTPN14 mRNA
expression was calculated for each cell cluster. Graphs display the mean of PTPN14 mRNA
expression for each donor (circles) as well as the mean of all five donors ± SEM (bars and error
bars). Statistical significance was determined by ANOVA using the Holm-Sídák correction for
multiple comparisons (*p<0.05, **p<0.01). (C-F) Basal and suprabasal layers from organotypic
cultures were dissected using laser capture microdissection. (C) Representative images of HFK
cultures before and after individual laser dissections. Hundreds of such cuts were performed per
sample. (D-F) RNA was purified from isolated layers and qRT-PCR was used to assess the
expression of PTPN14 (D), basal cell markers ITGA6 and ITGB4 (E), and differentiation markers
KRT1 and IVL (F). Graphs display the mean and each individual data point.
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layer (Figure 4.3E) and the differentiation markers KRT1 and IVL were expressed in the
suprabasal layers (Figure 4.3F). The same pattern of PTPN14 mRNA expression was
observed in an organotypic culture grown from primary HFK expressing HPV18 E7 WT
(Supplemental Figure 4.8A-C). We conclude that PTPN14 mRNA is enriched in basal
keratinocytes in the presence or absence of HPV E7. Our data support that PTPN14 acts
as a YAP1 inhibitor specifically in the basal compartment of stratified epithelia.

YAP1/TAZ regulate differentiation downstream of PTPN14
In previous unbiased experiments we found that the primary effect of PTPN14
inactivation on transcription is to repress epithelial differentiation gene expression (176,
177). However, we also observed that PTPN14 inactivation did not increase expression
of the canonical YAP1/TAZ targets CTGF and CYR61. Consistent with this difference
there was minimal overlap between PTPN14-dependent differentially expressed genes
and the genes listed in the MSigDB conserved YAP1 signature (Figure 4.4A). We
therefore asked whether the ability of PTPN14 to regulate differentiation gene expression
requires YAP1/TAZ as intermediates. Transduction of keratinocytes with a PTPN14
lentivirus induced the expression of the differentiation markers KRT10 and IVL in a dosedependent manner (Supplemental Figure 4.9A-C). To test whether PTPN14 required
YAP1/TAZ to increase differentiation marker gene expression, we transfected HFK with
siRNAs targeting YAP1 and WWTR1 (the gene encoding TAZ) then transduced the cells
with PTPN14 lentivirus (Figure 4.4B). HFK transfected with control siRNA exhibited the
expected increase in KRT1 and IVL after transduction with PTPN14 lentivirus (Figure
4.4C,D and Supplemental Figure 4.10A,B). However, keratinocytes depleted of
YAP1/TAZ did not express relatively more KRT1 or IVL when PTPN14 was overexpressed
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Figure 4.4. YAP1/TAZ regulate differentiation downstream of PTPN14.
(A) Venn diagram comparing the MSigDB YAP conserved signature to the differentially expressed
genes (DEG) from our two published experiments that reflect PTPN14 loss in keratinocytes. (B–D)
YAP1 and WWTR1 were simultaneously knocked down by siRNA transfection in human foreskin
keratinocytes (HFK). Transfected HFK were then transduced with PTPN14 lentivirus at 24 hr posttransfection. Cells were lysed for protein and total cellular RNA at 72 hr post-transfection. (B) Cell
lysates were subjected to SDS-PAGE/Western blot analysis and probed with antibodies to
PTPN14, YAP1, TAZ, and actin (Figure 4—source data 1). TAZ blot was generated by reprobing
the membrane that was originally probed for YAP1. (C and D) qRT-PCR was used to measure the
expression of the differentiation markers KRT1 and IVL relative to G6PD. Graphs display fold
change in gene expression relative to the mock transduced cells. (E–I) Primary HFK were
transfected with siRNAs targeting YAP1, WWTR1 (TAZ), PTPN14, LATS1, and LATS2. Two
siRNAs were used per target. qRT-PCR was used to measure gene expression for: the
differentiation markers IVL (E) and KRT1 (F), and the canonical YAP1/TAZ targets CTGF (G) and
CYR61 (H). Data confirming that individual siRNA transfections depleted intended transcripts are
summarized in a heatmap of log2(fold-change) levels (I). Bar graphs display the mean ± SD of
three independent replicates. Statistical significance of each treatment compared to siC was
determined by ANOVA using the Holm-Sídák correction for multiple comparisons (*p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001).
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than when it was not. We conclude that PTPN14 requires YAP1 and/or TAZ to regulate
differentiation gene expression in keratinocytes. Both pairs of YAP1/TAZ siRNA had the
same effect on differentiation in response to PTPN14 overexpression yet only one pair
efficiently depleted TAZ protein levels (Figure 4.4B), leading us to speculate that YAP1 is
the key intermediate connecting PTPN14 levels to differentiation gene expression.
Next, we tested whether repression of keratinocyte differentiation occurs upon loss
of LATS1 and LATS2, the core Hippo pathway kinases that phosphorylate and inhibit
YAP1 and TAZ. We used siRNAs to deplete PTPN14, LATS1, or LATS2 and measured
the expression of the differentiation markers KRT1 and IVL (Figure 4.4E,F). Depletion of
PTPN14, LATS1, or LATS2 all decreased differentiation gene expression to a similar
degree. None of the three knockdowns significantly affected the levels of CTGF or CYR61
(Figure 4.4G-H). Direct depletion of YAP1 or WWTR1 affected both differentiation gene
expression and CTGF/CYR61 levels. Other than siWWTR1-08, all siRNAs used in these
experiments reduced the expression of their target genes by twofold or greater (Figure
4.4I). YAP1 knockdown always had a stronger effect than did WWTR1 knockdown and
our qRT-PCR analyses supported that WWTR1 transcript levels were low in HFK. This
result shows that inactivation of three different YAP1 inhibitors dampens differentiation
gene expression even in the absence of a differentiation stimulus and does not increase
canonical YAP1 target gene expression in keratinocytes. We have previously observed
that PTPN14 knockout or E7 expression reduces differentiation gene expression both in
undifferentiated cells and in cells stimulated to differentiate (176, 177). Taken together,
these data support that PTPN14 promotes differentiation through inhibition of YAP1/TAZ
despite not affecting canonical YAP1/TAZ target genes.
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HPV-positive HNSCC are less differentiated than HPV-negative HNSCC
We next asked whether the gene expression pattern observed downstream of
PTPN14 loss is reflected in HPV-positive cancers. HPV-positive HNSCC have a strong
propensity toward poorly differentiated, basaloid histology (235, 236), which is reflected in
their transcriptional profile (176). We confirmed the relationship between HPV positivity
and greater impairment of differentiation by immunohistochemical analysis of the
differentiation marker KRT1 in sections of 14 HPV-negative tumors and 48 HPV-positive
tumors (Figure 4.5A). Forty-three percent of HPV-negative tumors and 12.5% of HPVpositive tumors stained positive for KRT1. We also measured gene expression in patientderived xenograft (PDX) models generated from human HNSCC. We measured KRT1,
KRT10, and IVL levels using RNA extracted from 11 HPV-negative and 8 HPV-positive
HNSCC PDX. Each differentiation marker was expressed at a lower level in HPV-positive
PDX than in HPV-negative PDX (Figure 4.5B). We observed the same pattern of
differentiation marker gene expression in an analysis of transcriptomic data from other
cohorts (Supplemental Figure 4.11A-C) (249). Having confirmed that HPV-positive
HNSCC exhibit reduced expression of differentiation markers compared to HPV-negative
HNSCC, we measured CTGF and CYR61 levels. We found no significant difference in
expression of these canonical YAP1/TAZ target genes in HPV-positive vs HPV-negative
PDX, although there was a trend toward higher CTGF in the HPV-positive PDX (Figure
4.5C). In the transcriptomic analyses, CTGF and CYR61 expression trended higher in the
HPV-negative HNSCC (Supplemental Figure 4.11D,E). The pattern of low expression of
differentiation markers and unchanged canonical YAP1/TAZ target gene expression in
HPV-positive versus HPV-negative patient samples is consistent with the effects of
PTPN14 inactivation in cultured cells.
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Figure 4.5. HPV-positive HNSCC are less differentiated than HPV-negative HNSCC.
(A) Human HNSCC tumor samples were stained for KRT1 (left). Scale bar = 100 μm. Graph
displays the percentage of tumors that were KRT1+ (right). Statistical significance was determined
by Fisher’s exact test. (B–C) Total RNA was purified from patient-derived xenograft samples and
qRT-PCR was used to assess gene expression of (B) the differentiation markers KRT1, KRT10,
and IVL and (C) the canonical yes-associated protein 1/TAZ targets CTGF and CYR61. Statistical
significance was determined by Mann-Whitney nonparametric test (*p<0.05, **p<0.01).
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High-risk HPV E7 require YAP1/TAZ-TEAD transcriptional activity to extend the lifespan
of primary keratinocytes.
High-risk but not low-risk HPV E7 proteins can extend the lifespan of primary
keratinocytes (184). The TEADi protein is a genetically encoded competitive inhibitor that
prevents binding between YAP1/TAZ and TEAD transcription factors (169). We used
TEADi to test whether YAP1/TAZ-TEAD transcriptional activity was required for high-risk
HPV E7 to extend the lifespan of primary HFK. We transduced HFK with retroviral vectors
encoding GFP, HPV16 E7, or HPV18 E7 plus a lentiviral vector encoding doxycyclineinducible GFP-TEADi. As anticipated, HPV16 E7 or HPV18 E7 extended the lifespan of
primary HFK based on cumulative population doublings (Figures 4.6A,B). TEADi induction
upon doxycycline treatment decreased the lifespan of primary HFK in the presence or
absence of E7, but the effect of YAP1/TAZ-TEAD inhibition was greater in the HPV16 E7
and HPV18 E7 cells, where E7 had minimal ability to promote growth in the presence of
TEADi. We conclude that high-risk HPV E7 proteins require YAP1/TAZ-TEAD
transcriptional activity for their lifespan extending capacity in primary keratinocytes.

PTPN14 loss and YAP1 activation promote basal cell retention in organotypic cultures
YAP1 overexpression impairs differentiation and promotes progenitor cell identity
in squamous and nonsquamous epithelia. HPV infection is maintained in a reservoir of
infected basal cells and productive virus replication begins upon commitment to
differentiation. To better understand how repression of differentiation downstream of YAP1
activation affects HPV viral biology, we developed an assay to measure cell retention in
the basal epithelial layer. We hypothesized that YAP1 activation by HPV E7 might promote
the adoption or maintenance of a basal cell identity in stratified squamous epithelia. In our
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Figure 4.6. High-risk HPV E7 requires YAP1/TAZ-TEAD transcriptional activity to extend the
lifespan of primary keratinocytes.
Primary human foreskin keratinocytes (HFK) were transduced with retroviruses encoding HPV16
E7, HPV18 E7, or GFP, plus pInducer20 TEADi lentivirus. Each cell population was cultured with
or without 1 μg/mL doxycycline (dox) in the media for 38 days and population doublings were
tracked with each passage. Graph displays the mean ± SD of two independently transduced cell
populations per condition. Statistical significance when comparing cell growth with and without
doxycycline was determined by two-way ANOVA using the Sídák correction for multiple
comparisons (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).
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cell fate monitoring assay, a small proportion of GFP-labeled cells were mixed with
unmodified parental HFK and the pool was used to generate organotypic cultures in which
normal labeled cells are randomly distributed throughout the epithelium.
Our initial experiment tested whether YAP1 activation altered cell fate in stratified
squamous epithelia. We used GFP-labeled tracing cells that expressed doxycyclineinducible YAP1 WT, YAP1 S127A (hyperactive), or YAP1 S94A (cannot bind TEAD
transcription factors) (Supplemental Figure 4.12A,B). In organotypic cultures grown from
a 1:25 mixture of GFP-labeled cells and unmodified HFK, about 20% of uninduced GFP+
cells were found in the basal layer. Induction of YAP1 WT or YAP1 S127A expression was
sufficient to promote the retention of nearly 60% of labeled cells in the basal layer of the
epithelium (Figure 4.7A,B). Only around 40% of GFP+ cells were found in the basal layer
when YAP1 S94A was induced. These data indicate that YAP1 activation causes cells to
be retained in the basal layer of a stratified squamous epithelium. The ability of YAP1 to
bind TEAD transcription factors contributed to its activity in the cell fate assay.
We next tested whether loss of PTPN14 expression was sufficient to promote
basal cell identity. We grew organotypic cultures from mixtures of unmodified primary HFK
and GFP-labeled control or PTPN14 KO HFK (Supplemental Figure 4.12C,D). 60%-70%
of PTPN14 KO tracer cells were found in the basal layer when either of two PTPN14 guide
RNAs were used whereas about 20% of control tracer cells were retained in the basal
layer (Figure 4.7C,D). Thus, PTPN14 knockout is sufficient to promote basal cell fate
determination in keratinocytes.
Next, we tested whether HPV E7 promoted basal cell retention and if so, whether
its cell retention activity required PTPN14 degradation. We grew organotypic cultures from
mixtures of GFP-labeled HFK expressing HPV18 E7 WT, HPV18 E7 R84S, or the empty
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Figure 4.7. PTPN14 loss and YAP1 activation by HPV E7 promote basal cell retention in
organotypic cultures.
Organotypic cultures were grown from GFP-labeled human foreskin keratinocytes (HFK) mixed
with unmodified HFK. (A–B) GFP-labeled HFK were transduced with lentiviral vectors encoding
YAP1 WT, YAP1 S127A, or YAP1 S94A under the control of a doxycycline (dox) inducible
promoter. GFP-labeled YAP1 cells were mixed 1:25 into unmodified HFK and organotypic cultures
were grown from the mixture. Cultures were grown ±1 μg/mL doxycycline. (C–D) GFP-labeled HFK
were transduced with LentiCRISPR v2 vectors encoding control or PTPN14 targeting sgRNAs.
GFP-labeled cells were mixed 1:25 into unmodified HFK and organotypic cultures were grown from
the mixture. (E–F) GFP-labeled HFK were transduced with HPV18 E7 WT, HPV18 E7 R84S, or
the empty vector (EV). GFP-labeled HPV18 E7 cells were mixed 1:50 into unmodified HFK and
organotypic cultures were grown from the mixture. Two different images for 18E7 R84S reflect
cases in which all tracer cells migrated to the suprabasal layers (differentiated) or in which some
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tracer cells remained in the basal layer (basal). (A, C, E) Formalin-fixed paraffin-embedded sections
of cultures were stained for GFP (green), IVL (gray), and Hoechst (blue). Scale bar = 100 μm. (B,
D, F) Quantification of the percentage of GFP+ cells found in the basal layer. Graphs display the
mean ± SD and each individual data point (independent organotypic cultures). Shapes indicate
cultures grown from different HFK donors. Statistical significance was determined by ANOVA using
the Holm-Sídák correction for multiple comparisons (*p<0.05, **p<0.01).

vector control diluted 1:50 into unmodified primary HFK (Supplemental Figure 4.12E,F).
We found that nearly 80% of GFP-labeled HPV18 E7 WT tracer cells were retained in the
basal layer compared to about 10% of labeled control cells (Figure 4.7E,F). HPV18 E7
WT labeled cells were numerous and grouped in clusters in the basal layer, suggesting
that E7 promoted the clonal expansion of labeled basal cells. Both effects were dampened
in experiments using HPV18 E7 R84S tracer cells (cannot degrade PTPN14). Labeled
HPV18 E7 R84S cells exhibited varying degrees of basal cell expansion and basal cell
retention and approximately 60% of labeled cells were in the basal layer. HPV18 E7 R84S
retains the ability to inactivate RB1 and we interpret these data to mean that the
proliferation of labeled basal cells resulted from RB1 inactivation. Finally, HPV18 E7
∆DLLC cannot bind RB1 but can bind and degrade PTPN14. In a cell fate experiment
using GFP-labeled HPV18 E7 ∆DLLC tracer cells, the labeled cells were present mainly
as single cells in the basal layer (Supplemental Figure 4.13A-B). The behavior of the two
mutant HPV E7 proteins supports that PTPN14 degradation is required for basal cell
retention and RB1 inactivation is required for basal cell expansion. We conclude that
PTPN14 degradation and YAP1 activation by HPV18 E7 promote basal cell retention.

Discussion
YAP1 and TAZ are oncogenes that promote growth and inhibit differentiation in
stratified squamous epithelia (149, 156, 157, 163, 169). Here we report that HPV E7
activates YAP1 (Figure 4.1). YAP1/TAZ-TEAD transcriptional activity is required for the
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carcinogenic activity of HPV E7 (Figure 4.6) and YAP1 activation by E7 biases HPV E7expressing cells to be retained in the basal epithelial layer (Figure 4.7). Based on these
findings we propose that YAP1 activation by HPV E7 enables HPV-infected cells to persist
in stratified epithelia. There is substantial evidence that RB1 inactivation is necessary but
insufficient for the transforming activity of high-risk HPV E7 (82, 112, 116-120, 172-175).
We propose that YAP1 activation cooperates with RB1 inactivation to enable the
transforming activity of HPV E7.
PTPN14 binding by HPV18 E7 was required for activation of YAP1 in the basal
layer and PTPN14 KO was sufficient for the same effect (Figure 4.2). Highly conserved
amino acids in E7 participate in binding to PTPN14 (154, 177), indicating that YAP1
activation and maintenance of basal cell state is likely shared among diverse
papillomavirus E7 proteins. Some minor genotype-specific differences were apparent.
HPV18 E7 depletes PTPN14 protein levels more efficiently than HPV16 E7 (128, 177),
which is consistent with the observed stronger effect of HPV18 E7 on YAP1 nuclear
localization in basal cells (Figure 4.1). Genotype-specific differences could also explain
the stronger effect of TEADi on HPV18 E7 in lifespan extension assays (Figure 4.6).
Although other reports have suggested that HPV might activate YAP1 (251-254), no
specific activity of an HPV protein has previously been shown to enable YAP1 activation.
Other groups have proposed that HPV E6 activates YAP1 (251, 254), and we observed
modest YAP1 activation by HPV E6 compared to E7. We conclude that activation of YAP1
by HPV E7 is contingent upon its ability to bind and degrade PTPN14.
Even when HPV E7 was expressed in all layers of a stratified epithelium, YAP1
levels and nuclear localization increased only in basal epithelial cells. We found that E7
required PTPN14 degradation to activate YAP1 and that PTPN14 was expressed
predominantly in basal keratinocytes (Figure 4.3). Basal cell-specific expression of
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PTPN14 is consistent with the observation that it is regulated by p63, the master regulator
of basal cell identity in stratified epithelia (219). We propose that PTPN14 inhibits YAP1
primarily in basal cells and that unlike the effects of E7 on RB1 in both differentiated and
undifferentiated cells, E7 activates YAP1 primarily in basal cells.
Degradation of PTPN14 by HPV E7 represses keratinocyte differentiation but does
not induce canonical Hippo pathway target genes (176, 177). Nonetheless, we found that
PTPN14 overexpression required YAP1/TAZ to promote differentiation gene expression
(Figure 4.4C,D). Few studies have tested how YAP1 inhibitor inactivation alters gene
expression downstream of YAP1. Here we demonstrate that inactivation of LATS1 or
LATS2, two well-characterized inhibitors of YAP1/TAZ, also decreased expression of
differentiation genes in unstimulated cells but did not induce canonical YAP1/TAZ targets
(Figure 4.4E-I). Taken together, these experiments indicate that PTPN14 acts through
YAP1/TAZ to regulate differentiation in keratinocytes. It is so far unclear why CTGF and
CYR61 expression is sensitive to large changes in total levels of YAP1 or TAZ yet is
unaffected by alterations in regulators upstream of YAP1/TAZ. Nonetheless, the pattern
of low differentiation gene expression and unchanged expression of canonical YAP1/TAZ
target genes caused by PTPN14 loss is consistent with gene expression differences
between HPV-positive and HPV-negative HNSCC.
PTPN14 knockout and knockdown reduced differentiation gene expression in
monolayer culture. Even so, we did not observe reduced differentiation in suprabasal
layers of organotypic cultures grown from PTPN14 knockout cells (Figure 4.2A and
Supplemental Figure 4.6A-C). Using our cell fate monitoring assay, we determined that
instead, HPV18 E7 promotes basal cell retention and that either YAP1 overexpression or
PTPN14 KO is sufficient for this activity (Figure 4.7). The HPV18 E7 R84S mutant that
cannot degrade PTPN14 was impaired, but not completely deficient, in its ability to
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promote basal cell retention. We interpret these data to mean that E7 activities in addition
to PTPN14 degradation might contribute to basal cell retention. GFP-labeled basal cells
in the HPV18 E7 R84S cell fate monitoring experiments were present in clusters,
suggesting that cells that were able to remain in the basal layer had undergone clonal
expansion. It is possible that RB1 inactivation by the mutant E7 drives an apparent
increase in R84S mutant basal cells in this assay. The effect of YAP1 activation on cell
fate in our assay resembles several experiments in which YAP1 promotes progenitor cell
identity in airway and liver epithelia (145, 170). Our findings demonstrate that YAP1
activation enables basal cell fate determination in stratified squamous epithelia and show
that loss of an inhibitor of YAP1 has the same effect. We conclude that one consequence
of YAP1 activation by HPV E7 is that E7-expressing cells are retained in the basal layer
of stratified squamous epithelia.
Although persistent infection is a prerequisite for HPV-mediated carcinogenesis,
the mechanisms used by papillomaviruses to establish persistent infections remain
incompletely understood. Maintaining infection in the basal cell compartment is critical for
papillomavirus persistence. Substantial effort has been devoted to the mechanistic
understanding of how the papillomavirus genome is stably maintained in the basal layer
upon cell division. However, much less is known about how papillomaviruses manipulate
epithelial cell fate to establish and expand the pool of infected basal cells. Previously, HPV
E7 was believed to be primarily required to establish a cellular environment conducive to
HPV DNA replication in suprabasal cells (67, 68, 94, 115). We propose that a so far
unappreciated role of E7 is that it activates YAP1 to facilitate HPV persistence by biasing
infected cells to remain in the basal layer of the epithelium. Not every HPV E7-expressing
cell was retained in the basal layer, so we do not anticipate that YAP1 activation would
block differentiation-dependent HPV replication. HPV E6 also represses differentiation
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gene expression in keratinocytes and has been proposed to promote basal cell retention
(100). Further research is needed to determine the extent to which different HPV
genotypes depend on the activities of E6 or E7 for basal cell retention activity.
To the best of our knowledge, no other viruses are recognized to modulate cell
fate decisions in solid tissues in a way that facilitates persistence. Some herpesviruses
impact the choice between progenitor/differentiated cell fates in infected immune cells, for
example Epstein-Barr virus (EBV) and human herpesvirus 6B (HHV6B) restrict
differentiation in infected cells (255-259). Herpesviruses, polyomaviruses, and
hepadnaviruses encode proteins proposed to activate YAP1/TAZ or alter Hippo signaling
(260-265). Not all of the mechanisms used by these viruses to activate YAP1 nor the
downstream consequences of YAP1 activation have been well defined. Our finding that
HPV E7 activates YAP1 to manipulate cell fate opens up an exciting new line of inquiry
into how YAP1, TAZ, and the Hippo signaling pathway could impact viral infections by
regulating tissue developmental processes.
YAP1 activation and PTPN14 are relevant to both viral and non-viral cancers. We
found that a genetically encoded inhibitor of YAP1/TAZ-TEAD transcription inhibited the
growth of high-risk HPV E7 expressing cells (Figure 4.6), indicating that high-risk HPV E7
proteins require YAP1 or TAZ for carcinogenesis. YAP1/TAZ activation is sufficient to drive
carcinogenesis in mouse models of cervical and oral cancer (160, 161, 266), and the YAP1
inhibitor verteporfin reduced the growth of HPV-positive tumors in a xenograft model (162).
YAP1 activation correlates with the clinical stage of HPV infection (161), and YAP1
localizes to the nucleus in HPV-positive cancers (267). Basal cell carcinoma (BCC) is the
non-viral cancer that is most clearly linked to PTPN14. Germline inactivating mutations in
PTPN14 are associated with a fourfold to eightfold increase in risk of BCC by age 70 (131)
and somatic mutations in PTPN14 are frequent in BCC (129). YAP1/TAZ-TEAD
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transcriptional activity also restricts differentiation in BCC cells (268). We propose that the
specific association of PTPN14 with BCC is related to our observation that PTPN14 loss
activates YAP1 in basal epithelial cells. YAP1 inhibition is of major clinical interest for
several cancer types, and it is appealing to speculate that targeting YAP1 could treat
persistent HPV infection and/or HPV-positive cancers.

Materials and Methods
Key Resources Table
Reagent
type
(species)
or resource

Designation

Antibody

anti-Actin
(Mouse
monoclonal)

Source or
reference

Identifiers

Additional
information

Sigma-Aldrich

Cat#: MAB1501;
RRID:AB_2223041

WB
(1:20,000)

Antibody

anti-GFP
(Rabbit
polyclonal)

Invitrogen

Cat#: A6455;
RRID:AB_221570

WB
(1:1,000);
IHC-P
(1:2000)

Antibody

anti-Mouse
IgG Alexa
Fluor 488
(Goat
polyclonal)

Invitrogen

Cat#: A11001;
RRID:AB_2534069

IHC-P
(1:250)

Antibody

anti-Mouse
IgG HRP
(Horse
monoclonal)

Cell Signalling
Technologies

Cat#: 7076;
RRID:AB_330924

WB
(1:2000)

Antibody

anti-Rabbit IgG
Alexa Fluor
594 (Goat
polyclonal)

Invitrogen

Cat#: A11012;
RRID:AB_2534079

IHC-P
(1:250)

Antibody

anti-Rabbit IgG
HRP (Goat
monoclonal)

Cell Signalling
Technologies

Cat#: 7074;
RRID:AB_2099233

WB
(1:2000)
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Antibody

anti-HAPeroxidase
(Rat
monoclonal)

Roche

Cat#:
12013819001;
RRID:AB_390917

WB
(1:500)

Antibody

anti-ITGB4
(Rabbit
polyclonal)

Sigma-Aldrich

Cat#:
HPA036348;
RRID:AB_2675077

IHC-P
(1:100)

Antibody

anti-IVL
(Mouse
monoclonal)

Santa Cruz
Biotechnology

Cat#:
sc-398952

IHC-P
(1:100)

Antibody

anti-KRT1
(Mouse
monoclonal

Enzo Life
Sciences

Cat#:
C34904;
RRID:AB_2265594

Antibody

anti-PCNA

Santa Cruz
Biotechnology

Cat#:
sc-56;
RRID:AB_628110

IHC-P
(1:100)

Antibody

Anti-PTPN14
(Rabbit
monoclonal)

Cell Signalling
Technology

D5T6Y; Cat#:
13808;
RRID:AB_2798318

WB
(1:500)

Antibody

anti-TAZ
(Rabbit
monoclonal)

Cell Signalling
Technology

D3I6D; Cat#:
70148;
RRID:AB_2799776

WB
(1:1000)

Antibody

anti-V5 (Mouse
monoclonal)

Invitrogen

Cat#: 46-0705

WB
(1:1000)

Antibody

anti-YAP1
(Rabbit
monoclonal)

Cell Signalling
Technology

D8H1X; Cat#:
14074;
RRID:AB_2650491

WB
(1:1000);
IHC-P
(1:50)

transfected
construct
(human)

nontargeting
siRNA

Dharmacon

Cat#: D-001810-01

transfected
construct
(human)

siRNA to YAP1
(OnTarget
Plus)

Dharmacon

Cat#: J-012200-06

transfected
construct
(human)

siRNA to YAP1
(OnTarget
Plus)

Dharmacon

Cat#: J-012200-08
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transfected
construct
(human)

siRNA to
WWTR1
(OnTarget
Plus)

Dharmacon

Cat#: J-016083-06

transfected
construct
(human)

siRNA to
WWTR1
(OnTarget
Plus)

Dharmacon

Cat#: J-016083-08

transfected
construct
(human)

siRNA to
PTPN14
(OnTarget
Plus)

Dharmacon

Cat#: J-008509-05

transfected
construct
(human)

siRNA to
PTPN14
(OnTarget
Plus)

Dharmacon

Cat#: J-008509-08

transfected
construct
(human)

siRNA to
LATS1
(OnTarget
Plus)

Dharmacon

Cat#: J-004632-05

transfected
construct
(human)

siRNA to
LATS1
(OnTarget
Plus)

Dharmacon

Cat#: J-004632-08

transfected
construct
(human)

siRNA to
LATS2
(OnTarget
Plus)

Dharmacon

Cat#: J-003865-09

transfected
construct
(human)

siRNA to
LATS2
(OnTarget
Plus)

Dharmacon

Cat#: J-003865-10

Plasmids and cloning
pInducer20 EGFP-TEADi was a gift from Ramiro Iglesias-Bartolome (Addgene
plasmid # 140145) (169). pQCXIH-Myc-YAP (Addgene plasmid # 33091), pQCXIH-FlagYAP-S127A (Addgene plasmid # 33092), and pQCXIH-Myc-YAP-S94A (Addgene plasmid
# 33094) were gifts from Kun-Liang Guan (269). Each YAP1 ORF was amplified by PCR
from pQCXIH, cloned into pDONR223, and transferred into pLIX_402 lentiviral backbone
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using Gateway recombination. pLIX_402 was a gift from David Root (Addgene plasmid #
41394). pLenti CMV GFP Hygro (656-4) was a gift from Eric Campeau & Paul Kaufman
(Addgene plasmid # 17446) (270). pHAGE-P-CMVt N-HA GFP was previously described
(271). pNeo-loxP-HPV18 was the kind gift of Thomas Broker and Louise Chow (230). The
∆DLLC mutation was introduced into the pDONR HPV18 E7 vector using site-directed
mutagenesis. HPV18 E7 ∆DLLC and GFP ORFs were cloned into MSCV-P C-FlagHA
GAW or MSCV-Neo C-HA GAW destination vectors using Gateway recombination. The
remaining MSCV-P C-FlagHA and MSCV-Neo C-HA HPV E6 and HPV E7 retroviral
plasmids and pHAGE lentiviral plasmids have been previously described (126, 128, 171,
176, 177). A complete list of all plasmids used in this study is in Supplemental File 1.

Cell culture, retrovirus production, and lentivirus production
Deidentified primary HFK and human foreskin fibroblasts (HFF) were provided by
the University of Pennsylvania Skin Biology and Disease Resource-Based Center
(SBDRC). N/Tert-1 cells are hTert-immortalized HFK (201), and N/Tert-Cas9 mock and
sgPTPN14-1 are N/Tert-1 cells further engineered to constitutively express Cas9 (176).
Keratinocytes for cell fate experiments were cultured in keratinocyte serum-free media
(KSFM) (Life Technologies, Carlsbad, California) mixed 1:1 with Medium 154 (Thermo
Fisher Scientific, Waltham, Massachusetts) with the human keratinocyte growth
supplement (HKGS) (Thermo Fisher Scientific) (272). Keratinocytes for all other
experiments were cultured as previously described (171). SBDRC-sourced primary HFK
were derived from independent donors and were used within the first 2-8 passages after
isolation. N/Tert-1 keratinocytes were obtained directly from the laboratory in which they
were derived (201) and were used in the first 2-4 passages post thawing. HFK are a shortlived source material that are not routinely STR profiled or tested for mycoplasma
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contamination. N/Tert-1 keratinocytes were observed at every passage to ensure that they
retained keratinocyte morphology, displayed the cobblestone growth pattern characteristic
of human skin keratinocytes, and were immortalized (grew indefinitely past the time at
which they were used in the experiments reported herein). These cells also express
keratinocyte specific genes (e.g. KRT1 and IVL) and retain the capacity to stratify and
differentiate in organotypic culture. HFF were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) (Thermo Fisher Scientific) supplemented with antibiotic and antimycotic.
HFK harboring the HPV18 genome were previously described (177), and were generated
by transfecting cells with the pNeo-loxP-HPV18 vector (230) along with NLS-Cre and
selecting with G418 to generate a stable population. Lentiviruses and retroviruses were
produced in 293T or 293 Phoenix cells respectively as previously described (128). Stable
keratinocyte populations were generated following transduction by selection with
puromycin, G418, or hygromycin alone or in combination.

Lifespan extension assay
Primary HFK were engineered and cultured as described in cell culture, retrovirus
production, and lentivirus production. The growth of engineered HFK was monitored in
culture for 38 days. Population doublings were calculated using the number of cells at the
beginning and end of each passage.

Organotypic epithelial culture
Devitalized human dermis was provided as deidentified material from the
University of Pennsylvania SBDRC. Stands for organotypic epithelial cultures were printed
using high temperature, autoclavable resin at the University of Pennsylvania Biotech
Commons 3D-printing facility. Organotypic cultures were generated as previously
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described (273, 274). Devitalized dermis was seeded with primary HFF on the dermal side
at a density of 3 x 104 cells per cm2 of culturing area and cultured for four days. Dermis
and fibroblasts were then stretched across 3D-printed stands. The epidermal side of the
dermis was seeded with unmodified or engineered keratinocytes at a density of 1 x 106
cells per cm2. Organotypic cultures were cultured in E media (275) with the dermal layer
maintained at the air-liquid interface starting on the day of seeding keratinocytes. Cultures
were allowed to stratify for 12-14 days, then trimmed and fixed in 10% neutral buffer
formalin for 24 hr. Tissues were embedded in paraffin and sectioned by the SBDRC Core
A. A complete list of all organotypic cultures used in this study is in Supplemental File 2.

siRNA transfection
Primary HFK were transfected with siRNAs using the Dharmafect 1 transfection
reagent. All siRNA experiments were collected 72 hr post-transfection. Two siRNAs were
used to target each gene in an experiment. The siRNAs used in this study were all
purchased from Dharmacon (Lafayette, Colorado): nontargeting siRNA, siYAP1-06,
siYAP1-08, siWWTR1-06, siWWTR1-08, siPTPN14-05, siPTPN14-08, siLATS1-05,
siLATS1-08, siLATS2-09, siLATS2-10.

Laser capture microdissection
Formalin-fixed paraffin-embedded (FFPE) organotypic cultures were sectioned
onto polyethylene naphthalate membrane glass slides by the SBDRC Core A. Laser
capture microdissection was performed on a Leica LMD 7000 microscope. Hundreds of
microdissections were made per sample amounting to ~1.5 mm2 of total dissected area
per sample. RNA was isolated using the RNeasy FFPE kit (Qiagen, Germantown,
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Maryland). RNA concentration was determined using Qubit RNA HS assay kit (Life
Technologies).

Patient-derived xenografts
The PDXs were previously established from surgical resections of treatment-naive
HPV-positive OPSCC as described (276). Human tumors were engrafted subcutaneously
in NSG mice and passaged at least twice before cryopreservation when they reached a
volume of 0.5-1.0 cm3. Total tumor RNA was isolated using the QIAamp RNA Blood Mini
Kit (Qiagen).

Western blotting
Western blots were performed using Mini-PROTEAN (Bio-Rad Laboratories,
Hercules, California) or Criterion (Bio-Rad) Tris/Glycine SDS-PAGE gels and transfers
were performed onto polyvinylidene difluoride. Membranes were blocked with 5% nonfat
dry milk in Tris-buffered saline with 0.05% Tween 20 (TBST). Membranes were incubated
with primary antibodies as specified in Supplemental File 1. Following TBST washes,
membranes were incubated with horseradish peroxidase-coupled secondary antibodies
and imaged using chemiluminescent substrate on an Amersham Imager 600 (GE
Healthcare, Chicago, Illinois).

qRT-PCR
Unless otherwise specified, total cellular RNA was isolated using the NucleoSpin
RNA extraction kit (Macherey-Nagel/Takara, San Jose, California). cDNA was generated
from bulk RNA with the high-capacity cDNA reverse transcription kit (Applied Biosystems,
Waltham, Massachusetts). cDNAs were used as a template for qPCR using Fast SYBR
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green master mix (Applied Biosystems) and a QuantStudio 3 system (Thermo Fisher
Scientific). 18S rRNA qRT-PCR primers were ordered from Integrated DNA Technologies
(Integrated

DNA

Technologies,

CGCCGCTAGAGGTGAAATTCT;

REV,

Inc,

Coralville,

Iowa):

FWD,

5- CGAACCTCCGACTTTCGTTCT

5(277).

KiCqStart SYBR green primers for qRT-PCR (MilliporeSigma, St. Louis, Missouri) were
used for the remaining genes assayed in this study: KRT1, KRT10, IVL, ITGB4, ITGA6,
CYR61, CTGF, PTPN14, YAP1, WWTR1, LATS1, LATS2, G6PD, and GAPDH.

Immunofluorescence, immunohistochemistry, and microscopy
FFPE sections were prepared for immunofluorescence by deparaffinization with
xylene washes, rehydration through an ethanol gradient, and heat induced epitope
retrieval (HIER). Tissue sections were blocked with PBS containing 1% bovine serum
albumin, 10% normal goat serum, and 0.3% Triton X-100. Tissue sections were incubated
with primary antibodies at 4°C overnight, washed with PBS with 0.05% Tween 20, and
incubated with fluorescently labeled secondary antibodies and Hoechst 33342 at room
temperature. Antibody dilutions and HIER conditions are specified in Supplemental File 1.
Fluorescent micrographs were captured using an Olympus IX81 microscope. All
fluorescent micrograph images within the same figure panels were captured using the
same exposure time and batch processed using the same contrast settings.
YAP1 localization in basal epithelial cells was quantified by visual classification of
the YAP1 staining in each cell as predominantly nuclear, predominantly cytoplasmic, or
comparably distributed between the nucleus and cytoplasm using Hoechst stain to
demarcate the nucleus. Basal or suprabasal cell identity in the cell fate monitoring assays
was determined by visual classification based on co-staining of GFP+ with the suprabasal
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cell marker IVL. All image analysis was performed using deidentified images with codified
names.
The tissue microarray (TMA) was constructed from surgical resection specimens
of 120 HNSCC that vary by TNM stage and HPV status (Supplemental File 3). Archival
FFPE tumors of the oral cavity and oropharynx were identified retrospectively and
oropharyngeal tumors were evaluated for HPV status as per College of American
Pathologists criteria (278) using IHC for p16. When present, lymph node metastases were
included in association with the primary tumor of origin. All FFPE specimens were
represented in the TMA by at least three tissue cores that incorporate both non-necrotic
central tumor regions and invasive margins. Staining for KRT1 was performed by the
Clinical Services Laboratory in the University of Pennsylvania Department of Pathology
and Laboratory Medicine. Antibody information can be found in Supplemental File 1. The
KRT1 stained slides were reviewed with a standard light microscope, and evaluation was
based on the presence or absence of staining in the cytoplasm of tumor cells.

Bioinformatic analysis
Genomic mutation and copy number variation data as well as tumor RNA-seq gene
expression data from TCGA (249) were analyzed using the cBioPortal.org graphical
interface (279, 280). RNA-seq V2 RSEM (RNA-Seq by Expectation Maximization)
normalized expression values for individual genes were downloaded directly from
cBioPortal.org. OPSCC were distinguished from HNSCC by clinical annotation of primary
tumor site and HPV-positive and HPV-negative status was assigned based on previously
reported HPV transcript status (281). Genes included in pathway analysis are listed in
Supplemental File 4. Missense, truncating, and splice mutations of unknown significance
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as well as amplifications of tumor suppressor genes and deletion of oncogenes were
excluded from total alteration tallies.
Single cell-RNA sequencing dataset derived from the human neonatal foreskin
epidermis and subsequent clustering analysis were retrieved from GitHub (45) and
reanalyzed with MATLAB. PTPN14 expression was calculated by averaging mRNA
expression for all cells by cluster and donor.
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All patient-derived materials and clinical data in this study were obtained from
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Patients were counseled preoperatively and provided informed consent under University
of Pennsylvania IRB-approved protocol #417200 “Head and Neck Cancer Specimen
Bank” (PI: D. Basu) by signing a combined informed consent and HIPAA form for use of
tissue for research. Consent under this longstanding and currently active protocol explicitly
provides permission to access surgically removed fresh tumor tissue that is not needed
for pathologic analysis as well as to access FFPE tumor tissue in the pathology archive at
a later date. It also provides explicit permission to publish deidentified analyses of these
resources. Patient care is not altered under this protocol, which carries minimal risk.
Minors and other vulnerable populations are not included in the study.
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Supplemental Figures

Supplemental Figure 4.1. HPV-positive HNSCC have fewer Hippo pathway alterations and
lower expression of differentiation genes.
cBioPortal analysis for genomic mutations and copy number alterations in HPV-positive and HPVnegative HNSCC and oropharyngeal squamous cell carcinoma (OPSCC). Oncoprint displays
specific genomic alterations in individual tumor samples.
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Supplemental Figure 4.2. HPV18 E7 activates YAP1 in basal keratinocytes.
(A–B) Additional replicates of organotypic cultures grown from primary human foreskin
keratinocytes (HFK) or HFK harboring the HPV18 genome. Formalin-fixed paraffin-embedded
sections were stained for YAP1 (magenta), proliferating cell nuclear antigen (PCNA) (green), and
Hoechst (gray). White dashed lines indicate the basement membrane. White boxes indicate the
location of insets in main images. Main image scale bars = 100 μm. Inset scale bars = 25 μm. (C–
E) Quantification of the percentage of basal cells in which YAP1 is predominantly localized to the
cytoplasm (C), comparably distributed between the nucleus and the cytoplasm (D), or
predominantly localized to the nucleus (E). Graphs display the mean ± SD and each individual data
point (independent organotypic cultures). Statistical significance was determined by t-test
(*p<0.05).
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Supplemental Figure 4.3. HPV E7 activates YAP1 in basal keratinocytes.
Additional replicates of organotypic cultures grown from primary human foreskin keratinocytes
(HFK) or HFK transduced with retroviral expression vectors encoding HPV E7 proteins. Formalinfixed paraffin-embedded sections of cultures grown from (A) HFK or HFK expressing HPV16 E7 or
HPV18 E7, (B) HFK or HFK expressing HPV16 E7, or (E) HFK and HFK expressing HPV18 E7
were stained for YAP1 (magenta), proliferating cell nuclear antigen (PCNA) (green), and Hoechst
(gray). White dashed lines indicate the basement membrane. White boxes indicate the location of
insets in main images. Main image scale bars = 100 μm. Inset scale bars = 25 μm.
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Supplemental Figure 4.4. HPV E6 does not activate YAP1 in basal keratinocytes.
Additional replicates of organotypic cultures grown from primary HFK or HFK transduced with
retroviral expression vectors encoding HPV E6 or E7 proteins. Formalin-fixed paraffin-embedded
sections were stained for YAP1 (magenta), proliferating cell nuclear antigen (PCNA) (green), and
Hoechst (gray). White dashed lines indicate the basement membrane. White boxes indicate the
location of insets in main images. Main image scale bars = 100 μm. Inset scale bars = 25 μm.
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Supplemental Figure 4.5. Quantification of YAP1 activation by HPV E7 in basal
keratinocytes.
(A–C) Quantification of the percentage of basal cells in which YAP1 is predominantly localized to
the cytoplasm (A), comparably distributed between the nucleus and the cytoplasm (B), or
predominantly localized to the nucleus (C). Graphs display the mean ± SD and each individual data
point (independent organotypic cultures). Statistical significance was determined by ANOVA using
the Holm-Sídák correction for multiple comparisons (*p<0.05, **p<0.01).
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Supplemental Figure 4.6. PTPN14 knockout activates YAP1 in basal keratinocytes.
Additional replicates of organotypic cultures grown from N/Tert-Cas9 keratinocytes. (A–C)
Formalin-fixed paraffin-embedded sections from mock or sgPTPN14 transfected N/Tert-Cas9
keratinocytes were stained for YAP1 (magenta), IVL (green), and Hoechst (gray). White dashed
lines indicate the basement membrane. White boxes indicate the location of insets in main images.
Main image scale bars = 100 μm. Inset scale bars = 25 μm. (D–F) Quantification of the percentage
of basal cells in which YAP1 is predominantly localized to the cytoplasm (D), comparably distributed
between the nucleus and cytoplasm (E), or predominantly localized to the nucleus (F). Graphs
display the mean ± SD and each individual data point (independent organotypic cultures). Statistical
significance was determined by t-test (*p<0.05).
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Supplemental Figure 4.7. HPV E7 activates YAP1 in basal keratinocytes through PTPN14
degradation.
Additional replicates of organotypic cultures grown from primary human foreskin keratinocytes
(HFK) transduced with retroviral expression vectors encoding HPV18 E7 WT or R84S. Formalinfixed paraffin-embedded sections from parental HFK, HPV18 E7 WT, or HPV18 E7 R84S
expressing HFK were stained for YAP1 (magenta), proliferating cell nuclear antigen (PCNA)
(green), and Hoechst (gray). White dashed lines indicate the basement membrane. White boxes
indicate the location of insets in main images. Main image scale bars = 100 μm. Inset scale bars =
25 μm.
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Supplemental Figure 4.8. PTPN14 expression is enriched in basal keratinocytes in HPV 18
E7 expressing organotypic cultures.
Basal and suprabasal layers from a 3D organotypic culture grown from human foreskin
keratinocytes transduced with a retroviral expression vector encoding HPV18 E7 were dissected
using laser capture microdissection. RNA was purified from isolated layers and qRT-PCR was used
to assess the expression of PTPN14 (A), the basal cell markers ITGA6 and ITGB4 (B), and the
differentiation marker IVL (C). Graphs display individual data points.
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Supplemental Figure 4.9. PTPN14 overexpression promotes differentiation in keratinocytes.
NTert-Cas9 Mock and sgPTPN14-1 keratinocytes were transduced with lentiviruses encoding
green fluorescent protein (GFP) or PTPN14 or the empty vector control. (A) Cell lysates were
subjected to SDS-PAGE/Western blot analysis and probed with antibodies to PTPN14, V5-tag,
involucrin, and actin (Figure 4—figure supplement 1—source data 1). (B) qRT-PCR was used to
measure the expression of the differentiation markers IVL and KRT10 relative to G6PD. Graphs
display the mean ± SD of two independent replicates.
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Supplemental Figure 4.10. YAP1 and TAZ are required for PTPN14 to promote keratinocyte
differentiation.
Primary human foreskin keratinocytes (HFK) were transfected with control or YAP1 and WWTR1
targeting siRNAs then transduced with PTPN14 encoding lentivirus. qRT-PCR was used to
measure the expression of the differentiation markers (A) KRT1 and (B) IVL relative to G6PD.
Graphs portray the change in gene expression relative to siC. Graphs display the mean ± SD of
three independent replicates. Statistical significance was determined by ANOVA using the HolmSídák correction for multiple comparisons (**p<0.01, ***p<0.001).
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Supplemental Figure 4.11. HPV-positive HNSCC express lower levels of differentiation
genes.
RNA-seq data from The Cancer Genome Atlas were accessed through cBioPortal. Violin plots
display the distribution in log2 mRNA expression of differentiation markers (A) KRT1, (B) KRT10,
and (C) IVL, and the canonical YAP1/TAZ targets (D) CTGF and (E) CYR61. Statistical significance
was determined by Mann-Whitney nonparametric test (**p<0.01, ***p<0.001, ****p<0.0001).
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Supplemental Figure 4.12. PTPN14 degradation by HPV E7 promotes basal cell retention.
(A–B) GFP-labeled human foreskin keratinocytes (HFK) were transduced with yes-associated
protein (YAP1) WT, YAP1 S127A, or YAP1 S94A under the control of a doxycycline inducible
promoter. (A) GFP expression was confirmed by fluorescence microscopy. Scale bar = 100 μm.
(B) Total RNA was purified from monolayer cells ± treatment with 1 μg/mL doxycycline for 72 hr.
qRT-PCR was used to assess gene expression of YAP1 and CTGF. (C–D) GFP-labeled HFK were
transduced with LentiCRISPR v2 sgNT-1, sgPTPN14-3, or sgPTPN14-4 vectors. (C) GFP
expression was confirmed by fluorescence microscopy. Scale bar = 100 μm (D) Cell lysates were
subjected to SDS-PAGE/Western blot analysis and probed with antibodies to PTPN14 and actin
(Figure 7—figure supplement 1—source data 1). (E–F) GFP-labeled HFK were transduced with
retroviral vectors encoding HPV18 WT, HPV18 ΔDLLC, HPV18 E7 R84S, or the empty vector
control (EV). (E) GFP expression was confirmed by fluorescence microscopy. Scale bar = 100 μm.
(F) Cell lysates were subjected to SDS-PAGE/Western blot analysis and probed with antibodies to
PTPN14, RB1, and actin (Figure 7—figure supplement 1—source data 2).
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Supplemental Figure 4.13. HPV18 E7 can promote basal cell retention in the absence of RB1
binding.
Organotypic cultures were grown from GFP-labeled cells mixed with unmodified human foreskin
keratinocytes (HFK). GFP-labeled HFK were transduced with HPV18 E7 ΔDLLC or the empty
vector (EV). GFP-labeled cells were mixed 1:50 into unmodified HFK. (A) Formalin-fixed paraffinembedded sections were stained for GFP (green), IVL (gray), and Hoechst (blue). Scale bar = 100
μm (B) Quantification of the percentage of GFP+ cells found in the basal layer. Graphs display the
mean ± SD and each individual data point (independent cultures). Statistical significance was
determined by t-test. (**p<0.01).

145

CHAPTER 5 | DISCUSSION
HPV E7 is the primary driver of HPV-mediated carcinogenesis and plays a critical
role in the virus replicative cycle. It has long been appreciated that HPV E7 likely has
activities in addition to inactivating RB1 (82, 112, 116-120, 172-175). This dissertation
sought to uncover how a more recently described activity of HPV E7, degradation of the
tumor suppressor PTPN14, impacts HPV biology. In this chapter, I will summarize the
findings from Chapters two, three, and four, discuss how they fit into the broader context
of HPV biology and disease, and point to interesting open questions and future directions
that would build upon this work. As much is already discussed in chapters two-four, this
chapter will primarily focus on topics directly related to future directions.

Summary of findings
In Chapter 2, we identified that PTPN14 degradation by HPV E7 leads to
repression of keratinocyte differentiation gene expression and that PTPN14 degradation
contributed to the carcinogenic activity of HPV16 E7. We characterized the HPV16 E7
E10K variant that cannot bind to UBR4 or degrade PTPN14. We then used poly(A)
selection RNA sequencing to assess gene expression differences between keratinocytes
expressing HPV16 E7 WT, E10K, and Δ21-24 (cannot bind RB1). We found that genes
related to keratinocyte differentiation dominated the signature associated with UBR4
binding by E7. Analysis of the differentially expressed genes between control and PTPN14
knockout keratinocytes identified a very similar signature. These experiments also
revealed that HPV16 E7 represses differentiation in the absence of RB1 binding, in
agreement with PTPN14 degradation by HPV16 E7 being an RB1-independent activity.
Interestingly, canonical YAP1/TAZ transcriptional targets were not observed to be altered
in these experiments. Finally, we found that binding to UBR4 and degrading PTPN14
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improved survival of keratinocytes following growth in suspension and contributed to the
immortalization of primary keratinocytes by HPV16 E6/E7. This provided the first evidence
that PTPN14 degradation by HPV E7 may contribute to HPV-mediated carcinogenesis.
In Chapter 3, we explored a conserved arginine residue in the C-terminal domain
of HPV E7 proteins. We found that mutation of this residue blocks PTPN14 binding by
HPV16 E7 and HPV18 E7 and restores PTPN14 protein levels in keratinocytes expressing
many E7 proteins. We used poly(A) selection RNA sequencing to assess differences in
gene expression associated with HPV18 binding to PTPN14. We observed that HPV18
E7 repressed keratinocyte differentiation in a PTPN14 binding-dependent manner.
PTPN14 degradation by E7 was necessary for the complete HPV18 genome to repress
differentiation as well. Like UBR4 binding by HPV16 E7, binding to PTPN14 was required
for HPV18 E7 to extend the lifespan of primary HFK. This phenotype could be rescued by
knocking out PTPN14, indicating that PTPN14 degradation and not inactivation of another
E7 target (such as PTPN21) is responsible for the observed growth defect in HPV18 E7
R84S expressing keratinocytes.
In Chapter 4, we used three-dimensional organotypic epithelial cultures to
investigate the mechanism through which PTPN14 degradation by HPV E7 leads to
repression of differentiation. We hypothesized that this would be mediated by YAP1 and/or
TAZ. Consistent with this hypothesis, we observed that the HPV18 genome promoted
elevated

YAP1

nuclear

localization

in

specifically

basal

keratinocytes

by

immunofluorescence microscopy. HPV16 E7, but not HPV16 E6 promoted YAP1
activation in the basal layer. Furthermore, HPV18 E7 required PTPN14 binding to activate
YAP1, and PTPN14 knockout was sufficient to promote basal layer activation of YAP1.
Using laser capture microdissection followed by qRT-PCR, we found that PTPN14 mRNA
expression is enriched in basal keratinocytes, indicating that compartmentalized PTPN14
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expression could explain the basal layer specificity of this phenotype. Using PTPN14
overexpression and siRNA knockdown of YAP1/TAZ, we found that PTPN14 requires
YAP1/TAZ to promote differentiation, even though PTPN14 does not regulate canonical
YAP1/TAZ transcriptional targets in keratinocytes. HPV16 and HPV18 E7 required
YAP1/TAZ-TEAD transcriptional activity to extend the lifespan or primary keratinocytes.
Finally, we explored how repression of differentiation manifests in the three-dimensional
cell culture model. Interestingly, we found that YAP1 activation by HPV18 E7 promotes
basal cell retention, rather than blocking terminal differentiation. This indicates that
PTPN14 degradation by HPV E7 may help HPV resist epithelial turnover and facilitate
persistence. Put together with our previous studies, this led us to our model that PTPN14
degradation by HPV E7 activates YAP1 to promote basal cell identity (Figure 5.1).

Discussion and future directions
The mechanism by which PTPN14 degradation by HPV E7 represses differentiation
The central finding of this dissertation is that PTPN14 degradation by HPV E7
represses keratinocyte differentiation (176-178). Through these studies, we also
uncovered aspects of the mechanism between PTPN14 and regulation of keratinocyte
differentiation. PTPN14 is expressed primarily in basal cells. Thus, PTPN14 degradation
by HPV E7 leads to basal cell specific YAP1 activation, which represses differentiation
and promotes basal cell identity (Figure 5.1). However, there remain several unanswered
questions surrounding this mechanism. These can be broken down into three major parts:
1) how do YAP1/TAZ regulate gene expression to promote basal cell identity in
keratinocytes, 2) how does PTPN14 inhibit YAP1/TAZ in keratinocytes, and 3) what are
the signals upstream of PTPN14 that prompt YAP1 inhibition.
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Figure 5.1. Model of the mechanism downstream of PTPN14 degradation by HPV E7.
PTPN14 is primarily expressed in the basal layer of stratified squamous epithelia, and PTPN14
degradation by HPV E7 activates YAP1 specifically in basal cells. This leads to repression of
differentiation gene expression and the promotion of basal cell identity. Delaying differentiation may
promote resistance to epithelial turnover, thus expanding the reservoir of infected cells and
facilitating persistence.
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How YAP1/TAZ regulate gene expression is complex. Several different
mechanisms through which YAP1/TAZ regulate gene expression in keratinocytes are
described in Chapter 1. These include stabilization of the basal cell transcription factor
ΔNp63α, crosstalk and inhibition of the NOTCH signaling pathway, and regulation of
KLF4-dependent transcriptional programs (145, 163, 169). Our differential gene
expression analyses from Chapters 1 and 2 could be consistent with any of these
mechanisms. This question is further complicated by the observation that PTPN14 loss in
keratinocytes does not impact the expression of canonical YAP1/TAZ transcriptional
targets despite requiring YAP1/TAZ to regulate differentiation. Exploration of how PTPN14
degradation by HPV E7 impacts the binding sites of YAP1/TAZ on chromatin could provide
a more nuanced understanding of how PTPN14, YAP1, and TAZ regulate differentiation
in stratified squamous epithelia.
There are several important open questions concerning the mechanism through
which PTPN14 inhibits YAP1/TAZ in basal keratinocytes. The first is whether PTPN14
degradation activates TAZ as well as YAP1. Most reports in the literature investigate
specifically the role of PTPN14 in regulating YAP1 (130, 133, 135). However, a handful of
reports have suggested that PTPN14 can also inhibit TAZ (138, 217). When testing
whether YAP1/TAZ are required for PTPN14 overexpression to promote differentiation
gene expression in Chapter 4, one of the siRNAs targeting TAZ transcripts (siWWTR1-8),
was inefficient at reducing TAZ protein levels. However, PTPN14 was unable to promote
differentiation in cells that were simultaneously transfected with this siRNA and a YAP1
targeting siRNA. This result suggests that YAP1 may play a larger role than TAZ in
regulating differentiation downstream of PTPN14. However, this does not discount that
PTPN14 could still inhibit TAZ in keratinocytes.
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Additionally, we do not know what binding partners of PTPN14 contribute to
regulating YAP1/TAZ in keratinocytes, nor whether this mechanism involves the HIPPO
pathway or changes in YAP1 phosphorylation. There are two predominating models for
how PTPN14 regulates YAP1/TAZ (highlighted in Chapter 1): direct binding to YAP1 (135)
and binding to the scaffolding protein KIBRA (also known as WWC1) (138). In the
Appendix, we begin to explore some of these questions by mapping the differentiation
promoting activity of PTPN14 to specific regions and protein-protein interaction motifs. We
found that the differentiation promoting activity of PTPN14 depends on two PY motifs
found in the L1 portion of the linker region of PTPN14. These PY motifs mediate high
affinity binding to KIBRA (147). While these results are consistent with the KIBRA-binding
model of PTPN14 activity, we have not yet identified if KIBRA-binding is necessary for
PTPN14 to promote differentiation. It is possible that KIBRA may be redundant, and that
its homologs WWC2 or WWC3 or another WW-domain containing protein could also
interact with these residues of PTPN14.
The HIPPO pathway integrates many signals to regulate the activity of YAP1/TAZ
(139, 163). Although our data support that PTPN14 is a basal cell specific inhibitor of YAP1
in keratinocytes, the signals that are upstream of PTPN14 in this tissue remain unclear.
PTPN14 expression has been proposed to be regulated by cell density in normal breast
epithelial cells (MCF10A), suggesting that PTPN14 participates in cell density-dependent
regulation YAP1/TAZ (135). In PTPN14 KO raft cultures, we observed increased YAP1
nuclear localization in basal cells, despite the simultaneous increased density of cells in
this layer. These observations could be consistent with a role of PTPN14 in transducing
cell density signals to YAP1/TAZ in stratified squamous epithelia as well.
Recently, another study identified that PTPN14 localizes to the apical domain of
colonic epithelial organoids (Caco-2 cells) and associates with the Par complex (282). The
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Par complex defines apical cell polarity in many cell types and regulates vertical,
asymmetric cell division in stratified squamous epithelia (46, 283, 284). KIBRA also
localizes to the apical domain of epithelial cells and has been reported to associate with
the Par complex (149, 285). PTPN14 expression has been found to be enriched in one
subset of basal cells in the human foreskin epidermis (45, 178). This subset was identified
to potentially be a transitional state between proliferative basal cells and differentiated
suprabasal cells (45). It is interesting to speculate that a PTPN14/KIBRA complex may
associate with the Par complex to inhibit YAP1/TAZ in a subset of basal cells—possibly
prior to or during vertical cell division or delamination. This could provide an explanation
for how PTPN14 is expressed predominantly in the basal layer yet regulates
differentiation. However, the basal cell subsets in stratified squamous epithelia are not yet
well defined. Exactly what the PTPN14-expressing basal cell subset represents and
whether an analogous subset is present in all stratified squamous epithelia remains
unknown. Identifying the discrete signals that are upstream of PTPN14 will be crucial to
better understand PTPN14 function in stratified squamous epithelia and HPV infection.

E7, PTPN14, and basal cell identity in the HPV replicative cycle
Although PTPN14 degradation by HPV E7 leads to repression of keratinocyte
differentiation in monolayer culture (176, 177), CRISPR knockout of PTPN14 does not
impact the ability of keratinocytes to terminally differentiate once they are in the suprabasal
layers of the epithelium (178). Instead, repression of differentiation gene expression
downstream of PTPN14 knockout or degradation delays commitment to differentiation and
promotes basal cell identity in the three-dimensional epithelial model. However, our
understanding of how HPV promotes basal cell identity and how this impacts the HPV
replicative cycle and persistence remains incomplete.
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This effect on keratinocyte cell fate decisions suggests that PTPN14 degradation
by HPV E7 may help HPV resist epithelial turnover and facilitate persistent infection. The
basal layer of the stratified squamous epithelium is believed to serve as the reservoir for
HPV persistence (30, 88, 89). This is because the basal layer contains all of the long-lived,
stem-like cells. In contrast, the cells of the suprabasal layers are committed to terminal
differentiation and an eventual death by desquamation at the surface of the epithelium.
Thus, because PTPN14 degradation by HPV E7 biases cells to remain in the basal layer,
we propose that this activity may contribute to expanding the reservoir of infected basal
cells. HPV does not activate vegetative replication until an infected cell enters the
suprabasal layers and begins to differentiate (2, 25). Accordingly, there are comparatively
fewer copies of the HPV genome and lower levels of viral gene expression in basal cells
(62, 65). As PTPN14 degradation by HPV E7 promotes basal cell identity, it is interesting
to speculate that this activity may also contribute to maintaining a low number of viral
genome copies and low levels of viral gene expression. The impacts of PTPN14
degradation on aspects of HPV virology such as facilitating persistence, regulating viral
genome replication, and regulating viral gene expression merit further investigation.
In the context of HPV infection, other viral gene products could contribute to
promoting basal cell identity. If this is true, PTPN14 degradation by HPV E7 may be
redundant. Therefore, we asked whether PTPN14 degradation by HPV E7 alters cell fate
decisions made by keratinocytes harboring the complete HPV18 genome. We observed
that GFP-labeled cells that harbor HPV18 LoxP E7WT are predominantly found in the basal
layer, as we observed with HPV18 E7 expression alone in Chapter 4 (Figure 5.2A-B).
HPV18 LoxP E7R84S cells were less able to promote basal cell retention. This result
indicates that PTPN14 degradation by HPV18 E7 contributes to promoting basal cell
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Figure 5.2. PTPN14 binding by HPV18 E7 is required for HPV18 genome-containing cells to
adopt basal cell identity in organotypic cultures.
Primary HFK harboring HPV18 LoxP E7WT or HPV18 LoxP E7R84S (described in Chapter 3 Materials
and Methods) were transduced with pLenti CMV GFP, and homogenous population was selected
with hygromycin. GFP-labeled HPV18 LoxP cells were mixed 1:100 into unmodified donor-matched
HFK and organotypic cultures were grown from the mixture (method described in Chapter 4
Materials and Methods). (A) FFPE sections of cultures were stained for GFP (green), IVL (grey),
and Hoechst (blue). Scale bar = 100 μm. Three different images for HPV18 LoxP E7R84S reflect
cases in which the tracer cells were predominantly found in the basal layer (basal), suprabasal
layers (supra) or a mixture (mixed). (B) Quantification of the percentage of GFP+ cells found in the
basal layer. Graph displays the mean ± SD and each individual data point (independent organotypic
cultures).
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identity in the context of the complete HPV18 genome. However, it also suggests that
other activities of HPV18 proteins contribute to this phenotype. This could include activities
of another viral protein or additional activities of HPV E7 itself.
Our data suggest that HPV18 E7 alone has activities in addition to PTPN14
degradation that impact basal cell retention. In Chapter 4, HPV18 E7 R84S mutation only
partially ablated the basal cell retaining activity of HPV18 E7, and HPV18 E7 WT promoted
a greater degree of basal cell retention than PTPN14 KO or YAP1 overexpression alone.
RB1 inactivation is one logical E7 activity that could contribute to expanding the basal cell
pool. In Chapter 2 we reported that the HPV16 E7 Δ21-24 mutant that cannot bind to RB1
was still able to repress the expression of genes related to differentiation. In agreement
with this, expression of the HPV18 E7 ΔDLLC (analogous to HPV16 E7 Δ21-24) in
Chapter 4 promoted basal cell retention. Yet, HPV18 E7 ΔDLLC promoted basal cell
retention to a lesser degree than the WT protein. These data support a potential
contribution of RB1 inactivation to expanding the pool of infected basal cells.
Both E6 and E7 from various HPV genotypes have been shown to impair
keratinocyte differentiation at the level of gene expression and in organotypic raft cultures
[reviewed in (104)]. Therefore, HPV E6 could also contribute to promoting basal cell
identity. High-risk HPV E6 represses differentiation, which is proposed to occur by
impairing NOTCH signaling in a manner that is dependent upon p53 degradation (95,
100). MmuPV1 E6 and beta-HPV E6 directly impair NOTCH signaling and repress
differentiation by binding to MAML1 (96-99). It was recently reported that expression of
MmuPV1 E6 and high-risk alpha-HPV E6 proteins enable normal immortal keratinocytes
(NIKS) to out compete neighboring cells for space in the basal layer at confluence (30, 95,
96). However, high-risk HPV16 E7 did not have activity in these assays, indicating that the
effects measured in cell competition assays are likely not identical to those measured in
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our cell fate monitoring assay (95). The cell fate monitoring assay developed in Chapter 4
would be amenable to directly comparing the genotype-specific contributions of E6 and
E7 to altering cell fate decisions in the three-dimensional tissue. It would be interesting to
test how diverse HPV genotypes differ in their capacity to promote basal cell identity as
well as in which oncoprotein protein primarily drives in this activity.
Promoting basal cell identity may be an advantageous strategy employed by many
HPV genotypes with logical implications for resisting epithelial turnover and promoting
persistence. However, additional open questions remain. If HPV promotes basal cell
identity, what mechanisms allow HPV-infected cells to ultimately differentiate? Also, to
what degree does this activity impact the length of time an HPV-infected cell can remain
in the epithelium? Further characterization of the dynamics of HPV-infected basal cells
over time could help to address these questions. This would likely require the development
of longer-term models of HPV persistence in the epithelium. Such models would also be
invaluable for studying interventions that could be used to clear persistent HPV infections.

PTPN14 degradation by HPV E7 and HPV-mediated carcinogenesis
The final key finding from these studies was that both PTPN14 degradation and
YAP1/TAZ transcriptional activity contribute to the capacity of high-risk HPV E7 to extend
the lifespan of primary keratinocytes. There are several future directions that could build
on these findings: 1) to use the newly developed tools for studying PTPN14 degradation
test how this E7 activity contributes to other aspects of carcinogenesis, 2) to test how
PTPN14 degradation by HPV E7 contributes to cooperation with E6 to promote
transformation, and 3) to directly test whether PTPN14 degradation by HPV E7 contributes
to the poorly differentiated state in HPV-positive tumor cells.
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So far, we have primarily tested how PTPN14 degradation contributes to E7
carcinogenic activity using lifespan extension assays, which best model early stages of
HPV-mediated carcinogenesis. However, HPV E7 has activity in many transformation
assays. Mutations in the C-terminal domain of high-risk HPV E7 proteins that were later
shown to block PTPN14 binding (128, 216), also impair E7 activity in assays of
transformation (107, 117, 118, 286). More recently, the crystal structure of the C-terminal
domain of HPV18 E7 bound to the PTP domain of PTPN14 was solved, enabling the
logical design of mutations in both E7 and PTPN14 that disrupt this interaction (154).
Blocking PTPN14 binding by HPV18 E7 reduced proliferation and migration in E7expressing HaCaT cells, and overexpression of a PTPN14 construct that is not targetable
by E7 reduced proliferation, migration, and invasion in HeLa cells (154). The E7 and
PTPN14 mutations used in this study and those identified through our research, solidify
the mechanistic link between PTPN14 degradation and aspects of E7 carcinogenic
activity. However, these recently developed tools also could enable the direct testing how
PTPN14 degradation by HPV E7 contributes to other assays of transformation such as
cooperating with other oncogenes to promote anchorage-independent growth as well as
mouse models of tumorigenesis.
HPV-positive tumors are addicted to the expression of HPV E6 as well as HPV E7.
The most well-studied activities of E6 and E7 are believed to synergize to promote cellular
transformation. Briefly, by inactivating RB1, HPV E7 promotes unscheduled reentry into
the cell cycle. This would normally lead to stabilization of the p53 tumor suppressor protein
and result in apoptosis. However, HPV E6 directs p53 for proteosome-mediated
degradation, bypassing growth restriction by this tumor suppressive pathway. Both
PTPN14 and YAP1/TAZ have been described to have crosstalk with the cell cycle and
p53 pathways (130, 287, 288). Indeed, in one study, it was found that PTPN14 was a
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transcriptional target of a super tumor-suppressive mouse p53 mutant, and its increased
expression led to inactivation of YAP1 (130). It is unclear whether PTPN14 is a target of
wild-type human p53 in keratinocytes. Additional studies exploring how PTPN14
degradation and YAP1 activation by HPV E7 interact with RB1 inactivation by E7 and p53
degradation by HPV E6 will be required to better understand how this E7 activity fits into
previous models of HPV E6/E7 mediated cellular transformation.
HPV-positive HNSCC tumors are frequently histologically characterized as more
poorly differentiated and basaloid (235, 236), and we have validated this phenotypic
difference in sections of tumor samples, patient derived xenografts, and publicly available
gene expression data from HNSCC tumors (176, 178). This phenotype is consistent with
PTPN14 degradation by HPV E7 delaying differentiation. However, HPV E6 can also
repress differentiation. It will be necessary to directly test the extent to which PTPN14
degradation and YAP1/TAZ activation contribute to the poorly differentiated phenotype in
these tumors. In support a potential role of YAP1 in repressing differentiation in HNSCC,
YAP1 activation downstream of epigenetic repression of KIBRA has been shown to
mediate repression of differentiation in two HPV-negative HNSCC cells lines (289).
Furthermore, YAP1/TAZ transcriptional activity represses differentiation in basal cell
carcinoma (268). Inducing differentiation in tumors can reduce the proportion of tumor
stem cells capable of self-renewal. This is the concept behind differentiation therapy,
which has proven an efficacious strategy based on the successful treatment of acute
promyelocytic leukemia with all-trans retinoic acid (225). If PTPN14 degradation by HPV
E7 does contribute to the poorly differentiated phenotype in HPV-positive tumors, it is
interesting to speculate that targeting PTPN14 degradation by HPV E7, or YAP1/TAZ
activity directly could be a strategy to induce differentiation and block continued cell growth
in these tumors.
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Concluding Remarks
Overall, my dissertation work has provided a more complete understanding of the
function of PTPN14 degradation by HPV E7 in HPV biology and HPV-mediated
carcinogenesis. We found that PTPN14 degradation by HPV E7 promotes basal cell
identity through activating YAP1. Exploration of this mechanism led us to propose that
PTPN14 degradation likely promotes resistance to epithelial turnover, which has
significant implications for HPV persistence. We also provide evidence that PTPN14
degradation and YAP1/TAZ activity contribute to the carcinogenic activity of HPV E7.
Many open questions remain concerning the mechanism downstream of PTPN14
degradation and its role in persistence and carcinogenesis, underscoring the need for
continued investigation into this HPV E7 activity.

159

APPENDIX | MAPPING THE DIFFERENTIATION PROMOTING ACTIVITY OF PTPN14
Summary
HPV E7 proteins from diverse HPV genotypes bind to the host non-receptor protein
tyrosine phosphatase, PTPN14 (125, 126). Many HPV E7 proteins also direct PTPN14 for
proteasome mediated degradation (128, 216). We have identified that PTPN14
degradation by HPV E7 delays differentiation in keratinocytes (176-178). Inversely,
PTPN14 overexpression promotes differentiation, and it does so by inhibiting YAP1 and/or
TAZ (178). However, how PTPN14 inhibits YAP1/TAZ in keratinocytes remains obscure.
In Chapter 1, two mechanisms through which PTPN14 can inhibit YAP1/TAZ are
described. Briefly, PTPN14 can either directly bind and inhibit YAP1 or bind the HIPPO
pathway protein KIBRA leading to indirect inhibition YAP1/TAZ (135, 147). Neither of
these activities require the catalytic activity of PTPN14.
In this appendix, we used the overexpression of various PTPN14 constructs to
map the differentiation promoting activity of PTPN14 to specific regions within the protein.
We found that PTPN14 requires the proline-proline-x-tyrosine (PY) motifs 1 and 2 located
in the L1 portion of the linker to promote differentiation. These two PY motifs have been
previously shown to mediate tight binding to KIBRA (147). KIBRA coimmunoprecipitated
with overexpressed PTPN14 WT but not with PTPN14 ΔPY1/2 in keratinocytes. Future
experiments will directly test whether KIBRA or another WW domain-containing protein is
required for PTPN14 to promote differentiation.

Results and Discussion
Although we have shown that PTPN14 requires YAP1/TAZ expression to regulate
differentiation, much of the mechanism between PTPN14 and differentiation remains
unknown. We speculated that mapping the differentiation promoting activity of PTPN14 to
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specific portions of the protein could grant insight into possible downstream mechanisms.
To test whether PTPN14 required specific domains to promote differentiation, N/Tert-1
keratinocytes were transduced with lentiviral expression vectors encoding WT, truncation,
or deletion PTPN14 constructs (Figure A.1A-B). We then measured the mRNA expression
of the differentiation marker KRT1 by qRT-PCR (Figure A.1C). PTPN14 WT induced
around a 5-fold increase in KRT1 expression in comparison to mock and GFP transduced
negative controls. Deletion of the FERM domain had little impact of the differentiation
promoting activity of PTPN14. Disruption of the L1 or L2 portions of the PTPN14 linker
impaired the KRT1 promoting capacity of PTPN14. Interestingly, PTPN14 was able to
induce a higher level of KRT1 expression when the L3 portion of the PTPN14 linker or the
PTP domain were deleted.
We next asked whether the impaired differentiation caused by deleting L1 is
attributable to the known protein-protein interaction motifs present in L1: PY1/2 (Figure
A.1A). N/Tert-1 keratinocytes were transduced with lentiviral expression vectors encoding
WT, L1-deleted, or PY1/2-deleted PTPN14 constructs, and KRT1 mRNA expression was
measured by qRT-PCR (Figure A.2A-B). Because these motifs are located within two
amino acids of each other, we only tested simultaneous deletion of both. Without PY motifs
1 and 2, PTPN14 overexpression induced much lower levels of KRT1 mRNA expression.
This indicates that PTPN14 likely requires binding to a WW domain-containing protein at
this site to promote differentiation.
As the L2 portion of the PTPN14 linker was also required for PTPN14 induce
differentiation, we next asked whether this activity required PY motifs 3 and 4 (Figure
A.1A). N/Tert-1 keratinocytes were transduced with lentiviral expression vectors encoding
WT, L2-deleted, or singly/doubly PY3/4-deleted PTPN14 constructs (Figure A.3A). PY3
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Figure A.1. PTPN14 requires portions of the linker region to promote differentiation.
(A) Schematic of the domain structure of PTPN14. Relevant protein sequence motifs are identified
below along with their names and reported functions. (B-C) N/Tert-1 keratinocytes were transduced
with lentiviral vectors encoding truncation and deletion constructs of V5-PTPN14 under the CMV
promotor. Protein and RNA samples were collected at 48h post transduction. (A) Cell lysates were
subjected to SDS-PAGE/Western blot analysis and probed with antibodies to V5 (PTPN14) and
Actin. (B) qRT-PCR was used to measure the expression of the differentiation marker KRT1 relative
to GAPDH. Bar graphs display the mean ± SEM and each individual data point (independent
transductions). Statistical significance of each treatment compared to V5-PTPN14 WT was
determined by ANOVA using the Dunnett correction for multiple comparisons (*p<0.05, **p<0.01,
***p<0.001, ****p<0.0001).
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Figure A.2. PTPN14 requires PY motifs 1 and 2 to promote differentiation.
N/Tert-1 keratinocytes were transduced with lentiviral vectors encoding V5-PTPN14 WT, ΔL1, or
ΔPY1/2 under the CMV promotor. Protein and RNA samples were collected at 48h post
transduction. (A) Cell lysates were subjected to SDS-PAGE/Western blot analysis and probed with
antibodies to V5 (PTPN14) and Actin. (B) qRT-PCR was used to measure the expression of the
differentiation marker KRT1 relative to GAPDH. Bar graphs display the mean ± SEM and each
individual data point (independent transductions). Statistical significance of each treatment
compared to V5-PTPN14 WT was determined by ANOVA using the Dunnett correction for multiple
comparisons (**p<0.01, ****p<0.0001).
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and PY4 deletions were made both independently and in combination because they are
178 amino acids apart making it feasible that they could mediate distinct protein-protein
interactions. KRT1 mRNA expression was measured by qRT-PCR (Figure A.3B). Neither
deletion of PY3 nor PY4 impacted differentiation induction by PTPN14. It is interesting that
both the L1 and L2 portions of the linker were necessary for PTPN14 to induce
differentiation in Figure A.1C, while only the PY motifs in L1 were required. It is possible
that L2 makes protein-protein interactions through other unidentified amino acid motifs or
that it contributes additional necessary contacts to binding partners of the PY1/2 tandem
motif.
Deletion of the PTP domain of PTPN14 did not impair induction of KRT1
expression by PTPN14, suggesting that the catalytic activity of PTPN14 is not required for
PTPN14 to induce differentiation. In fact, PTPN14 induced greater levels of differentiation
gene expression when its C-terminal portions were deleted. Therefore, we next asked
whether PTPN14 catalytic activity is responsible for this increased differentiation induction.
N/Tert-1 keratinocytes were transduced with lentiviral expression vectors encoding WT,
L3-deleted, PTP-deleted, or C1121S-mutated (catalytically deficient) PTPN14 constructs
(Figure A.4A). KRT1 mRNA expression was again measured by qRT-PCR as a marker of
differentiation (Figure A.4B). PTPN14 C1121S induced around a 10-fold increase in KRT1
expression in comparison mock and GFP-transduced negative controls, confirming that
PTPN14 catalytic activity is not required for differentiation induction. PTPN14 C1121S
induced slightly higher levels of KRT1 expression in comparison to the WT protein but did
not reach statistical significance. Additionally, PTPN14 C1121S induced lower levels of
KRT1 expression than L3- or PTP-deleted PTPN14. This intermediate phenotype
suggests that both the catalytic activity of PTPN14 as well as another activity of the C-
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Figure A.3. PTPN14 does not require PY motifs 3 or 4 to induce differentiation.
N/Tert-1 keratinocytes were transduced with lentiviral vectors encoding V5-PTPN14 WT, ΔL2 521781, ΔPY3, ΔPY4, or ΔPY3/4 under the CMV promotor. Protein and RNA samples were collected
at 48h post transduction. (A) Cell lysates were subjected to SDS-PAGE/Western blot analysis and
probed with antibodies to V5 (PTPN14) and Actin. (B) qRT-PCR was used to measure the
expression of the differentiation marker KRT1 relative to GAPDH. Bar graphs display the mean ±
SEM and each individual data point (independent transductions). Statistical significance of each
treatment compared to V5-PTPN14 WT was determined by ANOVA using the Dunnett correction
for multiple comparisons (**p<0.01).
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Figure A.4. PTPN14 does not require catalytic activity to promote differentiation.
N/Tert-1 keratinocytes were transduced with lentiviral vectors encoding V5-PTPN14 WT, ΔL3,
ΔPTP, or C1121S (catalytically deficient) under the CMV promotor. Protein and RNA samples were
collected at 48h post transduction. (A) Cell lysates were subjected to SDS-PAGE/Western blot
analysis and probed with antibodies to V5 (PTPN14) and Actin. (B) qRT-PCR was used to measure
the expression of the differentiation marker KRT1 relative to GAPDH. Bar graphs display the mean
± SEM and each individual data point (independent transductions). Statistical significance of each
treatment compared to V5-PTPN14 WT was determined by ANOVA using the Dunnett correction
for multiple comparisons (*p<0.05, **p<0.01, ****p<0.0001).
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terminal portion of PTPN14, such as binding to a yet unidentified negative regulator of
PTPN14, may contribute to this enhanced differentiation promotion.
PTPN14 requires PY1/2 to induce differentiation. PY1/2 of PTPN14 have been
identified to bind tightly to KIBRA, which is a WW domain containing scaffolding protein
upstream of the HIPPO signaling pathway (147). To test whether PTPN14 binds KIBRA
in keratinocytes and whether this is mediated by PY1/2, we transduced N/Tert-Cas9
sgPTPN14-1 keratinocytes with lentiviral vectors encoding WT, PY1/2-deleted, and
PY3/4-deleted HA-tagged PTPN14 constructs under a doxycycline inducible promoter.
PTPN14 expression was induced with 1 μg/mL doxycycline in these cells, and PTPN14
was

immunoprecipitated

to

assess

KIBRA

binding.

As

expected,

KIBRA

coimmunoprecipitated with PTPN14 WT and ΔPY3/4, but not with PTPN14 ΔPY1/2
(Figure A.5). These data suggest that PTPN14 may require binding to KIBRA to induce
keratinocyte differentiation. However, this does not eliminate the possibility that other
proteins that bind to PTPN14 PY1/2 may be mediating this effect. For instance, the
homologs of KIBRA, WWC2 and WWC3, may also bind to this PTPN14 amino acid motif
in keratinocytes. It will be important to directly test whether expression of KIBRA, WWC1,
WWC2, or another WW domain containing protein are required for PTPN14 to induce
differentiation.

Materials and Methods
Plasmids and cloning
pHAGE-P N-V5 PTPN14 WT, ΔFERM, ΔL1, ΔL2 481-821, ΔL2 521-781, ΔL3,
ΔPTP were previously described (128). PTPN14 ΔPY1/2, ΔPY3, ΔPY4, ΔPY3/4, and
C1121S mutations were generated by site-directed mutagenesis in pDONR PTPN14 and
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Figure A.5. PTPN14 requires PY motifs 1 and 2 to bind KIBRA in keratinocytes.
N/Tert-Cas9 sgPTPN14-1 cells were transduced with Dox inducible HA-tagged PTPN14 WT,
ΔPY1/2, and ΔPY3/4. Cells were treated +/- 1 μg/mL Dox for 48h, and HA-PTPN14 was
immunoprecipitated with anti-HA beads from total cell lysates. Coimmunoprecipitation of KIBRA
was assessed by SDS/PAGE/Western analysis (upper). Total cell lysates were subjected to
SDS/PAGE/Western analysis and probed with antibodies to KIBRA, PTPN14, and actin (lower).
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transferred into the pHAGE-P N-V5 lentiviral backbone using gateway cloning. PTPN14
WT, ΔPY1/2, and ΔPY3/4 were also transferred into the pLIX_402 lentiviral backbone
using gateway cloning. pHAGE-P-CMVt N-HA GFP was previously described (271).

Cell culture and lentivirus production
N/Tert-1 cells are previously described hTert-immortalized HFK (201), and N/TertCas9 sgPTPN14-1cells are N/Tert-1 cells engineered to express Cas9 and transfected
with a PTPN14-targeting guide RNA (176). Keratinocytes were cultured as described in
previous reports (126). Lentiviruses were generated in 293T cells as previously described
(128). pHAGE-P N-V5 PTPN14 were all performed transiently, and samples were
collected at 48h post transduction. Stable pLIX PTPN14 cells populations were generated
by transduction followed by selection with puromycin.

Western blot
Protein samples were lysed in RIPA buffer and run on Mini-PROTEAN (Bio-Rad)
Tris/Glycine SDS-PAGE gels. Protein was then transferred onto polyvinylidene difluoride
(PVDF). 5% nonfat dry milk in Tris-buffered saline with 0.05% Tween 20 (TBST) was used
for blocking. Membranes were incubated with anti-V5 (1:1000 dilution; Invitrogen; 460705), anti-Actin (1:20,000 dilution; Sigma-Aldrich; MAB1501), anti-PTPN14 (1:500; Cell
Signaling Technology; 13808), or anti-KIBRA (1:1000; Cell Signaling Technology; 8774)
primary

antibodies.

Horseradish

peroxidase-coupled

secondary

antibodies

and

chemiluminescence were used for imaging. HA-tagged PTPN14 constructs were
immunoprecipitated using previously described protocol for HA-tagged HPV E7
immunoprecipitation (128).
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qPCR
Total cellular RNA was isolated from N/Tert-1 keratinocytes using the NucleoSpin
RNA extraction kit (Macherey-Nagel/Takara) and used to template cDNA generation using
the high-capacity cDNA reverse transcription kit (Applied Biosystems). qPCR was
performed using Fast SYBR green master mix (Applied Biosystems) and a QuantStudio
3 system (Thermo Fisher Scientific). KiCqStart SYBR green primers for qRT-PCR
(MilliporeSigma) were used to assess KRT1 and GAPDH mRNA expression.

170

BIBILOGRAPHY
1.

de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. 2020. Global burden of cancer
attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health
8:e180-e190.

2.

Graham SV. 2017. The human papillomavirus replication cycle, and its links to cancer
progression: a comprehensive review. Clin Sci (Lond) 131:2201-2221.

3.

Egawa N, Egawa K, Griffin H, Doorbar J. 2015. Human Papillomaviruses; Epithelial
Tropisms, and the Development of Neoplasia. Viruses 7:3863-90.

4.

Mashiana SS, Navale P, Khandakar B, Sobotka S, Posner MR, Miles BA, Zhang W, Gitman
M, Bakst RL, Genden EM, Westra WH. 2021. Human papillomavirus genotype distribution
in head and neck cancer: Informing developing strategies for cancer prevention, diagnosis,
treatment and surveillance. Oral Oncol 113:105109.

5.

Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, Roberts S. 2013.
Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and
neck cancer--systematic review and meta-analysis of trends by time and region. Head
Neck 35:747-55.

6.

Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. 2013. A systematic review of the
prevalence of mucosal and cutaneous human papillomavirus types. Virology 445:224-31.

7.

Rector A, Van Ranst M. 2013. Animal papillomaviruses. Virology 445:213-23.

8.

Bravo IG, Felez-Sanchez M. 2015. Papillomaviruses: Viral evolution, cancer and
evolutionary medicine. Evol Med Public Health 2015:32-51.

9.

Van Doorslaer K, Li Z, Xirasagar S, Maes P, Kaminsky D, Liou D, Sun Q, Kaur R, Huyen
Y, McBride AA. 2017. The Papillomavirus Episteme: a major update to the papillomavirus
sequence database. Nucleic Acids Res 45:D499-D506.

10.

Van Doorslaer K, Tan Q, Xirasagar S, Bandaru S, Gopalan V, Mohamoud Y, Huyen Y,
McBride AA. 2013. The Papillomavirus Episteme: a central resource for papillomavirus
sequence data and analysis. Nucleic Acids Res 41:D571-8.

11.

Nunes EM, Talpe-Nunes V, Sichero L. 2018. Epidemiology and biology of cutaneous
human papillomavirus. Clinics (Sao Paulo) 73:e489s.

12.

Carter JR, Ding Z, Rose BR. 2011. HPV infection and cervical disease: a review. Aust N Z
J Obstet Gynaecol 51:103-8.

13.

Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L,
Guha N, Freeman C, Galichet L, Cogliano V, Wo WIARCM. 2009. A review of human
carcinogens-Part B: biological agents. Lancet Oncology 10:321-322.

14.

Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW, Steinau M,
Watson M, Wilkinson EJ, Hopenhayn C, Copeland G, Cozen W, Peters ES, Huang Y,
Saber MS, Altekruse S, Goodman MT, Workgroup HPVToC. 2015. US assessment of HPV
types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst
107:djv086.

15.

Omland T, Lie KA, Akre H, Sandlie LE, Jebsen P, Sandvik L, Nymoen DA, Bzhalava D,
Dillner J, Brondbo K. 2014. Recurrent respiratory papillomatosis: HPV genotypes and risk
of high-grade laryngeal neoplasia. PLoS One 9:e99114.

16.

Bacaj P, Burch D. 2018. Human Papillomavirus Infection of the Skin. Arch Pathol Lab Med
142:700-705.

171

17.

de Jong SJ, Imahorn E, Itin P, Uitto J, Orth G, Jouanguy E, Casanova JL, Burger B. 2018.
Epidermodysplasia Verruciformis: Inborn Errors of Immunity to Human BetaPapillomaviruses. Front Microbiol 9:1222.

18.

Ramoz N, Rueda LA, Bouadjar B, Montoya LS, Orth G, Favre M. 2002. Mutations in two
adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet
32:579-81.

19.

Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC, Su J, Xu F,
Weinstock H. 2013. Sexually transmitted infections among US women and men:
prevalence and incidence estimates, 2008. Sex Transm Dis 40:187-93.

20.

Van Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB. 2018. Trends
in Human Papillomavirus-Associated Cancers - United States, 1999-2015. MMWR Morb
Mortal Wkly Rep 67:918-924.

21.

Della Fera AN, Warburton A, Coursey TL, Khurana S, McBride AA. 2021. Persistent
Human Papillomavirus Infection. Viruses 13:321-321.

22.

Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. 2008. Persistent human
papillomavirus infection and cervical neoplasia: A systematic review and meta-analysis,
vol 168, p 123-137.

23.

Rositch AF, Koshiol J, Hudgens MG, Razzaghi H, Backes DM, Pimenta JM, Franco EL,
Poole C, Smith JS. 2013. Patterns of persistent genital human papillomavirus infection
among women worldwide: a literature review and meta-analysis. Int J Cancer 133:127185.

24.

Radley D, Saah A, Stanley M. 2016. Persistent infection with human papillomavirus 16 or
18 is strongly linked with high-grade cervical disease. Hum Vaccin Immunother 12:768-72.

25.

McBride AA. 2022. Human papillomaviruses: diversity, infection and host interactions. Nat
Rev Microbiol 20:95-108.

26.

Gravitt PE. 2011. The known unknowns of HPV natural history. J Clin Invest 121:4593-9.

27.

Meites E, Szilagyi PG, Harrell, Chesson W, Unger ER, Romero JR, Markowitz LE.
Morbidity and Mortality Weekly Report Human Papillomavirus Vaccination for Adults:
Updated Recommendations of the Advisory Committee on Immunization Practices.

28.

Pingali C, Yankey D, Elam-Evans LD, Markowitz LE, Williams CL, Fredua B, McNamara
LA, Stokley S, Singleton JA. 2020. MMWR, National, Regional, State, and Selected Local
Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States,
2020.

29.

Oren-Shabtai M, Snast I, Lapidoth M, Sherman S, Noyman Y, Mimouni D, Hodak E, Levi
A. 2021. Topical and Systemic Retinoids for the Treatment of Genital Warts: A Systematic
Review and Meta-Analysis. Dermatology 237:389-395.

30.

Zheng K, Egawa N, Shiraz A, Katakuse M, Okamura M, Griffin HM, Doorbar J. 2022. The
Reservoir of Persistent Human Papillomavirus Infection; Strategies for Elimination Using
Anti-Viral Therapies. Viruses 14:214-214.

31.

Sand FL, Frederiksen K, Kjaer SK. 2022. Risk of recurrent disease following conization of
cervical intraepithelial neoplasia grade 3 according to post-conization HPV status and
surgical margins. Gynecol Oncol doi:10.1016/j.ygyno.2022.03.015.

32.

Prendiville W, Sankaranarayanan R. 2017. Colposcopy and Treatment of Cervical
Precancer. World Health Organization Press, Geneva, Switzerland.

172

33.

Leerunyakul K, Thammarucha S, Suchonwanit P, Rutnin S. 2022. A comprehensive review
of treatment options for recalcitrant nongenital cutaneous warts. J Dermatolog Treat 33:2340.

34.

Cohen PA, Jhingran A, Oaknin A, Denny L. 2019. Cervical cancer. Lancet 393:169-182.

35.

Elisi GM, Santucci M, D'Arca D, Lauriola A, Marverti G, Losi L, Scalvini L, Bolognesi ML,
Mor M, Costi MP. 2018. Repurposing of Drugs Targeting YAP-TEAD Functions. Cancers
(Basel) 10:329-329.

36.

McBride AA. 2008. Chapter 4 Replication and Partitioning of Papillomavirus Genomes.
Advances in Virus Research 72:155-205.

37.

Bergvall M, Melendy T, Archambault J. 2013. The E1 proteins. Virology 445:35-56.

38.

McBride AA. 2013. The papillomavirus E2 proteins. Virology 445:57-79.

39.

DiMaio D, Petti LM. 2013. The E5 proteins. Virology 445:99-114.

40.

Doorbar J. 2013. The E4 protein; structure, function and patterns of expression. Virology
445:80-98.

41.

Roman A, Munger K. 2013. The papillomavirus E7 proteins. Virology 445:138-68.

42.

Vande Pol SB, Klingelhutz AJ. 2013. Papillomavirus E6 oncoproteins. Virology 445:11537.

43.

Buck CB, Day PM, Trus BL. 2013. The papillomavirus major capsid protein L1. Virology
445:169-74.

44.

Wang JW, Roden RB. 2013. L2, the minor capsid protein of papillomavirus. Virology
445:175-86.

45.

Wang S, Drummond ML, Guerrero-Juarez CF, Tarapore E, MacLean AL, Stabell AR, Wu
SC, Gutierrez G, That BT, Benavente CA, Nie Q, Atwood SX. 2020. Single cell
transcriptomics of human epidermis identifies basal stem cell transition states. Nat
Commun 11:4239.

46.

Poulson ND, Lechler T. 2012. Asymmetric cell divisions in the epidermis. Int Rev Cell Mol
Biol 295:199-232.

47.

Lechler T, Fuchs E. 2005. Asymmetric cell divisions promote stratification and
differentiation of mammalian skin. Nature 437:275-80.

48.

Williams SE, Beronja S, Pasolli HA, Fuchs E. 2011. Asymmetric cell divisions promote
Notch-dependent epidermal differentiation. Nature 470:353-8.

49.

Lopez-Pajares V, Qu K, Zhang J, Webster DE, Barajas BC, Siprashvili Z, Zarnegar BJ,
Boxer LD, Rios EJ, Tao S, Kretz M, Khavari PA. 2015. A LncRNA-MAF:MAFB transcription
factor network regulates epidermal differentiation. Dev Cell 32:693-706.

50.

Pozzi S, Zambelli F, Merico D, Pavesi G, Robert A, Maltere P, Gidrol X, Mantovani R,
Vigano MA. 2009. Transcriptional network of p63 in human keratinocytes. PLoS One
4:e5008.

51.

Cutright DE, Bauer H. 1967. Cell renewal in the oral mucosa and skin of the rat. I. Turnover
time. Oral Surg Oral Med Oral Pathol 23:249-59.

52.

Iizuka H. 1994. Epidermal turnover time. J Dermatol Sci 8:215-7.

53.

Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM. 2009. The initial steps leading
to papillomavirus infection occur on the basement membrane prior to cell surface binding.
Proc Natl Acad Sci U S A 106:20458-63.

173

54.

Pyeon D, Pearce SM, Lank SM, Ahlquist P, Lambert PF. 2009. Establishment of human
papillomavirus infection requires cell cycle progression. PLoS Pathog 5:e1000318.

55.

Sapp M, Day PM. 2009. Structure, attachment and entry of polyoma- and papillomaviruses.
Virology 384:400-9.

56.

Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M. 2001. Human papillomavirus infection
requires cell surface heparan sulfate. J Virol 75:1565-70.

57.

DiGiuseppe S, Bienkowska-Haba M, Guion LG, Sapp M. 2017. Cruising the cellular
highways: How human papillomavirus travels from the surface to the nucleus. Virus Res
231:1-9.

58.

Keiffer TR, Soorya S, Sapp MJ. 2021. Recent Advances in Our Understanding of the
Infectious Entry Pathway of Human Papillomavirus Type 16. Microorganisms 9:2076-2076.

59.

Zhang P, Monteiro da Silva G, Deatherage C, Burd C, DiMaio D. 2018. Cell-Penetrating
Peptide Mediates Intracellular Membrane Passage of Human Papillomavirus L2 Protein to
Trigger Retrograde Trafficking. Cell 174:1465-1476 e13.

60.

Aydin I, Weber S, Snijder B, Samperio Ventayol P, Kuhbacher A, Becker M, Day PM,
Schiller JT, Kann M, Pelkmans L, Helenius A, Schelhaas M. 2014. Large scale RNAi
reveals the requirement of nuclear envelope breakdown for nuclear import of human
papillomaviruses. PLoS Pathog 10:e1004162.

61.

Day PM, Baker CC, Lowy DR, Schiller JT. 2004. Establishment of papillomavirus infection
is enhanced by promyelocytic leukemia protein (PML) expression. Proc Natl Acad Sci U S
A 101:14252-7.

62.

McBride AA. 2017. Mechanisms and strategies of papillomavirus replication. Biol Chem
398:919-927.

63.

Parish JL, Bean AM, Park RB, Androphy EJ. 2006. ChlR1 is required for loading
papillomavirus E2 onto mitotic chromosomes and viral genome maintenance. Mol Cell
24:867-76.

64.

You J, Croyle JL, Nishimura A, Ozato K, Howley PM. 2004. Interaction of the bovine
papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes.
Cell 117:349-60.

65.

Graham SV. 2017. Keratinocyte Differentiation-Dependent Human Papillomavirus Gene
Regulation. Viruses 9:245-245.

66.

Sakakibara N, Chen D, McBride AA. 2013. Papillomaviruses use recombination-dependent
replication to vegetatively amplify their genomes in differentiated cells. PLoS Pathog
9:e1003321.

67.

Collins AS, Nakahara T, Do A, Lambert PF. 2005. Interactions with pocket proteins
contribute to the role of human papillomavirus type 16 E7 in the papillomavirus life cycle. J
Virol 79:14769-80.

68.

McLaughlin-Drubin ME, Bromberg-White JL, Meyers C. 2005. The role of the human
papillomavirus type 18 E7 oncoprotein during the complete viral life cycle. Virology 338:618.

69.

Graham SV, Faizo AAA. 2017. Control of human papillomavirus gene expression by
alternative splicing. Virus Res 231:83-95.

70.

Francis DA, Schmid SI, Howley PM. 2000. Repression of the integrated papillomavirus
E6/E7 promoter is required for growth suppression of cervical cancer cells. J Virol 74:267986.

174

71.

Goodwin EC, DiMaio D. 2000. Repression of human papillomavirus oncogenes in HeLa
cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor
pathways. Proc Natl Acad Sci U S A 97:12513-8.

72.

Hu Z, Ding W, Zhu D, Yu L, Jiang X, Wang X, Zhang C, Wang L, Ji T, Liu D, He D, Xia X,
Zhu T, Wei J, Wu P, Wang C, Xi L, Gao Q, Chen G, Liu R, Li K, Li S, Wang S, Zhou J, Ma
D, Wang H. 2015. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related
cervical malignancy. J Clin Invest 125:425-36.

73.

Bedell MA, Jones KH, Grossman SR, Laimins LA. 1989. Identification of human
papillomavirus type 18 transforming genes in immortalized and primary cells. J Virol
63:1247-55.

74.

Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. 1989. HPV16 E6 and
E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 8:3905-10.

75.

Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. 1989. The E6 and E7 genes of
the human papillomavirus type 16 together are necessary and sufficient for transformation
of primary human keratinocytes. J Virol 63:4417-21.

76.

Mirabello L, Yeager M, Yu K, Clifford GM, Xiao YZ, Zhu B, Cullen M, Boland JF,
Wentzensen N, Nelson CW, Raine-Bennett T, Chen ZG, Bass S, Song L, Yang Q,
Steinberg M, Burdett L, Dean M, Roberson D, Mitchell J, Lorey T, Franceschi S, Castle
PE, Walker J, Zuna R, Kreimer AR, Beachler DC, Hildesheim A, Gonzalez P, Porras C,
Burk RD, Schiffman M. 2017. HPV16 E7 Genetic Conservation Is Critical to
Carcinogenesis. Cell 170:1164-1174.

77.

Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL,
Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz
SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth
C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS,
Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD,
Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F,
Meyerson M, Cancer Genome Atlas Research N, et al. 2018. Oncogenic Signaling
Pathways in The Cancer Genome Atlas. Cell 173:321-337 e10.

78.

Warburton A, Markowitz TE, Katz JP, Pipas JM, McBride AA. 2021. Recurrent integration
of human papillomavirus genomes at transcriptional regulatory hubs. NPJ Genom Med
6:101.

79.

Munger K, Jones DL. 2015. Human papillomavirus carcinogenesis: an identity crisis in the
retinoblastoma tumor suppressor pathway. J Virol 89:4708-11.

80.

Boyer SN, Wazer DE, Band V. 1996. E7 protein of human papilloma virus-16 induces
degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer
Research 56:4620-4624.

81.

Dyson N, Howley PM, Munger K, Harlow E. 1989. The human papilloma virus-16 E7
oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-7.

82.

Helt AM, Funk JO, Galloway DA. 2002. Inactivation of both the retinoblastoma tumor
suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to
inhibit cell cycle arrest in human epithelial cells. J Virol 76:10559-68.

83.

Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. 1989. Complex
formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor
gene product. EMBO J 8:4099-105.

84.

Seavey SE, Holubar M, Saucedo LJ, Perry ME. 1999. The E7 oncoprotein of human
papillomavirus type 16 stabilizes p53 through a mechanism independent of p19(ARF). J
Virol 73:7590-8.

175

85.

Sharma S, Munger K. 2020. KDM6A-Mediated Expression of the Long Noncoding RNA
DINO Causes TP53 Tumor Suppressor Stabilization in Human Papillomavirus 16 E7Expressing Cells. J Virol 94.

86.

Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6
oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation
of p53. Cell 63:1129-36.

87.

Werness BA, Levine AJ, Howley PM. 1990. Association of human papillomavirus types 16
and 18 E6 proteins with p53. Science 248:76-9.

88.

Doorbar J, Zheng K, Aiyenuro A, Yin W, Walker CM, Chen Y, Egawa N, Griffin HM. 2021.
Principles of epithelial homeostasis control during persistent human papillomavirus
infection and its deregulation at the cervical transformation zone. Curr Opin Virol 51:96105.

89.

Maglennon GA, McIntosh P, Doorbar J. 2011. Persistence of viral DNA in the epithelial
basal layer suggests a model for papillomavirus latency following immune regression.
Virology 414:153-63.

90.

Thomas JT, Hubert WG, Ruesch MN, Laimins LA. 1999. Human papillomavirus type 31
oncoproteins E6 and E7 are required for the maintenance of episomes during the viral life
cycle in normal human keratinocytes. Proc Natl Acad Sci U S A 96:8449-54.

91.

Steinbach A, Riemer AB. 2018. Immune evasion mechanisms of human papillomavirus:
An update. Int J Cancer 142:224-229.

92.

Westrich JA, Warren CJ, Pyeon D. 2017. Evasion of host immune defenses by human
papillomavirus. Virus Res 231:21-33.

93.

Zhou C, Tuong ZK, Frazer IH. 2019. Papillomavirus Immune Evasion Strategies Target the
Infected Cell and the Local Immune System. Front Oncol 9:682.

94.

Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR, Chow LT. 1995. Differentiationdependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA
replication in suprabasal differentiated keratinocytes. Genes Dev 9:2335-49.

95.

Brimer N, Vande Pol S. 2022. Human papillomavirus type 16 E6 induces cell competition.
PLoS Pathog 18:e1010431.

96.

Saunders-Wood T, Egawa N, Zheng K, Giaretta A, Griffin HM, Doorbar J. 2022. Role of
E6 in Maintaining the Basal Cell Reservoir during Productive Papillomavirus Infection. J
Virol 96:e0118121.

97.

Brimer N, Drews CM, Vande Pol SB. 2017. Association of papillomavirus E6 proteins with
either MAML1 or E6AP clusters E6 proteins by structure, function, and evolutionary
relatedness. PLoS Pathog 13:e1006781.

98.

Brimer N, Lyons C, Wallberg AE, Vande Pol SB. 2012. Cutaneous papillomavirus E6
oncoproteins associate with MAML1 to repress transactivation and NOTCH signaling.
Oncogene 31:4639-46.

99.

Tan MJ, White EA, Sowa ME, Harper JW, Aster JC, Howley PM. 2012. Cutaneous betahuman papillomavirus E6 proteins bind Mastermind-like coactivators and repress Notch
signaling. Proc Natl Acad Sci U S A 109:E1473-80.

100.

Kranjec C, Holleywood C, Libert D, Griffin H, Mahmood R, Isaacson E, Doorbar J. 2017.
Modulation of basal cell fate during productive and transforming HPV-16 infection is
mediated by progressive E6-driven depletion of Notch. J Pathol 242:448-462.

176

101.

Garner-Hamrick PA, Fostel JM, Chien WM, Banerjee NS, Chow LT, Broker TR, Fisher C.
2004. Global effects of human papillomavirus type 18 E6/E7 in an organotypic keratinocyte
culture system. J Virol 78:9041-50.

102.

McCance DJ, Kopan R, Fuchs E, Laimins LA. 1988. Human papillomavirus type 16 alters
human epithelial cell differentiation in vitro. Proc Natl Acad Sci U S A 85:7169-73.

103.

Nees M, Geoghegan JM, Munson P, Prabhu V, Liu Y, Androphy E, Woodworth CD. 2000.
Human Papillomavirus Type 16 E6 and E7 Proteins Inhibit Differentiation-dependent
Expression of Transforming Growth Factor-2 in Cervical Keratinocytes.

104.

White EA. 2019. Manipulation of Epithelial Differentiation by HPV Oncoproteins. Viruses
11:369-369.

105.

Figge J, Smith TF. 1988. Cell-division sequence motif. Nature 334:109.

106.

Phelps WC, Yee CL, Munger K, Howley PM. 1988. The Human Papillomavirus Type-16
E7 Gene Encodes Transactivation and Transformation Functions Similar to Those of
Adenovirus-E1a. Cell 53:539-547.

107.

McIntyre MC, Frattini MG, Grossman SR, Laimins LA. 1993. Human papillomavirus type
18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and
transformation but not for Rb binding. Journal of virology 67:3142-50.

108.

Alonso LG, Garcia-Alai MM, Nadra AD, Lapena AN, Almeida FL, Gualfetti P, Prat-Gay GD.
2002. High-risk (HPV16) human papillomavirus E7 oncoprotein is highly stable and
extended, with conformational transitions that could explain its multiple cellular binding
partners. Biochemistry 41:10510-8.

109.

García-Alai MM, Alonso LG, De Prat-Gay G. 2007. The N-terminal module of HPV16 E7 is
an intrinsically disordered domain that confers conformational and recognition plasticity to
the oncoprotein. Biochemistry 46:10405-10412.

110.

Liu X, Clements A, Zhao K, Marmorstein R. 2006. Structure of the human Papillomavirus
E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor.
J Biol Chem 281:578-86.

111.

Ohlenschlager O, Seiboth T, Zengerling H, Briese L, Marchanka A, Ramachandran R,
Baum M, Korbas M, Meyer-Klaucke W, Durst M, Gorlach M. 2006. Solution structure of the
partially folded high-risk human papilloma virus 45 oncoprotein E7. Oncogene 25:5953-9.

112.

Huh KW, DeMasi J, Ogawa H, Nakatani Y, Howley PM, Munger K. 2005. Association of
the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma proteinassociated factor, p600. Proc Natl Acad Sci U S A 102:11492-7.

113.

Huh K, Zhou X, Hayakawa H, Cho JY, Libermann TA, Jin J, Harper JW, Munger K. 2007.
Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase
complex, which contributes to degradation of the retinoblastoma tumor suppressor. J Virol
81:9737-47.

114.

Dyson N, Guida P, Munger K, Harlow E. 1992. Homologous sequences in adenovirus E1A
and human papillomavirus E7 proteins mediate interaction with the same set of cellular
proteins. J Virol 66:6893-902.

115.

Flores ER, Allen-Hoffmann BL, Lee D, Lambert PF. 2000. The human papillomavirus type
16 E7 oncogene is required for the productive stage of the viral life cycle. J Virol 74:662231.

116.

Strati K, Lambert PF. 2007. Role of Rb-dependent and Rb-independent functions of
papillomavirus E7 oncogene in head and neck cancer. Cancer Res 67:11585-93.

177

117.

Jewers RJ, Hildebrandt P, Ludlow JW, Kell B, McCance DJ. 1992. Regions of human
papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes.
J Virol 66:1329-35.

118.

White EA, Kramer RE, Hwang JH, Pores Fernando AT, Naetar N, Hahn WC, Roberts TM,
Schaffhausen BS, Livingston DM, Howley PM. 2015. Papillomavirus E7 oncoproteins
share functions with polyomavirus small T antigens. J Virol 89:2857-65.

119.

Ciccolini F, Di Pasquale G, Carlotti F, Crawford L, Tommasino M. 1994. Functional studies
of E7 proteins from different HPV types. Oncogene 9:2633-8.

120.

Ibaraki T, Satake M, Kurai N, Ichijo M, Ito Y. 1993. Transacting activities of the E7 genes
of several types of human papillomavirus. Virus Genes 7:187-96.

121.

Storey A, Osborn K, Crawford L. 1990. Co-transformation by human papillomavirus types
6 and 11. J Gen Virol 71 ( Pt 1):165-71.

122.

Neary K, Dimaio D. 1989. Open Reading Frame-E6 and Frame-E7 of Bovine
Papillomavirus Type-1 Are Both Required for Full Transformation of Mouse C127 Cells.
Journal of Virology 63:259-266.

123.

Sarver N, Rabson MS, Yang YC, Byrne JC, Howley PM. 1984. Localization and analysis
of bovine papillomavirus type 1 transforming functions. J Virol 52:377-88.

124.

Vande Pol SB, Brown MC, Turner CE. 1998. Association of Bovine Papillomavirus Type 1
E6 oncoprotein with the focal adhesion protein paxillin through a conserved protein
interaction motif. Oncogene 16:43-52.

125.

Rozenblatt-Rosen O, Deo RC, Padi M, Adelmant G, Calderwood MA, Rolland T, Grace M,
Dricot A, Askenazi M, Tavares M, Pevzner SJ, Abderazzaq F, Byrdsong D, Carvunis AR,
Chen AA, Cheng J, Correll M, Duarte M, Fan C, Feltkamp MC, Ficarro SB, Franchi R, Garg
BK, Gulbahce N, Hao T, Holthaus AM, James R, Korkhin A, Litovchick L, Mar JC, Pak TR,
Rabello S, Rubio R, Shen Y, Singh S, Spangle JM, Tasan M, Wanamaker S, Webber JT,
Roecklein-Canfield J, Johannsen E, Barabasi AL, Beroukhim R, Kieff E, Cusick ME, Hill
DE, Munger K, Marto JA, Quackenbush J, Roth FP, et al. 2012. Interpreting cancer
genomes using systematic host network perturbations by tumour virus proteins. Nature
487:491-5.

126.

White EA, Sowa ME, Tan MJ, Jeudy S, Hayes SD, Santha S, Munger K, Harper JW,
Howley PM. 2012. Systematic identification of interactions between host cell proteins and
E7 oncoproteins from diverse human papillomaviruses. Proc Natl Acad Sci U S A
109:E260-7.

127.

DeMasi J, Huh KW, Nakatani Y, Munger K, Howley PM. 2005. Bovine papillomavirus E7
transformation function correlates with cellular p600 protein binding. Proc Natl Acad Sci U
S A 102:11486-91.

128.

White EA, Munger K, Howley PM. 2016. High-Risk Human Papillomavirus E7 Proteins
Target PTPN14 for Degradation. mBio 7:e01530-16.

129.

Bonilla X, Parmentier L, King B, Bezrukov F, Kaya G, Zoete V, Seplyarskiy VB, Sharpe HJ,
McKee T, Letourneau A, Ribaux PG, Popadin K, Basset-Seguin N, Ben Chaabene R,
Santoni FA, Andrianova MA, Guipponi M, Garieri M, Verdan C, Grosdemange K, Sumara
O, Eilers M, Aifantis I, Michielin O, de Sauvage FJ, Antonarakis SE, Nikolaev SI. 2016.
Genomic analysis identifies new drivers and progression pathways in skin basal cell
carcinoma. Nat Genet 48:398-406.

130.

Mello SS, Valente LJ, Raj N, Seoane JA, Flowers BM, McClendon J, Bieging-Rolett KT,
Lee J, Ivanochko D, Kozak MM, Chang DT, Longacre TA, Koong AC, Arrowsmith CH, Kim
SK, Vogel H, Wood LD, Hruban RH, Curtis C, Attardi LD. 2017. A p53 Super-tumor

178

Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer.
Cancer Cell 32:460-473 e6.
131.

Olafsdottir T, Stacey SN, Sveinbjornsson G, Thorleifsson G, Norland K, Sigurgeirsson B,
Thorisdottir K, Kristjansson AK, Tryggvadottir L, Sarin KY, Benediktsson R, Jonasson JG,
Sigurdsson A, Jonasdottir A, Kristmundsdottir S, Jonsson H, Gylfason A, Oddsson A,
Fridriksdottir R, Gudjonsson SA, Zink F, Lund SH, Rognvaldsson S, Melsted P,
Steinthorsdottir V, Gudmundsson J, Mikaelsdottir E, Olason PI, Stefansdottir L, Eggertsson
HP, Halldorsson BV, Thorsteinsdottir U, Agustsson TT, Olafsson K, Olafsson JH, Sulem
P, Rafnar T, Gudbjartsson DF, Stefansson K. 2021. Loss-of-Function Variants in the
Tumor-Suppressor Gene PTPN14 Confer Increased Cancer Risk. Cancer Res 81:19541964.

132.

Liu X, Yang N, Figel SA, Wilson KE, Morrison CD, Gelman IH, Zhang J. 2013. PTPN14
interacts with and negatively regulates the oncogenic function of YAP. Oncogene 32:126673.

133.

Michaloglou C, Lehmann W, Martin T, Delaunay C, Hueber A, Barys L, Niu H, Billy E,
Wartmann M, Ito M, Wilson CJ, Digan ME, Bauer A, Voshol H, Christofori G, Sellers WR,
Hofmann F, Schmelzle T. 2013. The tyrosine phosphatase PTPN14 is a negative regulator
of YAP activity. PLoS One 8:e61916.

134.

Poernbacher I, Baumgartner R, Marada SK, Edwards K, Stocker H. 2012. Drosophila Pez
acts in Hippo signaling to restrict intestinal stem cell proliferation. Curr Biol 22:389-96.

135.

Wang W, Huang J, Wang X, Yuan J, Li X, Feng L, Park JI, Chen J. 2012. PTPN14 is
required for the density-dependent control of YAP1. Genes Dev 26:1959-71.

136.

Tonks NK. 2006. Protein tyrosine phosphatases: from genes, to function, to disease. Nat
Rev Mol Cell Biol 7:833-46.

137.

Wadham C, Gamble JR, Vadas MA, Khew-Goodall Y. 2003. The protein tyrosine
phosphatase Pez is a major phosphatase of adherens junctions and dephosphorylates
beta-catenin. Mol Biol Cell 14:2520-9.

138.

Knight JF, Sung VYC, Kuzmin E, Couzens AL, de Verteuil DA, Ratcliffe CDH, Coelho PP,
Johnson RM, Samavarchi-Tehrani P, Gruosso T, Smith HW, Lee W, Saleh SM, Zuo D,
Zhao H, Guiot MC, Davis RR, Gregg JP, Moraes C, Gingras AC, Park M. 2018. KIBRA
(WWC1) Is a Metastasis Suppressor Gene Affected by Chromosome 5q Loss in TripleNegative Breast Cancer. Cell Rep 22:3191-3205.

139.

Harvey KF, Zhang X, Thomas DM. 2013. The Hippo pathway and human cancer. Nat Rev
Cancer 13:246-57.

140.

Ma S, Meng Z, Chen R, Guan KL. 2019. The Hippo Pathway: Biology and Pathophysiology.
Annu Rev Biochem 88:577-604.

141.

Alarcon C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S, Barlas A, Miller AN, ManovaTodorova K, Macias MJ, Sapkota G, Pan D, Massague J. 2009. Nuclear CDKs drive Smad
transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 139:757-69.

142.

Chuang LSH, Ito Y. 2021. The multiple interactions of RUNX with the hippo–YAP pathway,
vol 10. MDPI.

143.

Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, Oren M, Sudol M,
Cesareni G, Blandino G. 2001. Physical interaction with Yes-associated protein enhances
p73 transcriptional activity. J Biol Chem 276:15164-73.

144.

Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC, Guan
KL. 2008. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev
22:1962-71.

179

145.

Zhao R, Fallon TR, Saladi SV, Pardo-Saganta A, Villoria J, Mou H, Vinarsky V, GonzalezCeleiro M, Nunna N, Hariri LP, Camargo F, Ellisen LW, Rajagopal J. 2014. Yap tunes
airway epithelial size and architecture by regulating the identity, maintenance, and selfrenewal of stem cells. Dev Cell 30:151-65.

146.

Wang W, Huang J, Chen J. 2011. Angiomotin-like proteins associate with and negatively
regulate YAP1. J Biol Chem 286:4364-70.

147.

Lin Z, Yang Z, Xie R, Ji Z, Guan K, Zhang M. 2019. Decoding WW domain tandemmediated target recognitions in tissue growth and cell polarity. Elife 8:e49439-e49439.

148.

Wilson KE, Li YW, Yang N, Shen H, Orillion AR, Zhang J. 2014. PTPN14 forms a complex
with Kibra and LATS1 proteins and negatively regulates the YAP oncogenic function. J Biol
Chem 289:23693-700.

149.

Elbediwy A, Vincent-Mistiaen ZI, Spencer-Dene B, Stone RK, Boeing S, Wculek SK,
Cordero J, Tan EH, Ridgway R, Brunton VG, Sahai E, Gerhardt H, Behrens A, Malanchi I,
Sansom OJ, Thompson BJ. 2016. Integrin signalling regulates YAP and TAZ to control skin
homeostasis. Development 143:1674-1687.

150.

Zhang L, Yang S, Wennmann DO, Chen Y, Kremerskothen J, Dong J. 2014. KIBRA: In the
brain and beyond, vol 26, p 1392-1399. Elsevier Inc.

151.

Zhang P, Guo A, Possemato A, Wang C, Beard L, Carlin C, Markowitz SD, Polakiewicz
RD, Wang Z. 2013. Identification and functional characterization of p130Cas as a substrate
of protein tyrosine phosphatase nonreceptor 14. Oncogene 32:2087-95.

152.

Belle L, Ali N, Lonic A, Li X, Paltridge JL, Roslan S, Herrmann D, Conway JR, Gehling FK,
Bert AG, Crocker LA, Tsykin A, Farshid G, Goodall GJ, Timpson P, Daly RJ, Khew-Goodall
Y. 2015. The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein
trafficking. Sci Signal 8:ra18.

153.

Choi J, Saraf A, Florens L, Washburn MP, Busino L. 2018. PTPN14 regulates Roquin2
stability by tyrosine dephosphorylation. Cell Cycle 17:2243-2255.

154.

Yun HY, Kim MW, Lee HS, Kim W, Shin JH, Kim H, Shin HC, Park H, Oh BH, Kim WK,
Bae KH, Lee SC, Lee EW, Ku B, Kim SJ. 2019. Structural basis for recognition of the tumor
suppressor protein PTPN14 by the oncoprotein E7 of human papillomavirus. PLoS Biol
17:e3000367.

155.

Sambandam SAT, Kasetti RB, Xue L, Dean DC, Lu Q, Li Q. 2015. 14-3-3sigma regulates
keratinocyte proliferation and differentiation by modulating Yap1 cellular localization. J
Invest Dermatol 135:1621-1628.

156.

Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D, Kreger BT,
Vasioukhin V, Avruch J, Brummelkamp TR, Camargo FD. 2011. Yap1 acts downstream of
alpha-catenin to control epidermal proliferation. Cell 144:782-95.

157.

Zhang H, Pasolli HA, Fuchs E. 2011. Yes-associated protein (YAP) transcriptional
coactivator functions in balancing growth and differentiation in skin. Proc Natl Acad Sci U
S A 108:2270-5.

158.

Lee MJ, Byun MR, Furutani-Seiki M, Hong JH, Jung HS. 2014. YAP and TAZ regulate skin
wound healing. J Invest Dermatol 134:518-525.

159.

Beverdam A, Claxton C, Zhang X, James G, Harvey KF, Key B. 2013. Yap controls
stem/progenitor cell proliferation in the mouse postnatal epidermis. J Invest Dermatol
133:1497-505.

160.

Omori H, Nishio M, Masuda M, Miyachi Y, Ueda F, Nakano T, Sato K, Mimori K, Taguchi
K, Hikasa H, Nishina H, Tashiro H, Kiyono T, Mak TW, Nakao K, Nakagawa T, Maehama

180

T, Suzuki A. 2020. YAP1 is a potent driver of the onset and progression of oral squamous
cell carcinoma. Sci Adv 6:eaay3324.
161.

Nishio M, To Y, Maehama T, Aono Y, Otani J, Hikasa H, Kitagawa A, Mimori K, Sasaki T,
Nishina H, Toyokuni S, Lydon JP, Nakao K, Wah Mak T, Kiyono T, Katabuchi H, Tashiro
H, Suzuki A. 2020. Endogenous YAP1 activation drives immediate onset of cervical
carcinoma in situ in mice. Cancer Sci 111:3576-3587.

162.

Liu K, Du S, Gao P, Zheng J. 2019. Verteporfin suppresses the proliferation, epithelialmesenchymal transition and stemness of head and neck squamous carcinoma cells via
inhibiting YAP1. J Cancer 10:4196-4207.

163.

Totaro A, Castellan M, Battilana G, Zanconato F, Azzolin L, Giulitti S, Cordenonsi M,
Piccolo S. 2017. YAP/TAZ link cell mechanics to Notch signalling to control epidermal stem
cell fate. Nat Commun 8:15206.

164.

Fisher ML, Kerr C, Adhikary G, Grun D, Xu W, Keillor JW, Eckert RL. 2016.
Transglutaminase Interaction with alpha6/beta4-Integrin Stimulates YAP1-Dependent
DeltaNp63alpha Stabilization and Leads to Enhanced Cancer Stem Cell Survival and
Tumor Formation. Cancer Res 76:7265-7276.

165.

Grun D, Adhikary G, Eckert RL. 2018. NRP-1 interacts with GIPC1 and alpha6/beta4integrins to increase YAP1/Np63alpha-dependent epidermal cancer stem cell survival.
Oncogene 37:4711-4722.

166.

Flores ER, Halder G. 2011. Stem cell proliferation in the skin: alpha-catenin takes over the
hippo pathway. Sci Signal 4:pe34.

167.

Nguyen BC, Lefort K, Mandinova A, Antonini D, Devgan V, Della Gatta G, Koster MI, Zhang
Z, Wang J, Tommasi di Vignano A, Kitajewski J, Chiorino G, Roop DR, Missero C, Dotto
GP. 2006. Cross-regulation between Notch and p63 in keratinocyte commitment to
differentiation. Genes Dev 20:1028-42.

168.

Chatterjee A, Sen T, Chang X, Sidransky D. 2010. Yes-associated protein 1 regulates the
stability of DeltaNp63alpha. Cell Cycle 9:162-7.

169.

Yuan Y, Park J, Feng A, Awasthi P, Wang Z, Chen Q, Iglesias-Bartolome R. 2020.
YAP1/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell
proliferation and limiting KLF4 activity. Nat Commun 11:1472.

170.

Yimlamai D, Christodoulou C, Galli GG, Yanger K, Pepe-Mooney B, Gurung B, Shrestha
K, Cahan P, Stanger BZ, Camargo FD. 2014. Hippo pathway activity influences liver cell
fate. Cell 157:1324-1338.

171.

White EA, Kramer RE, Tan MJ, Hayes SD, Harper JW, Howley PM. 2012. Comprehensive
analysis of host cellular interactions with human papillomavirus E6 proteins identifies new
E6 binding partners and reflects viral diversity. J Virol 86:13174-86.

172.

Balsitis S, Dick F, Lee D, Farrell L, Hyde RK, Griep AE, Dyson N, Lambert PF. 2005.
Examination of the pRb-dependent and pRb-independent functions of E7 in vivo. J Virol
79:11392-402.

173.

Balsitis S, Dick F, Dyson N, Lambert PF. 2006. Critical roles for non-pRb targets of human
papillomavirus type 16 E7 in cervical carcinogenesis. Cancer Res 66:9393-400.

174.

Banks L, Edmonds C, Vousden KH. 1990. Ability of the HPV16 E7 protein to bind RB and
induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells.
Oncogene 5:1383-9.

175.

Phelps WC, Munger K, Yee CL, Barnes JA, Howley PM. 1992. Structure-function analysis
of the human papillomavirus type 16 E7 oncoprotein. J Virol 66:2418-27.

181

176.

Hatterschide J, Bohidar AE, Grace M, Nulton TJ, Kim HW, Windle B, Morgan IM, Munger
K, White EA. 2019. PTPN14 degradation by high-risk human papillomavirus E7 limits
keratinocyte differentiation and contributes to HPV-mediated oncogenesis. Proc Natl Acad
Sci U S A 116:7033-7042.

177.

Hatterschide J, Brantly AC, Grace M, Munger K, White EA. 2020. A Conserved Amino Acid
in the C Terminus of Human Papillomavirus E7 Mediates Binding to PTPN14 and
Repression of Epithelial Differentiation. J Virol 94.

178.

Hatterschide J, Castagnino P, Kim HW, Sperry SM, Montone KT, Basu D, White EA. 2022.
YAP1 activation by human papillomavirus E7 promotes basal cell identity in squamous
epithelia. Elife 11:e75466.

179.

Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. 2015. Human papillomavirus
molecular biology and disease association. Rev Med Virol 25 Suppl 1:2-23.

180.

McBride AA, Munger K. 2018. Expert Views on HPV Infection. Viruses 10:94-94.

181.

Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. 2015. Epidemiology of Human
Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol 33:323542.

182.

Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ,
Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study
G. 2003. Epidemiologic classification of human papillomavirus types associated with
cervical cancer. N Engl J Med 348:518-27.

183.

Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC,
Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen
Z, Schussler J, Castle PE, Burk RD. 2005. The carcinogenicity of human papillomavirus
types reflects viral evolution. Virology 337:76-84.

184.

Halbert CL, Demers GW, Galloway DA. 1991. The E7 Gene of Human Papillomavirus
Type-16 Is Sufficient for Immortalization of Human Epithelial-Cells. Journal of Virology
65:473-478.

185.

Gonzalez SL, Stremlau M, He X, Basile JR, Munger K. 2001. Degradation of the
retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is
important for functional inactivation and is separable from proteasomal degradation of E7.
J Virol 75:7583-91.

186.

Jones DL, Alani RM, Munger K. 1997. The human papillomavirus E7 oncoprotein can
uncouple cellular differentiation and proliferation in human keratinocytes by abrogating
p21Cip1-mediated inhibition of cdk2. Genes Dev 11:2101-11.

187.

Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA. 1997. Inhibition of CDK
activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the
HPV-16 E7 oncoprotein. Genes Dev 11:2090-100.

188.

Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz JW, Jansen-Durr P. 1996.
Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7
oncoprotein. Oncogene 13:2323-30.

189.

Duffy CL, Phillips SL, Klingelhutz AJ. 2003. Microarray analysis identifies differentiationassociated genes regulated by human papillomavirus type 16 E6. Virology 314:196-205.

190.

Hudson JB, Bedell MA, McCance DJ, Laiminis LA. 1990. Immortalization and altered
differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of
human papillomavirus type 18. J Virol 64:519-26.

182

191.

Zehbe I, Richard C, DeCarlo CA, Shai A, Lambert PF, Lichtig H, Tommasino M, Sherman
L. 2009. Human papillomavirus 16 E6 variants differ in their dysregulation of human
keratinocyte differentiation and apoptosis. Virology 383:69-77.

192.

Shin MK, Sage J, Lambert PF. 2012. Inactivating all three rb family pocket proteins is
insufficient to initiate cervical cancer. Cancer Res 72:5418-27.

193.

McLaughlin-Drubin ME, Park D, Munger K. 2013. Tumor suppressor p16INK4A is
necessary for survival of cervical carcinoma cell lines. Proceedings of the National
Academy of Sciences of the United States of America 110:16175-16180.

194.

McLaughlin-Drubin ME, Crum CP, Munger K. 2011. Human papillomavirus E7 oncoprotein
induces KDM6A and KDM6B histone demethylase expression and causes epigenetic
reprogramming. Proc Natl Acad Sci U S A 108:2130-5.

195.

Todorovic B, Nichols AC, Chitilian JM, Myers MP, Shepherd TG, Parsons SJ, Barrett JW,
Banks L, Mymryk JS. 2014. The human papillomavirus E7 proteins associate with
p190RhoGAP and alter its function. J Virol 88:3653-63.

196.

Au AC, Hernandez PA, Lieber E, Nadroo AM, Shen YM, Kelley KA, Gelb BD, Diaz GA.
2010. Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic function and
choanal development in humans. Am J Hum Genet 87:436-44.

197.

Benzinou M, Clermont FF, Letteboer TG, Kim JH, Espejel S, Harradine KA, Arbelaez J,
Luu MT, Roy R, Quigley D, Higgins MN, Zaid M, Aouizerat BE, van Amstel JK, Giraud S,
Dupuis-Girod S, Lesca G, Plauchu H, Hughes CC, Westermann CJ, Akhurst RJ. 2012.
Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary
haemorrhagic telangiectasia. Nat Commun 3:616.

198.

Smith AL, Mitchell PJ, Shipley J, Gusterson BA, Rogers MV, Crompton MR. 1995.
1995_Pez a novel human cDNA encoding protein tyrosine phosphatase and ezrin like
domains.pdf, vol 209, p 959-965.

199.

Wyatt L, Wadham C, Crocker LA, Lardelli M, Khew-Goodall Y. 2007. The protein tyrosine
phosphatase Pez regulates TGFbeta, epithelial-mesenchymal transition, and organ
development. J Cell Biol 178:1223-35.

200.

Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters
BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson
JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. 2004. Mutational analysis of
the tyrosine phosphatome in colorectal cancers. Science 304:1164-6.

201.

Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, Louis DN, Li FP,
Rheinwald JG. 2000. Human keratinocytes that express hTERT and also bypass a
p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal
growth and differentiation characteristics. Mol Cell Biol 20:1436-47.

202.

Adams JC, Watt FM. 1989. Fibronectin inhibits the terminal differentiation of human
keratinocytes. Nature 340:307-9.

203.

Banno T, Blumenberg M. 2014. Keratinocyte detachment-differentiation connection
revisited, or anoikis-pityriasi nexus redux. PLoS One 9:e100279.

204.

Green H. 1977. Terminal Differentiation of Cultured Human Epidermal Cells.

205.

DeMasi J, Chao MC, Kumar AS, Howley PM. 2007. Bovine papillomavirus E7 oncoprotein
inhibits anoikis. J Virol 81:9419-25.

206.

Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL. 2012. Cell detachment activates the
Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 26:54-68.

183

207.

Klein RH, Lin Z, Hopkin AS, Gordon W, Tsoi LC, Liang Y, Gudjonsson JE, Andersen B.
2017. GRHL3 binding and enhancers rearrange as epidermal keratinocytes transition
between functional states. PLoS Genet 13:e1006745.

208.

Miyai M, Tsunekage Y, Saito M, Kohno K, Takahashi K, Kataoka K. 2017. Ectopic
expression of the transcription factor MafB in basal keratinocytes induces
hyperproliferation and perturbs epidermal homeostasis. Exp Dermatol 26:1039-1045.

209.

Miyai M, Hamada M, Moriguchi T, Hiruma J, Kamitani-Kawamoto A, Watanabe H, HaraChikuma M, Takahashi K, Takahashi S, Kataoka K. 2016. Transcription Factor MafB
Coordinates Epidermal Keratinocyte Differentiation. J Invest Dermatol 136:1848-1857.

210.

Evans MR, James CD, Loughran O, Nulton TJ, Wang X, Bristol ML, Windle B, Morgan IM.
2017. An oral keratinocyte life cycle model identifies novel host genome regulation by
human papillomavirus 16 relevant to HPV positive head and neck cancer. Oncotarget
8:81892-81909.

211.

Evans MR, James CD, Bristol ML, Nulton TJ, Wang X, Kaur N, White EA, Windle B, Morgan
IM. 2019. Human Papillomavirus 16 E2 Regulates Keratinocyte Gene Expression Relevant
to Cancer and the Viral Life Cycle. Journal of Virology 93.

212.

Nulton TJ, Olex AL, Dozmorov M, Morgan IM, Windle B. 2017. Analysis of The Cancer
Genome Atlas sequencing data reveals novel properties of the human papillomavirus 16
genome in head and neck squamous cell carcinoma. Oncotarget 8:17684-17699.

213.

Mehra R, Vats P, Cieslik M, Cao X, Su F, Shukla S, Udager AM, Wang R, Pan J, Kasaian
K, Lonigro R, Siddiqui J, Premkumar K, Palapattu G, Weizer A, Hafez KS, Wolf JS, Jr.,
Sangoi AR, Trpkov K, Osunkoya AO, Zhou M, Giannico G, McKenney JK, Dhanasekaran
SM, Chinnaiyan AM. 2016. Biallelic Alteration and Dysregulation of the Hippo Pathway in
Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. Cancer Discov 6:1258-1266.

214.

Pellegrini C, Maturo MG, Di Nardo L, Ciciarelli V, Gutierrez Garcia-Rodrigo C, Fargnoli MC.
2017. Understanding the Molecular Genetics of Basal Cell Carcinoma. Int J Mol Sci 18.

215.

Schramm A, Koster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D,
Ernst C, Henssen AG, Stephan H, Schroder C, Heukamp L, Engesser A, Kahlert Y,
Theissen J, Hero B, Roels F, Altmuller J, Nurnberg P, Astrahantseff K, Gloeckner C, De
Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P,
Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH. 2015. Mutational dynamics
between primary and relapse neuroblastomas. Nat Genet 47:872-7.

216.

Szalmas A, Tomaic V, Basukala O, Massimi P, Mittal S, Konya J, Banks L. 2017. The
PTPN14 Tumor Suppressor Is a Degradation Target of Human Papillomavirus E7. J Virol
91:e00057-17.

217.

Huang JM, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A, Zhang H, Karlan B,
Greene MI, Wang Q. 2013. YAP modifies cancer cell sensitivity to EGFR and survivin
inhibitors and is negatively regulated by the non-receptor type protein tyrosine
phosphatase 14. Oncogene 32:2220-9.

218.

Armstrong SR, Wu H, Wang B, Abuetabh Y, Sergi C, Leng RP. 2016. The Regulation of
Tumor Suppressor p63 by the Ubiquitin-Proteasome System. Int J Mol Sci 17.

219.

Perez CA, Ott J, Mays DJ, Pietenpol JA. 2007. p63 consensus DNA-binding site:
identification, analysis and application into a p63MH algorithm. Oncogene 26:7363-70.

220.

Sethi I, Gluck C, Zhou H, Buck MJ, Sinha S. 2017. Evolutionary re-wiring of p63 and the
epigenomic regulatory landscape in keratinocytes and its potential implications on speciesspecific gene expression and phenotypes. Nucleic Acids Res 45:8208-8224.

184

221.

Soares E, Zhou H. 2018. Master regulatory role of p63 in epidermal development and
disease. Cell Mol Life Sci 75:1179-1190.

222.

Harden ME, Prasad N, Griffiths A, Munger K. 2017. Modulation of microRNA-mRNA Target
Pairs by Human Papillomavirus 16 Oncoproteins. mBio 8.

223.

Wong CF, Barnes LM, Dahler AL, Smith L, Serewko-Auret MM, Popa C, Abdul-Jabbar I,
Saunders NA. 2003. E2F modulates keratinocyte squamous differentiation: implications for
E2F inhibition in squamous cell carcinoma. J Biol Chem 278:28516-22.

224.

Meyers JM, Spangle JM, Munger K. 2013. The human papillomavirus type 8 E6 protein
interferes with NOTCH activation during keratinocyte differentiation. J Virol 87:4762-7.

225.

Ablain J, de The H. 2014. Retinoic acid signaling in cancer: The parable of acute
promyelocytic leukemia. Int J Cancer 135:2262-72.

226.

Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova
Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE. 2016. Optimized sgRNA design
to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol
34:184-191.

227.

Nakatani Y, Konishi H, Vassilev A, Kurooka H, Ishiguro K, Sawada J, Ikura T, Korsmeyer
SJ, Qin J, Herlitz AM. 2005. p600, a unique protein required for membrane morphogenesis
and cell survival. Proc Natl Acad Sci U S A 102:15093-8.

228.

Mi H, Huang X, Muruganujan A, Tang H, Mills C, Kang D, Thomas PD. 2017. PANTHER
version 11: expanded annotation data from Gene Ontology and Reactome pathways, and
data analysis tool enhancements. Nucleic Acids Res 45:D183-D189.

229.

de Martel C, Plummer M, Vignat J, Franceschi S. 2017. Worldwide burden of cancer
attributable to HPV by site, country and HPV type. Int J Cancer 141:664-670.

230.

Wang HK, Duffy AA, Broker TR, Chow LT. 2009. Robust production and passaging of
infectious HPV in squamous epithelium of primary human keratinocytes. Genes Dev
23:181-94.

231.

Meyers JM, Uberoi A, Grace M, Lambert PF, Munger K. 2017. Cutaneous HPV8 and
MmuPV1 E6 Proteins Target the NOTCH and TGF-beta Tumor Suppressors to Inhibit
Differentiation and Sustain Keratinocyte Proliferation. PLoS Pathog 13:e1006171.

232.

Moody CA, Fradet-Turcotte A, Archambault J, Laimins LA. 2007. Human papillomaviruses
activate caspases upon epithelial differentiation to induce viral genome amplification. Proc
Natl Acad Sci U S A 104:19541-6.

233.

Pentland I, Campos-Leon K, Cotic M, Davies KJ, Wood CD, Groves IJ, Burley M, Coleman
N, Stockton JD, Noyvert B, Beggs AD, West MJ, Roberts S, Parish JL. 2018. Disruption of
CTCF-YY1-dependent looping of the human papillomavirus genome activates
differentiation-induced viral oncogene transcription. PLoS Biol 16:e2005752.

234.

Peh WL, Middleton K, Christensen N, Nicholls P, Egawa K, Sotlar K, Brandsma J, Percival
A, Lewis J, Liu WJ, Doorbar J. 2002. Life cycle heterogeneity in animal models of human
papillomavirus-associated disease. J Virol 76:10401-16.

235.

Mendelsohn AH, Lai CK, Shintaku IP, Elashoff DA, Dubinett SM, Abemayor E, St John MA.
2010. Histopathologic findings of HPV and p16 positive HNSCC. Laryngoscope 120:178894.

236.

Pai SI, Westra WH. 2009. Molecular pathology of head and neck cancer: implications for
diagnosis, prognosis, and treatment. Annu Rev Pathol 4:49-70.

237.

Cheepala SB, Yin W, Syed Z, Gill JN, McMillian A, Kleiner HE, Lynch M, Loganantharaj R,
Trutschl M, Cvek U, Clifford JL. 2009. Identification of the B-Raf/Mek/Erk MAP kinase

185

pathway as a target for all-trans retinoic acid during skin cancer promotion. Mol Cancer
8:27.
238.

Verma AK. 1987. Inhibition of Both Stage-I and Stage-Ii Mouse Skin Tumor Promotion by
Retinoic Acid and the Dependence of Inhibition of Tumor Promotion on the Duration of
Retinoic Acid Treatment. Cancer Research 47:5097-5101.

239.

Zhang ML, Tao Y, Zhou WQ, Ma PC, Cao YP, He CD, Wei J, Li LJ. 2014. All-trans retinoic
acid induces cell-cycle arrest in human cutaneous squamous carcinoma cells by inhibiting
the mitogen-activated protein kinase-activated protein 1 pathway. Clin Exp Dermatol
39:354-60.

240.

Heck DV, Yee CL, Howley PM, Munger K. 1992. Efficiency of binding the retinoblastoma
protein correlates with the transforming capacity of the E7 oncoproteins of the human
papillomaviruses. Proc Natl Acad Sci U S A 89:4442-6.

241.

Kho EY, Wang HK, Banerjee NS, Broker TR, Chow LT. 2013. HPV-18 E6 mutants reveal
p53 modulation of viral DNA amplification in organotypic cultures. Proc Natl Acad Sci U S
A 110:7542-9.

242.

Totaro A, Castellan M, Di Biagio D, Piccolo S. 2018. Crosstalk between YAP/TAZ and
Notch Signaling. Trends Cell Biol 28:560-573.

243.

Moroishi T, Hansen CG, Guan KL. 2015. The emerging roles of YAP and TAZ in cancer.
Nat Rev Cancer 15:73-79.

244.

Day PM, Schelhaas M. 2014. Concepts of papillomavirus entry into host cells. Curr Opin
Virol 4:24-31.

245.

Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, Lowy DR, Schiller
JT. 2007. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9
and inhibited by carrageenan. Nat Med 13:857-61.

246.

Egawa N, Nakahara T, Ohno S, Narisawa-Saito M, Yugawa T, Fujita M, Yamato K, Natori
Y, Kiyono T. 2012. The E1 protein of human papillomavirus type 16 is dispensable for
maintenance replication of the viral genome. J Virol 86:3276-83.

247.

Heng BC, Zhang X, Aubel D, Bai Y, Li X, Wei Y, Fussenegger M, Deng X. 2020. Role of
YAP/TAZ in Cell Lineage Fate Determination and Related Signaling Pathways. Front Cell
Dev Biol 8:735.

248.

Hicks-Berthet J, Ning B, Federico A, Tilston-Lunel A, Matschulat A, Ai X, Lenburg ME,
Beane J, Monti S, Varelas X. 2021. Yap/Taz inhibit goblet cell fate to maintain lung
epithelial homeostasis. Cell Rep 36:109347.

249.

Cancer Genome Atlas N. 2015. Comprehensive genomic characterization of head and
neck squamous cell carcinomas. Nature 517:576-82.

250.

Lee HH, Chiang WH, Chiang SH, Liu YC, Hwang J, Ng SY. 1995. Regulation of cyclin D1,
DNA topoisomerase I, and proliferating cell nuclear antigen promoters during the cell cycle.
Gene Expr 4:95-109.

251.

He C, Mao D, Hua G, Lv X, Chen X, Angeletti PC, Dong J, Remmenga SW, Rodabaugh
KJ, Zhou J, Lambert PF, Yang P, Davis JS, Wang C. 2015. The Hippo/YAP pathway
interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer
progression. EMBO Mol Med 7:1426-49.

252.

Morgan EL, Patterson MR, Ryder EL, Lee SY, Wasson CW, Harper KL, Li Y, Griffin S, Blair
GE, Whitehouse A, Macdonald A. 2020. MicroRNA-18a targeting of the STK4/MST1
tumour suppressor is necessary for transformation in HPV positive cervical cancer. PLoS
Pathog 16:e1008624.

186

253.

Olmedo-Nieva L, Munoz-Bello JO, Manzo-Merino J, Lizano M. 2020. New insights in Hippo
signalling alteration in human papillomavirus-related cancers. Cell Signal 76:109815.

254.

Webb Strickland S, Brimer N, Lyons C, Vande Pol SB. 2018. Human Papillomavirus E6
interaction with cellular PDZ domain proteins modulates YAP nuclear localization. Virology
516:127-138.

255.

Knox KK, Carrigan DR. 1992. In vitro suppression of bone marrow progenitor cell
differentiation by human herpesvirus 6 infection. J Infect Dis 165:925-9.

256.

Niiya H, Lei J, Guo Y, Azuma T, Yakushijin Y, Sakai I, Hato T, Tohyama M, Hashimoto K,
Yasukawa M. 2006. Human herpesvirus 6 impairs differentiation of monocytes to dendritic
cells. Exp Hematol 34:642-53.

257.

Onnis A, Navari M, Antonicelli G, Morettini F, Mannucci S, De Falco G, Vigorito E, Leoncini
L. 2012. Epstein-Barr nuclear antigen 1 induces expression of the cellular microRNA hsamiR-127 and impairing B-cell differentiation in EBV-infected memory B cells. New insights
into the pathogenesis of Burkitt lymphoma. Blood Cancer J 2:e84.

258.

Romeo MA, Gilardini Montani MS, Falcinelli L, Gaeta A, Nazzari C, Faggioni A, Cirone M.
2019. HHV-6B reduces autophagy and induces ER stress in primary monocytes impairing
their survival and differentiation into dendritic cells. Virus Res 273:197757.

259.

Styles CT, Bazot Q, Parker GA, White RE, Paschos K, Allday MJ. 2017. EBV epigenetically
suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term
latency. PLoS Biol 15:e2001992.

260.

Hwang JH, Pores Fernando AT, Faure N, Andrabi S, Adelmant G, Hahn WC, Marto JA,
Schaffhausen BS, Roberts TM. 2014. Polyomavirus small T antigen interacts with yesassociated protein to regulate cell survival and differentiation. J Virol 88:12055-64.

261.

Liu G, Yu FX, Kim YC, Meng Z, Naipauer J, Looney DJ, Liu X, Gutkind JS, Mesri EA, Guan
KL. 2015. Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating
the Hippo pathway. Oncogene 34:3536-46.

262.

Nguyen HT, Hong X, Tan S, Chen Q, Chan L, Fivaz M, Cohen SM, Voorhoeve PM. 2014.
Viral small T oncoproteins transform cells by alleviating hippo-pathway-mediated inhibition
of the YAP proto-oncogene. Cell Rep 8:707-13.

263.

Shanzer M, Ricardo-Lax I, Keshet R, Reuven N, Shaul Y. 2015. The polyomavirus middle
T-antigen oncogene activates the Hippo pathway tumor suppressor Lats in a Srcdependent manner. Oncogene 34:4190-8.

264.

Tian Y, Li D, Dahl J, You J, Benjamin T. 2004. Identification of TAZ as a binding partner of
the polyomavirus T antigens. J Virol 78:12657-64.

265.

Wang Z, Lu W, Zhang Y, Zou F, Jin Z, Zhao T. 2019. The Hippo Pathway and Viral
Infections. Front Microbiol 10:3033.

266.

He C, Lv X, Huang C, Angeletti PC, Hua G, Dong J, Zhou J, Wang Z, Ma B, Chen X,
Lambert PF, Rueda BR, Davis JS, Wang C. 2019. A Human Papillomavirus-Independent
Cervical Cancer Animal Model Reveals Unconventional Mechanisms of Cervical
Carcinogenesis. Cell Rep 26:2636-2650 e5.

267.

Alzahrani F, Clattenburg L, Muruganandan S, Bullock M, MacIsaac K, Wigerius M, Williams
BA, Graham ME, Rigby MH, Trites JR, Taylor SM, Sinal CJ, Fawcett JP, Hart RD. 2017.
The Hippo component YAP localizes in the nucleus of human papilloma virus positive
oropharyngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg 46:15.

268.

Yuan Y, Salinas Parra N, Chen Q, Iglesias-Bartolome R. 2022. Oncogenic HedgehogSmoothened Signaling Depends on YAP1TAZ/TEAD Transcription to Restrain
Differentiation in Basal Cell Carcinoma. J Invest Dermatol 142:65-76 e7.

187

269.

Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye
K, Chinnaiyan A, Halder G, Lai ZC, Guan KL. 2007. Inactivation of YAP oncoprotein by the
Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev
21:2747-61.

270.

Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, Campisi J, Yaswen P,
Cooper PK, Kaufman PD. 2009. A versatile viral system for expression and depletion of
proteins in mammalian cells. PLoS One 4:e6529.

271.

Galligan JT, Martinez-Noel G, Arndt V, Hayes S, Chittenden TW, Harper JW, Howley PM.
2015. Proteomic analysis and identification of cellular interactors of the giant ubiquitin
ligase HERC2. J Proteome Res 14:953-66.

272.

Ridky TW, Chow JM, Wong DJ, Khavari PA. 2010. Invasive three-dimensional organotypic
neoplasia from multiple normal human epithelia. Nat Med 16:1450-5.

273.

Duperret EK, Dahal A, Ridky TW. 2015. Focal-adhesion-independent integrin-alphav
regulation of FAK and c-Myc is necessary for 3D skin formation and tumor invasion. J Cell
Sci 128:3997-4013.

274.

Egolf S, Aubert Y, Doepner M, Anderson A, Maldonado-Lopez A, Pacella G, Lee J, Ko EK,
Zou J, Lan Y, Simpson CL, Ridky T, Capell BC. 2019. LSD1 Inhibition Promotes Epithelial
Differentiation through Derepression of Fate-Determining Transcription Factors. Cell Rep
28:1981-1992 e7.

275.

Fehrmann F, Laimins LA. 2005. Human Papillomavirus Type 31 Life Cycle Methods for
Studying Using Tissue Culture Models. Methods in Molecular Biology 292:317-330.

276.

Facompre ND, Rajagopalan P, Sahu V, Pearson AT, Montone KT, James CD, GleberNetto FO, Weinstein GS, Jalaly J, Lin A, Rustgi AK, Nakagawa H, Califano JA, Pickering
CR, White EA, Windle BE, Morgan IM, Cohen RB, Gimotty PA, Basu D. 2020. Identifying
predictors of HPV-related head and neck squamous cell carcinoma progression and
survival through patient-derived models. Int J Cancer 147:3236-3249.

277.

Roh M, Song C, Kim J, Abdulkadir SA. 2005. Chromosomal instability induced by Pim-1 is
passage-dependent and associated with dysregulation of cyclin B1. J Biol Chem
280:40568-77.

278.

Lewis JS, Jr., Beadle B, Bishop JA, Chernock RD, Colasacco C, Lacchetti C, Moncur JT,
Rocco JW, Schwartz MR, Seethala RR, Thomas NE, Westra WH, Faquin WC. 2018.
Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College
of American Pathologists. Arch Pathol Lab Med 142:559-597.

279.

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A,
Sinha R, Larsson E, Cerami E, Sander C, Schultz N. 2013. Integrative analysis of complex
cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1.

280.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ,
Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. 2012. The
cBio cancer genomics portal: an open platform for exploring multidimensional cancer
genomics data. Cancer Discov 2:401-4.

281.

Chakravarthy A, Henderson S, Thirdborough SM, Ottensmeier CH, Su X, Lechner M,
Feber A, Thomas GJ, Fenton TR. 2016. Human Papillomavirus Drives Tumor Development
Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune
Response Largely Restricted to the Oropharynx. J Clin Oncol 34:4132-4141.

282.

Wang LT, Proulx ME, Kim AD, Lelarge V, McCaffrey L. 2021. A proximity proteomics
screen in three-dimensional spheroid cultures identifies novel regulators of lumen
formation. Sci Rep 11:22807.

188

283.

Williams SE, Ratliff LA, Postiglione MP, Knoblich JA, Fuchs E. 2014. Par3-mInsc and
Galphai3 cooperate to promote oriented epidermal cell divisions through LGN. Nat Cell
Biol 16:758-69.

284.

Vorhagen S, Niessen CM. 2014. Mammalian aPKC/Par polarity complex mediated
regulation of epithelial division orientation and cell fate. Exp Cell Res 328:296-302.

285.

Yoshihama Y, Sasaki K, Horikoshi Y, Suzuki A, Ohtsuka T, Hakuno F, Takahashi S, Ohno
S, Chida K. 2011. KIBRA suppresses apical exocytosis through inhibition of aPKC kinase
activity in epithelial cells. Curr Biol 21:705-11.

286.

Helt AM, Galloway DA. 2001. Destabilization of the retinoblastoma tumor suppressor by
human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human
keratinocytes. J Virol 75:6737-47.

287.

Raj N, Bam R. 2019. Reciprocal Crosstalk Between YAP1/Hippo Pathway and the p53
Family Proteins: Mechanisms and Outcomes in Cancer. Front Cell Dev Biol 7:159.

288.

Li Y, Yang S, Liu Y, Yang S. 2022. Mice with Trp53 and Rb1 deficiency in chondrocytes
spontaneously develop chondrosarcoma via overactivation of YAP signaling. Cell Death
Dis 13:570.

289.

Saladi SV, Ross K, Karaayvaz M, Tata PR, Mou H, Rajagopal J, Ramaswamy S, Ellisen
LW. 2017. ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP
Activation, Regenerative Proliferation, and Poor Prognosis. Cancer Cell 31:35-49.

189

